



Planet Depos®
We Make It *Happen™*

Transcript of Peter Sims, Ph.D.

Date: June 26, 2025

Case: Integrated DNA Technologies, Inc. -v- Tecan Genomics, Inc. (PTAB)

Planet Depos

Phone: 888.433.3767 | **Email:** transcripts@planetdepos.com

www.planetdepos.com

Michigan #8598 | Nevada #089F | New Mexico #566

WORLDWIDE COURT REPORTING & LITIGATION TECHNOLOGY

Transcript of Peter Sims, Ph.D.
Conducted on June 26, 2025

1 (1 to 4)

1	1 UNITED STATES PATENT AND TRADEMARK OFFICE	3	1 INDEX
2	2 BEFORE THE PATENT TRIAL AND APPEAL BOARD	4	2 WITNESS EXAMINATION BY PAGE
3	3 -----x	4	3 Peter Sims, Ph.D. Linnea Cipriano 4
4	4 INTEGRATED DNA TECHNOLOGIES, INC., Case IPR Nos:	5	4 EXHIBITS
5	5	6	5 EXHIBIT DESCRIPTION PAGE
6	6 IPR2024-01502	7	6 2022 BINF G4017 Deep Sequencing 23
7	7 Petitioner, U.S. Patent 9,546,399	8	7 Syllabus
8	8 IPR2024-01504	9	8
9	9 U.S. Patent 11,098,357	10	9
10	10 -against- IPR2024-01506	11	10
11	11 U.S. Patent 11,725,241	12	11
12	12 IPR2025-00015	13	12
13	13 TECAN GENOMICS, INC., U.S. Patent 10,036,012	14	13
14	14 IPR2025-00016	15	14
15	15 Patent Owner. U.S. Patent 10,876,108	16	15
16	16 -----x	17	16
17	17 DEPOSITION of PETER SIMS, PH.D. taken by the	18	17
18	18 Patent Owner, pursuant to Notice, held at the law	19	18
19	19 offices of Williams Connolly 650 5th Avenue, Suite 1500	20	19
20	20 New York, NY 10019, on June 26, 2025, at 9:15 a.m.,	21	20
21	21 before a Notary Public of the State of New York.	22	21
22	22 *****		22
2	2	4	4
1	1 A P P E A R A N C E S :	1	1 P E T E R S I M S, the witness herein, having been
2	2 WILLIAMS & CONNOLLY LLP	2	2 first duly sworn by a Notary Public of the State of New
3	3 Attorneys for Petitioner	3	3 York, was examined and testified as follows:
4	4 680 Maine Avenue SW	4	4 THE REPORTER: Please state your name
5	5 BY: THOMAS S. FLETCHER, ESQ.	5	5 for the record.
6	6 tfletcher@wc.com	6	6 THE WITNESS: Peter Sims, M.D.
7	7 KEVIN HOAGLAND-HANSON, ESQ.	7	7 THE REPORTER: Please state your
8	8 ANNA SEARLE, ESQ.	8	8 address for the record.
9	9	9	9 THE WITNESS: 54 Pine Street Ardsley,
10	10 GOODWIN PROCTER LLP	10	10 New York 10502.
11	11 Attorneys for Patent Owner	11	11 MS. CIPRIANO: Hi. I'm Linnea
12	12 The New York Times Building, 620 Eighth Avenue	12	12 Cipriano, counsel for patent owners in this
13	13 New York, NY 10018	13	13 case. With me is Timothy Beavers and -- and,
14	14 BY: LINNEA P. CIPRIANO, ESQ.	14	14 yeah, just with me is Timothy Beavers.
15	15 lcipriano@goodwinlaw.com	15	15 MR. FLETCHER: Tom Fletcher, Williams &
16	16 TIMOTHY BEAVERS, ESQ.	16	16 Connolly LLP, for the petitioner, Integrated
17	17 EUNBI CHOI, ESQ.	17	17 DNA Technologies. With me are my colleagues,
18	18	18	18 Kevin Hoagland-Hanson and Anna Searle. Also
19	19 ALSO PRESENT:	19	19 present is Mike Levy from Danaher.
20	20 MICHAEL LEVY- Danaher	20	20 EXAMINATION BY
21	21	21	21 MS. CIPRIANO:
22	22	22	22 Q. Good morning, Dr. Sims.

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Tecan Ex. 2036, Page 2 of 76

IDT, Inc. v. Tecan Genomics - IPR2025-00016

Conducted on June 26, 2025

5 1 A. Good morning. 2 Q. My name is Linnea Cipriano, as I said, and I'm 3 going to be asking you some questions today and possibly 4 tomorrow. 5 Have you ever been deposed before? 6 A. I have been deposed before. 7 Q. How many times? 8 A. I have been deposed twice. 9 Q. Okay. And when were those approximately? 10 A. Yeah, approximately two years ago and then one 11 earlier this year. 12 Q. And the deposition two years ago, was that -- 13 were you serving as an expert in that matter? 14 A. I was serving as an expert witness in that 15 matter. 16 Q. And what was the subject matter of that case? 17 A. It's related to single-cell sequencing. 18 Q. And who were you retained by in that matter? 19 A. The law firm was Wolf Greenfield. They're 20 representing Scale Biosciences. 21 Q. And in the deposition earlier this year, what 22 was the subject matter of that case?	7 1 to answer my questions to the best of your ability. 2 Do you understand that? 3 A. I understand that. 4 Q. As you probably noticed, we have a court 5 reporter taking down everything we say today. And so 6 that means that you and I have to be careful not to 7 speak over one another. 8 Is that fair? 9 A. Completely understand. 10 Q. So I will try to wait for you to finish your 11 answer, so please wait for me to try to finish my 12 question. 13 We'll take breaks from time to time, but I 14 would ask that we don't take a break while there's a 15 question. If you could answer my question before we 16 take a break, and then we can take a break at your 17 convenience? 18 Do you understand? 19 A. I understand. 20 Q. And along those same lines, if you need a 21 break, please just let me know. I'm happy to take a 22 break whenever.
6 1 A. That deposition was related to the same case. 2 Q. Okay. And that was a patent case? 3 A. It is a patent case. 4 Q. Okay. And are you representing the patent 5 holder or the accused infringer? 6 MR. FLETCHER: Objection. 7 Q. Excuse me. Let me rephrase that question. 8 Have you been retained by the patent holder or 9 the accused infringer in that case? 10 A. I have been retained by the patent holder in 11 that case. 12 Q. So I'm sure this deposition will be a lot like 13 your previous two depositions, but let's go through some 14 ground rules so we're on the same page. I will be 15 asking you questions, and your answers today will be 16 under oath. And that oath is the same as you would take 17 as if you were testifying in court. 18 Do you understand that? 19 A. I understand that. 20 Q. And during the course of the deposition, your 21 counsel may make objections, but unless you've been 22 instructed by counsel not to answer, I'm expecting you	8 1 A. I will let you know. 2 Q. I will ask you to listen carefully to my 3 questions. I'm sure that my questions will not always 4 be clear. So if you have any -- if there's any 5 confusion, please ask me to clarify and I will try to do 6 so. 7 Is that fair? 8 A. That is fair. 9 Q. But if you answer my question, I'm going to 10 assume that you understood it. 11 Is that also fair? 12 A. That is fair. 13 Q. Okay. And you understand that, while I'm 14 asking questions during the deposition, when the 15 deposition is over, you are not permitted to discuss the 16 substance of your testimony with your attorneys. 17 Do you understand? 18 A. I understand. 19 Q. Is there any reason that you would not be able 20 to answer my questions fully and truthfully today? 21 A. There is no reason. 22 Q. Did you prepare for today's deposition?

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Tecan Ex. 2036, Page 3 of 76

IDT, Inc. v. Tecan Genomics - IPR2025-00016

9 1 A. I prepared for today's deposition. 2 Q. And without revealing any privileged 3 communication with your counsel, at a high level, what 4 did you do to prepare for this deposition? 5 A. I reviewed my declaration, I reviewed 6 references in my declaration, and I met with counsel. 7 Q. Did you speak to anyone besides counsel in 8 preparation for this deposition? 9 A. I did not speak to anyone besides counsel in 10 preparation for this deposition. 11 Q. And when did your preparation -- when did your 12 meetings with counsel occur? 13 A. All of my meetings related to preparation for 14 this deposition occurred in the month of June of this 15 year. 16 Q. And approximately how many hours did you spend 17 preparing? 18 A. I would guess probably about 40 hours. 19 Q. There's a lot of material here. I understand. 20 A. Indeed. 21 Q. You said you reviewed some documents in your 22 preparation for the deposition; is that accurate?	11 1 lost. 2 Q. Okay. So if we look at the exhibit marked 3 1079, do you have that? 4 A. I have that. 5 Q. And is Exhibit 1079 the declaration that you 6 submitted in IPRs 2024-01502, '1504, and '1506? 7 A. That is correct. 8 Q. And if you turn to the last -- last page of the 9 exhibit before the Exhibit A at the back, that's on the 10 page marked 0327 at the bottom corner. 11 A. I see that. 12 Q. Is that your signature? 13 A. That is my signature. 14 Q. Okay. And if you could just look at the 15 other -- other declaration -- let's pause. 16 Exhibit 1079, that relates to, just for the 17 record, U.S. Patents 9,546,399, 11,098,357, and 18 11,725,241, correct? 19 A. That is correct. 20 Q. Okay. And then if we look at Exhibit 1085 in 21 IPRs 2025-00015 and '0016, do you have that in front of 22 you?
10 1 A. That is accurate. 2 Q. Besides your declaration, do you recall 3 specifically what documents you looked at? 4 A. I looked at the Iafrate patent application; 5 that's Exhibit 1011 in my declaration. I looked at a 6 research article by Kivioja, et al.; that's Exhibit 7 1012. I looked at a patent application by Bielas, 8 Exhibit 1013. There may have been a few others, but 9 those are three that I paid particular attention to. 10 Q. Now, you prepared two declarations in 11 connection with the proceedings that are at issue, 12 correct? 13 A. I prepared two declarations. So the materials 14 that I just described are related to my declaration on 15 the '399, '357, and '241 patents. 16 Q. Understood. Understood. 17 So just to get it out of the way, let's just 18 get in front of you both declarations and confirm that 19 those are accurate copies. We'll only be looking at one 20 for a little bit, but just for the logistics -- 21 MR. FLETCHER: Counsel, we gave him 22 bound copies so they don't fall apart or get	12 1 A. I have that in front of me. 2 Q. Is Exhibit 1085 the declaration that you 3 submitted in these proceedings? The referenced 4 proceedings on the face of the document? 5 A. That is correct. 6 Q. And then on the page in Exhibit 1085, at the 7 bottom of -- bottom right-hand corner is marked 0206? 8 A. I see that. 9 Q. Is that your signature? 10 A. That is my signature. 11 Q. So throughout the deposition, typically we'll 12 be talking about one declaration or the other, but there 13 are sections of the declarations that are either 14 identical or very similar. 15 Is that fair? 16 A. There are sections of the two declarations that 17 are very similar. 18 Q. Okay. So I'll do my best to point out where 19 they're similar and where they're different, but to the 20 extent the concepts -- particularly the background 21 concepts are the same and I refer to Exhibit 1079, to 22 the extent that paragraph also appears in Exhibit 1085,

13 1 would your testimony still be the same as far as the 2 background concepts? 3 A. For background-related statements in the two 4 declarations that are the same, my testimony and 5 opinions would be the same. 6 Q. Great. Thank you. 7 And to the extent there would be differences 8 between the two proceedings, please let me know and I'll 9 try to alert you to that. 10 A. Okay. 11 Q. So at a high level, how did you prepare these 12 declarations? 13 A. I met with counsel many times. I researched 14 prior art references and background references. I 15 didn't do all the typing in these declarations, but I 16 ensured that they accurately represent my opinions in 17 this case. 18 Q. You said you researched prior art references. 19 Did you identify independently any of the prior art that 20 is cited in your declaration? 21 A. I identified some of the references, including 22 prior art references, that are cited in my declaration.	15 1 responses? 2 A. I have read patent owner's preliminary 3 responses. 4 Q. And in connection with the '00015 and '0016 5 proceedings, did you read Dr. Bustamante's declaration? 6 A. I have read Dr. Bustamante's declaration. 7 Q. Is there anything in the patent owner's 8 preliminary response that changes or makes you want to 9 amend your opinions in your declaration? 10 A. Nothing I read in the patent owner's response 11 makes me want to change my opinions that are laid out in 12 my declaration. 13 Q. Same question for Dr. Bustamante's declaration. 14 Anything in that make you want to change or amend your 15 declaration? 16 A. Nothing in Dr. Bustamante's declaration changes 17 my opinions as laid out in my declaration. 18 Q. Do you know Dr. Bustamante? 19 A. I know Dr. Bustamante by reputation. I don't 20 know that I've met him in person. 21 Q. And what is that reputation, in your view? 22 A. He's a successful and reputable scientist in
14 1 Q. And do you recall, sitting here today, which 2 references you identified? 3 A. I particularly recall identifying Exhibit 4 1013 -- this is in my declaration, Exhibit 1079 -- a 5 patent application by Bielas. I likely identified some 6 of the other background-related references, but I don't 7 completely recall the details. It was a while ago. 8 Q. Understood. 9 As part of preparing your declarations, did you 10 consult with anyone other than the attorney team? 11 A. I did not. 12 Q. Have you reviewed any of the documents that 13 have been submitted in connection with the litigation 14 that is associated with these patents? 15 A. I don't recall reviewing any of those 16 documents. 17 Q. Okay. So since submitting your declaration, 18 you understand that there's been -- or do you understand 19 there's been correspondence from patent owner and also 20 from the board in these proceedings? 21 A. I'm aware of those communications. 22 Q. Okay. Have you read patent owner's preliminary	16 1 the field of genomics, particularly computational 2 genomics. 3 Q. Have you read the Patent Trial and Appeal Board 4 panel's institution decision in these matters? 5 A. I have read the PTAB decision in these matters. 6 Q. Much easier to say. 7 Is there anything in the institution decisions 8 that you -- that would make you change your opinions or 9 positions in your declarations? 10 A. Nothing in the PTAB decision documents changes 11 my opinions as laid out in my declarations. 12 Q. Okay. Are there any corrections or edits that 13 would you like to make to your declarations sitting here 14 today? 15 A. None that I've encountered so far. 16 Q. Okay. Understood. There's always that stray 17 typo, right? 18 So let's turn to -- if you could turn to 19 Exhibit A in -- it's my -- from my comparison, it's the 20 same in both declarations, but we can look at the one 21 that's in Exhibit 1079. And that's -- on the page at 22 the bottom, it's marked 3290329.

17 1 A. Yes. 2 Q. Are you there? 3 A. Yes, I'm there. 4 Q. This is -- is this your CV? 5 A. This is my CV. 6 Q. Is it accurate? 7 A. It is accurate. It is very slightly out of 8 date, but it is accurate. 9 Q. Okay. And what changes would need to be made 10 to make it up to date? 11 A. It's just missing a few of my recent 12 publications from 2025. 13 Q. You are currently employed, correct? 14 A. I am currently employed. 15 Q. And what is your current position? 16 A. I am an associate professor at Columbia 17 University, and I am the scientific director of the 18 Columbia Genome Center. 19 Q. And what do you consider your area of 20 expertise? 21 A. My area of expertise is genomics, including 22 technology development and applications of genomics,	19 1 A. Experimental tools means that we are working at 2 a wet bench with cells, with genetic material, DNA and 3 RNA, and performing measurements on those materials. 4 Computational tools means that we're developing 5 algorithms and computer programs for analyzing the data 6 that arises from those measurements. 7 Q. In your current genomic work, do you use 8 next-generation sequencing? 9 A. We make extensive use of next-generation 10 sequencing. 11 Q. And which platforms do you typically use in 12 your lab? 13 A. Currently, my lab uses sequencers manufactured 14 by Illumina and Element Biosciences. 15 Q. Okay. So you also said you were the 16 scientific -- apologies if I get this -- scientific 17 director of the Genome Center? Is that -- 18 A. That's correct. 19 Q. Okay. What is your -- what does your role 20 entail in that position? 21 A. The Genome Center at Columbia is a core 22 facility that performs experiments and computational
18 1 mostly in the areas of cancer biology and immunology. 2 Q. So you gave two titles in your current -- in 3 your current roles. If we just think about your role as 4 an associate professor at Columbia. What is -- what 5 does that entail? 6 A. It entails two main things. One is teaching, 7 mentoring, and training students, and the other is 8 performing research. 9 Q. And what is that area of research? 10 A. My lab's research focuses on genomic technology 11 development mostly with applications in cancer biology 12 and immunology. 13 Q. And when you say "genomic technology 14 development," what do you mean by that? 15 A. We develop tools, both experimental and 16 computational, for interrogating the genomes and 17 transcriptomes of cells -- mostly human cells. 18 Q. Mostly genome cells? 19 A. Mostly human cells. 20 Q. Human cells. 21 And can you explain the difference between 22 experimental tools and computational tools?	20 1 analysis on a fee-for-service basis for other 2 investigators at Columbia and also some external 3 investigators. I supervise the staff in that facility. 4 Q. And then I'm guessing that also does a lot of 5 next generation sequencing in that facility? 6 A. The Genome Center does a lot of next generation 7 sequencings. 8 Q. And what platforms are used in that facility? 9 A. That facility uses sequencing instruments 10 manufactured by Illumina and Element Biosciences. 11 Q. Now are they the same instruments that you use 12 in your lab, in your research or are they separate? 13 A. My lab does almost all of its sequencing in the 14 Columbia Genome Center. 15 Q. So I'd like to talk a little bit about your 16 training and your educational -- I'm going to refer to 17 paragraph 5 of your declaration of the Exhibit 1079, but 18 feel free, if you need to look anywhere else -- I doubt 19 that you need to look somewhere for your background, but 20 just to let you know where I am, I'm on paragraph 5. 21 So you explained that you worked on NGS, excuse 22 me, can we agree that NGS stands for next-generation

21 1 sequencing? 2 A. I completely agree. 3 Q. Okay. You explained that you worked on NGS 4 technologies during your Ph.D. training; is that 5 correct? 6 A. I worked on NGS technologies during my Ph.D. 7 training. 8 Q. And could you please explain what your Ph.D. 9 work focused on? 10 A. The beginning of my Ph.D. work focused on 11 single-molecule biophysics. I was studying motor 12 proteins. Towards the end of my Ph.D. training, I 13 started to actually build a next-generation sequencing 14 platform in the lab. 15 Q. So you finished your Ph.D. in 2009. 16 Approximately when did that building of an NGS platform 17 begin prior to 2009? 18 A. I began that work in 2007. 19 Q. And what did that work entail? 20 A. That work entailed organic synthesis of 21 fluorescently labeled nucleotides. It involved 22 developing microfluidic devices and constructing a	23 1 A. I think I probably started working on both 2 projects towards the end of my Ph.D., but the bulk of 3 the work was done during my post-doctoral period which 4 was between 2009 and 2011. 5 Q. So when you started on building the NGS 6 platform in 2007, had you done any DNA sequencing 7 projects before then? 8 A. I don't think I had done any DNA sequencing 9 related projects before then. I had used DNA sequencing 10 on occasion, but not in the capacity of technology 11 development. 12 Q. Understood. 13 In your current role, you teach classes; is 14 that correct? 15 A. I teach classes. 16 Q. Okay. And doing a little bit of research, one 17 of those classes is called deep sequencing; is that 18 accurate? 19 A. I teach a course called deep sequencing. 20 MS. CIPRIANO: Okay. If we could look 21 at -- we'll mark this as Exhibit 2022. 22 (Whereupon, BINF G4017 Deep Sequencing
22 1 microscopy system 2 Q. Did you publish any work on that NGS platform 3 that you worked on? 4 A. I did. That research is reported in a paper 5 that's actually Number 90, publications Number 90 in my 6 CV. You can see it on 1079.0339. 7 Q. Okay. 8 A. First author Sims. It's entitled "Fluorogenic 9 DNA Sequencing in PDMS Microreactors." 10 Q. Was that system ultimately used anywhere 11 besides the lab you worked in? 12 A. A version of that system is commercially 13 available in China. 14 Q. So if I did the math right, you published two 15 other papers in the same timeframe as that -- the paper 16 Number 90 in your CV, but I'm specifically looking at 17 papers 89 and 88 on your list that were published in 18 2012. 19 Do you see those? 20 A. I see those. 21 Q. Is that work that you did as a post-doc or as a 22 grad student?	24 1 Syllabus was marked as Exhibit 2022, for 2 identification, as of this date.) 3 BY MS. CIPRIANO: 4 Q. So the court reporter has just handed you a 5 document that we've marked as Exhibit 2022. 6 Do you recognize this Exhibit? 7 A. I actually do not recognize this document, but 8 I believe that it's real and I recognize some of its 9 content very well. 10 Q. Okay. If we look at the second page of the 11 document, that's your name and your picture? 12 A. That's my name and a very old picture. 13 Q. The name of the course, BINF G4017 deep 14 sequencing, is that the name of the course that you 15 teach? 16 A. That's the name of the course that I teach. 17 Q. And if you can look at the course description, 18 does this appear to be the syllabus or the reading 19 material assigned for the deep sequencing course that 20 you teach? 21 A. This is the syllabus for the course that I 22 teach.

Conducted on June 26, 2025

25 1 Q. At a general level, what does this course 2 cover? 3 A. The course is a graduate-level introduction to 4 the field of genomics. It's a very broad course. 5 Q. So if we look at the section of text underneath 6 the pictures that starts on the second page of the 7 document, it's a little difficult to navigate the way 8 they printed it out, apologies for that. 9 But if I -- if we look at -- there's a section 10 called "Topics" that's underlined and there's a 11 little -- further down there's a section called "Goals" 12 that's underlined. 13 Do you see that? 14 A. Mm-hmm. Yes. 15 Q. And then a little bit further down there's 16 requirements? 17 A. I see that. 18 Q. Okay. And then onto the next page, following 19 the same convention, there's an introduction to 20 high-throughput sequencing technologies. 21 Do you see that? 22 A. I see that.	27 1 name of the lecture; is that accurate? 2 A. That's right. 3 Q. Did you select the articles that were assigned 4 reading for the lectures you gave in this course? 5 A. I selected those articles. 6 Q. And how did you go about selecting the articles 7 for these lectures? 8 A. Some of the articles are selected because I 9 think they are of particular historical importance to 10 the way in which the field developed. 11 Some of the articles I chose because of my 12 personal familiarity with them, making me more 13 comfortable in teaching about them. 14 Q. And some of these articles touch on concepts 15 in -- for next-generation sequencing, correct? 16 A. Most of these articles are related to 17 next-generation sequencing. 18 Q. And -- so when looking at the experimental 19 techniques for genomics, that lecture, what types of 20 experimental techniques do you touch on in your lecture? 21 A. That lecture focuses on methods for sequencing 22 DNA in particular.
26 1 Q. And then there's Sims in parenthesis? 2 A. I see that. 3 Q. Am I interpreting it that this the first 4 lecture of the course, at least according to this -- I 5 guess, I'll say before, Introduction to High-throughput 6 Sequencing Technologies, there is a lecture 109/05. 7 A. Introduction to High-throughput Sequencing 8 Technologies is the title of the first lecture. 9 Q. Okay. And have you given that lecture in this 10 course before? 11 A. I give that lecture when we teach this course. 12 Q. And then there are two more underlined lecture 13 titles, throughout the document; it's Lecture 2, 14 Experimental Techniques For Genomics. 15 Do you see that? 16 A. I see that. 17 Q. And then Lecture 3, Technologies for 18 Transcriptomics -- if I am pronouncing that correctly -- 19 and Regulatory Genomics. 20 Do you see that? 21 A. I see that. 22 Q. And each of those have a reading list after the	28 1 Q. And what kinds of methods for sequencing DNA? 2 A. Methods including whole genome sequencing and 3 exome sequencing. 4 Q. What do you mean by "exome"? 5 A. The exome is the part of the genome that 6 encodes exons, many of which are present in mRNA 7 transcripts that encode for protein, but not all. 8 Q. And when you're making reference to 9 experimental techniques, are you talking about 10 experimental techniques or computational techniques? 11 A. I would say that this lecture focuses on 12 experimental techniques, but alludes to computational 13 methods. Some of our experimental techniques are 14 designed with an -- analytical approaches in mind making 15 sure that the measurements are compatible with our 16 computational capabilities. 17 Q. And can you give an example of something like 18 that that you talk about in your lecture? 19 A. Exome sequencing is a good example. In exome 20 sequencing one limits the amount of data generated to a 21 small fraction of the genome, and that makes it easier 22 for computational methods to sensitively detect, for

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Tecan Ex. 2036, Page 8 of 76

IDT, Inc. v. Tecan Genomics - IPR2025-00016

29 1 example, mutations. 2 Q. And why does limiting something to a small 3 section of the genome allow for sensitively detecting 4 mutations? 5 A. Exome sequencing requires fewer sequencing 6 reads to gain sufficient coverage of the exome for 7 sensitively detecting mutations; and so it is more 8 tractable to very deeply sequence the exome from an 9 economic standpoint than to deeply sequence the entire 10 genome. 11 Although, I will say that sequencing costs are 12 decreasing really fast and this will not be true for 13 much longer. 14 Q. Understood. 15 MS. CIPRIANO: Okay. You can put that 16 to the side. 17 Q. So in paragraph 7 of your declaration, you 18 state: 19 "I have frequently developed and 20 employed library construction and computational 21 methods for single-cell analysis that 22 incorporate UMIs."	31 1 and information from a target sequence such as its 2 alignment position on the genome. 3 Q. Now, have you used UMIs outside the -- sorry. 4 Let me start over. 5 You've said that you most frequently 6 incorporate UMIs for single-cell sequencing experiments. 7 Do you use UMIs for any other type of 8 sequencing experiments? 9 A. I have used UMIs for other experiments where we 10 were not sequencing individual cells, but we were 11 sequencing from a sample that was really small, and so a 12 lot of amplification was required to construct a library 13 for sequencing. 14 Q. And so, in that context, are UMIs particularly 15 helpful when a lot of amplification is required to 16 construct a library for sequencing? 17 A. UMIs are very helpful when a lot of 18 amplification is required. 19 Q. And why is that? 20 A. Amplification can lead to certain types of 21 artifacts that are readily corrected by UMIs -- by 22 analysis of UMIs.
30 1 And that's the last sentence of -- or 2 the most of the last sentence of paragraph 7. 3 Do you see that? 4 A. I see that. 5 Q. When you refer to UMI in this sentence, what do 6 you mean? 7 A. UMI stands for unique molecular identifier. 8 I'm referring to a broad class of methods for 9 identifying, for example, PCR duplicates in a -- among 10 sequencing reads. 11 Q. And you say it's a "broad class." Can you give 12 me some examples of instances where you've incorporated 13 UMIs? 14 A. In my own research, I most frequently 15 incorporate UMIs for single-cell sequencing experiments. 16 Q. And when you say "incorporate UMI," what -- 17 what is the UMI that you are referring to when you say, 18 "incorporated into UMI single-cell sequencing 19 experiments"? 20 A. It is very application specific, but we 21 frequently define a unique molecular identifier using a 22 combination of a molecular tag, which is a DNA sequence,	32 1 Q. And what do you mean by "artifacts"? 2 A. Amplification can bias the relative proportion 3 of certain nucleic acid fragments in a sequencing 4 library. And during PCR, DNA polymerase can make 5 mistakes in copying DNA that leads the incorporation of 6 mutations. 7 Q. So I'd like to break that down and make sure 8 that we're speaking the same language. 9 When you say bias the relative proportion of 10 certain nucleic acids in the sequencing library, what do 11 you mean, and what happens in that bias? 12 A. In a PCR reaction, some nucleic acid fragments 13 might be amplified more efficiently than others even 14 though their relative proportion in the original sample 15 might be very similar. 16 Q. And the other example you gave was that DNA 17 polymerase can make a mistake in copying DNA. 18 What happens there to cause -- to cause 19 problems? 20 A. When DNA polymerase extends a primer, it 21 incorporates nucleotides one at a time, and occasionally 22 it will incorporate the wrong nucleotide -- for example,

33 1 one that is not complementary to the corresponding base 2 in the template strand. 3 Q. So that creates an error, correct? 4 A. We often refer to those as errors -- for 5 example, substitution errors. 6 Q. But do all DNA polymerases used in DNA 7 sequencing and amplification cause these errors? 8 A. Some are better than others, but to my 9 knowledge, all of them cause errors with some frequency. 10 Q. And would you agree that the concept that DNA 11 polymerases cause errors in -- in copying DNA, that 12 concept was known by 2011? 13 A. That concept was known by 2011. 14 Q. Okay. So I'd like to turn to some of the 15 background that you set forth in your declaration. And 16 here we're -- many of the paragraphs I'm going to be 17 talking about are in the first chunk of the substance of 18 your declaration starting at paragraph 19. But just so 19 we're on the same page -- and I don't know if it you've 20 done the comparison, but we tried to. 21 Paragraphs 19 through 96 appear to be the same 22 in both declarations? If you could just page through	35 1 understanding of the legal concepts at issue in these 2 proceedings? 3 A. These reflect my understanding of the legal 4 concepts that are important to these proceedings. 5 Q. And so if you could turn to paragraph 22, I'd 6 like to look at the second sentence of paragraph 22. It 7 says: 8 "In this regard, I understand that the 9 question for anticipation is what the POSA 10 would understand based on the teachings of the 11 prior art reference and not what the authors or 12 inventors of the prior art actually did in the 13 laboratory." 14 Do you see that? 15 A. I see that. 16 Q. What do you mean by "not what the authors or 17 inventors of the prior art actually did in the 18 laboratory"? 19 A. For example, my understanding is that I am 20 supposed to read a piece of prior art and interpret that 21 prior art for myself based on what is written there. 22 Q. So when you're talking about anticipation, if
34 1 and confirm. 2 A. They appear to be very similar, if not 3 identical. 4 Q. Okay. After -- after paragraph 96 in Exhibit 5 1079 and 1085, I think there's a difference for after -- 6 if I talk about paragraphs after that, I'll try to make 7 sure that I'm specific in which declaration I'm talking 8 about. But just so we're on the same page, if I refer 9 to a paragraph before 96 or between 19 and 96, can we 10 agree that it applies to both declarations? 11 A. I'm fine with that. 12 Q. Okay. So for ease of reference, I'm going to 13 be looking at the declaration that's Exhibit 1079, just 14 so we're on the same page. 15 So starting at paragraph 19, you have a section 16 entitled "Legal Standards." 17 Do you see that? 18 A. I see that. 19 Q. And these were provided by counsel; is that 20 accurate? 21 A. These were provided by counsel. 22 Q. And does this section accurately set forth your	36 1 the authors or inventors of the prior art didn't do 2 something or didn't report something in their paper, is 3 your understanding that you can fill in those gaps? 4 MR. FLETCHER: Objection. Form 5 A. I think the key aspect of this statement is 6 POSA. A POSA is someone who has a breadth of experience 7 that allows him or her to interpret the prior art 8 drawing on that experience. 9 So, for example, in a research article, there 10 may be certain measurements that are taken, and a POSA 11 would understand what could be gleaned from those 12 measurements even when not explicitly stated. A 13 reference can teach certain aspects that can be gleaned 14 in light of the POSA's breadth of understanding. 15 Q. So when you say "not what the authors or 16 inventors of the prior art actually did in their 17 laboratory," you're talking about the reasonable 18 inferences that a POSA would make based on the 19 disclosure; is that accurate? 20 MR. FLETCHER: Objection. 21 A. Can you please repeat the question? 22 Q. Sure. And I just want to -- what I'm getting

37 1 at is I'm trying to understand what information -- what 2 information you're referring to by this "not what the 3 authors or inventors of the prior art actually did." 4 What information are you pulling in in addition 5 to actually what's on the paper or what they did in the 6 reference? 7 MR. FLETCHER: Objection. 8 A. If the authors of a reference say that they 9 employed a specific technique, I know what information 10 can be gleaned from using that technique. 11 Q. Okay. Thanks for that clarification. 12 So if we could turn the page and look at the 13 section that starts with paragraph 31, there's a section 14 that is titled "DNA." 15 Do you see that? 16 A. I see that. I see that. 17 Q. And then the next section, section B that 18 starts with paragraph 39, is a section that starts 19 "RNA"? 20 A. I see that. 21 Q. Would you agree that DNA and RNA serve 22 different functions in a cell?	39 1 functions"-- or "regulatory functions," how -- can you 2 give me some examples of how that works? 3 A. There are proteins called transcription factors 4 that regulate the transcription of coding regions. They 5 often bind to sequences in non-coding regions of the 6 genome in order to perform this function. 7 Q. So when we think about the part of DNA that 8 encodes for -- let's just think about it as a single 9 protein, one gene. 10 The coding regions are not continuous in one 11 section; is that accurate? 12 A. In higher organisms, like mammals, coding 13 sequences include both exons and introns. The exons are 14 often coding for protein. The introns are often removed 15 prior to protein synthesis. In lower organisms, 16 continuous coding regions are more common. 17 Q. I appreciate that distinction. And I'll try to 18 be more specific in my questions. 19 So just to be clear, you say in higher 20 organisms, coding sequences include both exons and 21 introns, and those are interspersed with each other; is 22 that accurate?
38 1 A. DNA and RNA serve different functions in a 2 cell. 3 Q. And what is the function of DNA? In a broad 4 sense? We could speak for days on that. 5 A. DNA stores information about how to make and 6 regulate, for example, protein. RNA serves as a conduit 7 between the information on the genome and the synthesis 8 of protein, among other things. 9 Q. So for reference, this is in -- I'm going to 10 refer to paragraph 33, but you could probably talk about 11 this in your sleep. 12 You agree that DNA contains coding and 13 non-coding regions, right? 14 A. DNA codes -- I'm sorry. DNA contains both 15 coding and non-coding regions. 16 Q. And what's the difference between coding and 17 non-coding regions? 18 A. As stated in paragraph 33, coding regions 19 contain instructions for building cellular proteins, and 20 non-coding regions do not contain such information but 21 certainly regulatory functions. 22 Q. And when you say, "serve regulating	40 1 A. That is accurate. 2 Q. And so if you sequenced what we're talking 3 about -- one piece of DNA that includes both exons and 4 introns -- the resulting sequence would include both 5 sections that coded for proteins and sections that do 6 not code for proteins, correct? 7 A. That is correct. 8 Q. Are there reasons why a scientist would want to 9 sequence non-coding regions? 10 A. There are many reasons. Non-coding regions 11 often contain important sequences for regulating gene 12 expression; as a result, mutations in non-coding regions 13 can have important effects on gene expression. 14 Q. So when we refer to RNA, RNA is not just a -- 15 let me step back. 16 There are many different types of RNA, correct? 17 A. There are many types of RNA. 18 Q. And what are the common types of RNA found in a 19 cell? 20 A. In paragraph 40 of my declaration, there's a 21 non-exhaustive list that includes ribosomal RNA, 22 transfer RNA, and messenger RNA, but there are also many

Conducted on June 26, 2025

41 1 types of non-coding RNAs such as microRNAs. 2 Q. So for the categories that you list here, what 3 is the function of ribosomal RNA in a cell? Let me 4 rephrase that question so we can be a little more 5 specific. 6 What is the function of ribosomal RNA in a 7 mammalian cell? 8 A. Ribosomal RNA is an important structural 9 feature of the ribosome, but, importantly, it also 10 contains the catalytic domain of the ribosome; thus, it 11 plays a crucial role in the synthesis of protein. 12 Q. And what is the role of transfer RNA in 13 mammalian cells? 14 A. Transfer RNAs serve as a link between mRNA, 15 messenger RNA, and protein. They can interact with mRNA 16 in a sequence-specific manner, and they are also 17 attached to amino acids that are the building blocks of 18 protein. And so the ribosome uses transfer RNA in the 19 synthesis of protein from messenger RNA. 20 Q. And what is the role of messenger RNA in 21 mammalian cells? 22 A. The principal role of messenger RNA in	43 1 that are in DNA in general, right? 2 A. There is a molecule called pre-mRNA that 3 includes introns. Usually mRNA, in its mature form, 4 does not include introns, but not always. 5 Q. Thank you. 6 And in your answer, I think you said that many 7 or most MRNAs have a poly(A) tail; is that accurate? 8 A. Most MRNAs have a poly(A) tail in higher 9 organisms like mammals. 10 Q. And what is the purpose of a poly(A) tail? 11 A. This is a subject of active research, but the 12 poly(A) tail plays roles in mRNA stability and the 13 efficiency of protein synthesis from mRNA. 14 Q. So in parts of your declaration, you refer to 15 the poly(A) region of mRNA as a homopolymer. 16 Do you recall that? 17 A. I recall that. 18 Q. What does the term "homopolymer" mean? 19 A. A homopolymer is a nucleic acid sequence in 20 which the same nucleotide occurs more than once in a 21 row. For example, TTT would be a three-nucleotide 22 polymer.
42 1 mammalian cells is to present sequences from the genome 2 to the ribosome so that it can synthesize protein based 3 on that information. 4 Q. And messenger RNA is often referred to as mRNA; 5 is that accurate? 6 A. That is correct. 7 Q. Is it accurate that the mRNA in a mammalian 8 cell only contains coding regions of genetic material? 9 A. There are components of mRNA that do not encode 10 protein. 11 Q. And what are those components that do not 12 encode protein? 13 A. One component is the UTRs or untranslated 14 regions. They occur on the 3' and 5' ends of an mRNA. 15 Some MRNAs also have a poly(A) tail on their 3' end that 16 does not encode protein. 17 Q. So other than the UTRs and the poly(A) tail, 18 does the rest of material of mRNA, does that represent 19 coding, genetic material? 20 A. That is usually the case. 21 Q. So -- and this probably confuses vocabulary, 22 but in simplest terms, mRNA does not include the introns	44 1 Q. Is there an average length of a poly(A) tail? 2 A. Poly(A) tails undoubtedly have an average 3 length. There have been many attempts to measure the 4 length of a poly(A) tail. To my knowledge, poly(A) 5 tails are typically on the order of a couple hundred 6 bases long. 7 Q. Now, when you are looking to sequence mRNA, 8 would the goal or would one of the goals of that 9 sequencing be to sequence -- let me -- let me rephrase 10 my question to make it a little clearer. 11 Other than the specific study of poly(A) tails 12 when you're looking at the sequence of mRNA, do you 13 typically include the full poly(A) tail in the 14 sequencing library? 15 MR. FLETCHER: Objection. 16 A. Some library construction methods result in 17 inclusion of long stretches of poly(A) tails in the 18 final sequencing library. Some methods do this on 19 purpose; sometimes it happens spuriously. There are 20 certain applications where the poly(A) tail is very 21 important. 22 Q. And what are those applications where the

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

45 1 poly(A) tail is important? 2 A. The poly(A) tail is very important for studies 3 that are attempting to assemble mRNAs from an organism 4 for which there is no reference transcriptome. 5 Q. So let's break this down. How -- how do 6 studies assemble mRNAs when there is no reference 7 transcriptome? 8 A. Studies that use next-generation sequencing for 9 transcriptome assembly, will often generate cDNA 10 libraries from mRNA, fragment those libraries, sequence 11 the resulting fragments and then use computer algorithms 12 that can make inferences about how those smaller 13 fragments were assembled in the original mRNA sample. 14 It's sort of like doing a puzzle. 15 Q. And why is the poly(A) tail important in that 16 compilation? 17 A. Going back to my puzzle analogy, detecting the 18 poly(A) tail is sort of like finding the corner piece. 19 You know that you're looking at the 3' end of an mRNA. 20 Q. And how much of the poly(A) tail do you need to 21 know in your analogy that you have the corner piece? 22 A. I haven't formed a carefully considered opinion	47 1 that do not require cDNA synthesis. 2 Q. Do next-generation sequencing methods require 3 RNA to be converted into cDNA? 4 A. It depends on how you define next-generation 5 sequencing. If one thinks of it as the generation of 6 sequencing technologies that came after Sanger 7 sequencing, there are two that come to mind in which 8 direct RNA sequencing has been reported. 9 There is a company called Helicos that no 10 longer exists, that developed a direct RNA sequencing 11 technology, and there is a company called Oxford 12 Nanopore that has developed a direct RNA sequencing 13 technology. 14 Q. So for sequencing on the next-generation 15 sequencers that you talk about in your declaration, 16 specifically the 454, the Illumina and Ion Torrent, 17 would you need to convert RNA to cDNA to sequence on 18 those machines? 19 A. To my knowledge, converting RNA into cDNA is 20 necessary for RNA sequencing on those instruments. 21 Q. Excuse me. So I'd like to talk a little bit 22 about what you refer to as PCR.
46 1 on that subject, but one does not need to sequence the 2 entire poly(A) tail. 3 MS. CIPRIANO: It might be good for a 4 quick break time. 5 MR. FLETCHER: Sure, we can go off the 6 record. 7 (Whereupon, a short break was taken.) 8 BY MS. CIPRIANO: 9 Q. Okay. So I'd like to turn -- we were talking 10 about RNA, and I'd like to talk a little bit about RNA 11 sequencing. And I'm looking at -- there's a section 12 entitled "RNA Sequencing" at paragraph 30 -- excuse me 13 paragraph 60 in your declaration. 14 A. Okay. 15 Q. But my questions are probably more general than 16 is necessary here. But you state: 17 "To sequence RNA, scientists use 18 reverse transcriptase to convert RNA into 19 cDNA." 20 Is that always required for RNA 21 sequencing? 22 A. There are methods for direct RNA sequencing	48 1 PCR stands for polymerase chain reaction; is 2 that accurate? 3 A. PCR stands for polymerase chain reaction. 4 Q. And so I'm looking at paragraph 71 and 72 of 5 your declarations. You explain two ways PCR can amplify 6 particular regions of genetic material. 7 Do you see that? 8 A. I see that. 9 Q. And in paragraph 71, you explain that you can 10 use primers designed to bind to known sequences in front 11 and behind of the portion that you want to amplify, 12 right? 13 A. Paragraph 71 describes the use of primers, 14 specific to known sequences that are upstream and 15 downstream of the desired target. 16 Q. And in your declarations, you explain that 17 there's a directionality typically assigned to portions 18 of nucleic acids; is that accurate? 19 A. Nucleic acids have a 5' and a 3' end. 20 Q. So when you say "upstream," that is toward the 21 5' end; is that accurate? 22 A. It's a little tricky, because some nucleic

49 1 acids are double-stranded and so -- 2 Q. Okay. 3 A. -- upstream and downstream doesn't always mean 4 exactly that. 5 Q. So just so we're on the same page, when you 6 refer to upstream and downstream in paragraph 71, that 7 is referring to areas of the nucleic acid that surround 8 or are on either side of a particular target region; is 9 that fair? 10 A. Upstream and downstream regions might flank the 11 desired target region. 12 Q. Is there a situation where they wouldn't flank 13 a desired target region? 14 A. In some cases, the primers are complimentary to 15 sequences that are included in the target region, in 16 which case, those sequences are actually part of the 17 target region. 18 Q. Okay. So in paragraph 71, the PCR that -- PCR 19 process that you're talking about there, that is using 20 two primers directed to sequences that are known; is 21 that accurate? 22 Let me clarify just one thing. So the PCR	51 1 include scenarios where the primers are directed to 2 known sequences on the nucleic acid that you're 3 attempting to sequence, correct? 4 A. The primers referred to in paragraph 71 can be 5 complimentary to known sequences on the nucleic acid 6 fragment that you were trying to sequence. 7 Q. And in paragraph 72, you talk about the use of 8 adapters and -- I guess let's pause there, what do you 9 mean by "adapters" in paragraph 72? 10 A. Adapters are typically synthetic 11 oligonucleotides with a known sequence that can be 12 incorporated into a library of nucleic acid fragments by 13 a variety of methods. 14 Q. So in the PCR reactions that you are discussing 15 in paragraph 72, you say: 16 "PCR can also involve ligating adapters 17 with a phrase 'to both ends of each fragment.'" 18 So to think about it conceptually, you 19 have a sample full of fragments and the 20 adapters are introduced to basically stick 21 around both ends; is that accurate? 22 A. Paragraph 72 refers to the ligation of adapters
50 1 process that you're talking about in paragraph 71, that 2 is using two primers directed to sequences within the 3 genome that are known; is that right? 4 A. Paragraph 71 makes no reference to a genome, 5 but it does refer to primers that are specific to known 6 sequences. 7 Q. Okay. So let's put paragraph 72 in the mix 8 just because I think that it might make it easier to 9 talk about this in general. 10 Paragraph 72 talks about using PCR where 11 adapters have been ligated to the sequence, right? 12 A. Paragraph 72 refers to ligation of adapters to 13 a sequence. 14 Q. So to put paragraph 71 and 72 in context, 15 paragraph 71 could include scenarios where the primers 16 used in the PCR reaction are to known sequences on the 17 nucleotide that you are -- for the nucleic acid that 18 you're trying to sequence, right? 19 A. Can you please repeat the question? 20 Q. Yes, absolutely. I think I confused myself. 21 So paragraph 71, you talk about PCR with 22 primers specific to known sequences. And that can	52 1 to either end of a set of nucleic acid fragments. 2 Q. And if you're using adapters to facilitate a 3 PCR reaction, is it accurate that the goal would be that 4 all of the fragments get adapters attached to them? 5 MR. FLETCHER: Objection. 6 A. That is not the case in every application. 7 Q. Okay. And in what applications would you not 8 want adapters attached to all of the fragments in a 9 sample? 10 A. There are many such situations. There may be 11 nucleic acid fragments in a sample that are not to be 12 sequenced or amplified in that sample, and so adapter 13 ligation to those sequences might be undesirable. 14 There are situations where certain nucleic acid 15 fragments may already have appropriate adapters attached 16 to them, in which case, adding additional ones would be 17 problematic for some reason. 18 Q. After the section that you talk about -- after 19 the PCR section, you have a section that's included 20 "anchored PCR and genome mocking." 21 Do you see that? 22 A. I see that.

53 1 Q. Now, these are sequencing technologies that 2 were in use before the development of next-generation 3 sequencing; is that accurate? 4 A. That is correct. Many of the key references 5 are in the 1990s. 6 Q. So in paragraph 76 of your declaration, you 7 refer to a paper by Siebert. 8 Do you recall that? 9 A. I recall that. 10 Q. And that describes a method you refer to as 11 "genome walking," right? 12 A. That's right. 13 Q. And then I'm looking ahead at page 78. As you 14 describe it, Siebert's method uses a single 15 gene-specific primer and a nongene specific primer to 16 target an unknown sequence. 17 Is that your understanding of what that paper 18 described? 19 A. Siebert described methods for PCR amplification 20 of loci on the genome with both known and unknown 21 sequences. 22 Q. And in that method of amplification described	55 1 genetic sequence between the adapter on one end 2 and the known genetic sequence on the other end 3 of each fragment." 4 Do you see that? 5 A. I see that. 6 Q. What do you mean by "selectively amplify" here? 7 A. The authors were using PCR to cause 8 overrepresentation of certain sequences relative to 9 others in a sample. 10 Q. And how was that accomplished in Siebert? 11 A. Through Watson-Crick base pairing of the 12 gene-specific primer to a known genetic sequence, the 13 activity of DNA polymerase in the PCR reaction was 14 biased towards the sequence downstream of that primer. 15 Q. Can you explain what you mean by "the activity 16 of the DNA polymerase in the PCR reaction was biased 17 towards the sequence downstream of that primer"? 18 A. The design of the PCR reactions in Siebert made 19 it more likely that DNA polymerase would copy sequences 20 downstream of the gene-specific primer. 21 Q. And when you're talking about the design of the 22 PCR reactions, the purpose of the primers here is to get
54 1 in Siebert, they used one gene-specific primer, correct? 2 A. Siebert's method included the use of 3 gene-specific primers. 4 Q. So in paragraph 78 you have a sentence: 5 "The authors then introduced a 6 gene-specific primer, white arrow below, 7 complementary to a known sequence in the 8 genomic DNA, white box below, and a primer with 9 the sequence of the longer 5' ligated adapter." 10 Do you see that? 11 A. I see that. 12 Q. And is it correct to interpret that you're 13 saying they used one gene-specific primer and one 14 nongene specific primer in doing the PCR amplification? 15 MR. FLETCHER: Objection. 16 A. For amplification of a specific locus on the 17 genome, Siebert would use a gene-specific primer and an 18 adapter-specific primer. 19 Q. And in the next sentence, paragraph 78, you 20 state that -- well, the sentence reads: 21 "The authors then used PCR with those 22 two primers to selectively amplify the unknown	56 1 DNA polymerase to bind to those sections and copy that 2 section of the nucleic acid; is that accurate? 3 A. The purpose of the gene-specific primer is to 4 facilitate primer extension by DNA polymerase of the 5 sequence downstream of the primer. 6 Q. So sequences in the sample that Siebert used 7 that did not have a sequence complementary to the 8 gene-specific primer would be less likely to be copied 9 in that reaction -- in that PCR reaction, correct? 10 A. That is not strictly the case. There could be 11 sequences with partial complementary to the 12 gene-specific primer that are easy for the polymerase to 13 amplify that could also get copied efficiently. 14 Q. So what about the design of the PCR reaction in 15 Siebert made it more likely that the DNA polymerase 16 would copy sequences downstream of the gene-specific 17 primer? 18 A. Watson-Crick base pairing to the template 19 strand. 20 Q. That's a concept that happens in -- in DNA 21 structure. That's not specific to Siebert's method, 22 right?

57 1 A. Watson-Crick base pairing is not specific to 2 Siebert's method, but he is leveraging that mechanism to 3 facilitate primer extension. 4 Q. And so sequences in Siebert's sample that do 5 not bind to the gene-specific primer are less likely to 6 be copied in the PCR reaction that Siebert did, correct? 7 A. I don't want to say less likely to be copied, 8 but PCR is designed to facilitate exponential 9 amplification. And, in Siebert, the concept is that the 10 combination of complementary to the gene-specific primer 11 and the adapter-specific primer facilitates exponential 12 amplification of certain nucleic acid fragments, but I 13 do not doubt that there are many nucleic acid fragments 14 that could also get copied to some extent in such a 15 reaction. 16 Q. Understood. 17 So to clarify, the fragments in Siebert's 18 sample that contain both the sequence of the 19 gene-specific primer and the sequence of the adapter are 20 the fragments that will undergo exponential 21 amplification in the PCR reaction, correct? 22 A. Those fragments will undergo exponential	59 1 region in cloned or uncloned genomic DNA. The 2 methods are of three types: Inverse PCR, 3 randomly primed PCR, and adapter ligation PCR." 4 Do you see that? 5 A. I see that. 6 Q. And then it goes onto say: 7 "However, these methods have not been 8 generally applied to walking in uncloned 9 genomic DNA because they are either complicated 10 or inefficient." 11 Do you see that? 12 A. I see that. 13 Q. Do you have an understanding of what the 14 authors were referring to as "complicated" and 15 "inefficient" in this sentence? 16 A. I would probably need to read the other 17 references listed there to confidently interpret that 18 statement. 19 Q. Okay. Do you have an opinion on whether 20 those -- the three methods that are listed in the 21 previous sentence -- inverse PCR, randomly primed PCR, 22 and adapter ligation PCR -- whether those are
58 1 amplification. 2 Q. And only those fragments will undergo 3 exponential amplification in Siebert's reaction; is that 4 accurate? 5 A. I wouldn't make that claim because if Siebert's 6 input nucleic acids are from genomic DNA, there are 7 innumerate 3' ends in the sample that can hybridize all 8 over the place and facilitate primer extension. But 9 Siebert is attempting to amplify exponentially 10 particular sequences of interest. 11 Q. All right. Let's -- I'd like to look at the 12 Siebert paper, and that's an exhibit that's already been 13 marked in these proceedings as 1007. 14 Do you recognize this exhibit? 15 A. I recognize this exhibit. 16 Q. And in preparing your declaration, did you 17 fully review this paper? 18 A. I read the paper in preparing my declaration. 19 Q. So at the beginning of the substance of the 20 article, it says: 21 "Several PCR base methods are available 22 for walking from a known region to an unknown	60 1 complicated or inefficient? 2 A. I would want to read those references to 3 comment on that. I'm -- I -- I can't confidently answer 4 that question without looking at the papers carefully. 5 Q. Okay. So you don't have an opinion on those 6 methods as you sit here today? 7 MR. FLETCHER: Objection. 8 A. Yeah. I haven't formed a thoughtful opinion on 9 those methods. 10 Q. So the next paragraph of Siebert discusses 11 variations on the known methods, it seems in my 12 interpretation. Just so we're on the same page, it 13 says: 14 "We have investigated the application 15 of long and accurate PCR to walking in uncloned 16 genomic DNA. We initially examined the use of 17 unpredictably primed PCR, a new method based on 18 randomly primed PCR, and Vectorette PCR, which 19 is based upon adapter ligation." 20 Do you see that? 21 A. I see that. 22 Q. Do you have an understanding of what is meant

61 1 by "unpredictably primed PCR"? 2 A. Again, that's among the references in the first 3 paragraph, and I'd need to read it to ensure that I can 4 accurately answer that question. I might surmise from 5 the phrase that comes after that it involves degenerate 6 primers. 7 Q. Do you know what is meant by "Vectorette PCR"? 8 A. I can probably guess based on the six-word 9 description that follows Vectorette PCR, but, again, I 10 would want to study the reference to answer that with 11 confidence. 12 Q. Now, the method that Siebert used in his study, 13 he describes it as combining Vectorette PCR with a newly 14 developed method termed "suppression PCR." 15 Do you have an understanding of what the 16 combination of Vectorette PCR with suppression PCR 17 means? 18 A. Based on my reading of Siebert, what's referred 19 to here is the use of adapter ligation and an approach 20 to depleting certain sequences during the course of a 21 PCR reaction. 22 Q. So looking at the third full paragraph of	63 1 Siebert applied? 2 A. I would need to review this article more 3 carefully in order to confidently answer that question. 4 I haven't read this particular article in a while. 5 Q. Given the statement that "In our hands, both 6 unpredictably primed PCR and Vectorette PCR generated 7 multiple PCR products even after nested PCR was 8 performed," you can't -- you don't have any 9 understanding of why nested PCR would impact the 10 instance that Siebert is talking about here? 11 A. Can you remind me exactly where that sentence 12 is? 13 Q. Yeah. It's the first sentence of the third 14 paragraph of the article. 15 A. Let me read that. 16 My understanding of this paragraph is that 17 Siebert is referring to a nested PCR reaction that 18 generated multiple PCR products and some of these PCR 19 products were undesirable. 20 Q. Do you have an understanding of why some of the 21 products were undesirable? 22 A. This paragraph doesn't refer to any data that I
62 1 Siebert, it says: 2 "In our hands, both unpredictably 3 primed PCR and Vectorette PCR generated 4 multiple PCR products even after nested PCR was 5 performed." 6 Do you see that? 7 A. I see that. 8 Q. Do you have an understanding of what nested PCR 9 is? 10 A. There are many different implementations of 11 nested PCR. One example would be the use of more than 12 one forward primer in the amplification of nucleic acid 13 fragments. 14 Q. And what is the purpose in nested PCR in the 15 example that you gave of having more than one forward 16 primer in the amplification of nucleic acid fragments? 17 A. The objective of nested PCR is very application 18 specific. In some cases, nested PCR is used to enhance 19 the specificity with which certain target nucleic acids 20 are amplified. 21 Q. And based on your understanding of that Siebert 22 article, is that the objective of nested PCR that	64 1 can see, so there's very limited information here for me 2 to specifically comment. But Siebert may have been 3 attempting to amplify certain nucleic acid fragments, 4 and if some nucleic acid fragments that were not 5 targeted were also amplified, this could complicate 6 downstream analysis of the sample. 7 Q. Is it fair to say that the nested PCR reference 8 in that first sentence of the third paragraph was an 9 attempt to reduce the undesirable PCR products in the 10 reaction? 11 A. There's very little information about this 12 reaction described in the paper. A lot of times, when 13 the author refers to something that was done "in our 14 hands," they're often not showing the data or giving 15 sufficient detail. So having done a lot of PCR 16 reactions, I would want to look at those details myself 17 before making a strong claim about that. 18 Q. Okay. In the next sentence, Siebert says: 19 "Although, upon analysis, some of the 20 PCR products were found to be derived from 21 successful walks, the presence of multiple PCR 22 products would complicate further

65 1 characterization without Southern blot 2 hybridization or extensive cloning." 3 Do you see that? 4 A. I see that. 5 Q. And do you have an understanding of why the 6 multiple PCR products would complicate further 7 characterization? 8 A. My understanding of that paragraph is that the 9 multiple PCR products, which would be mixed together at 10 the end of the PCR reaction, would require additional 11 purification processes to purify them from each other. 12 Q. And what would be the need for the 13 purification? 14 A. There are many possible applications of such 15 PCR products. For example, if one wanted to sequence 16 the PCR products in 1995, they would need to be pure. 17 Q. Now was that still the case in 2011 with the 18 advancement of next-generation sequencing? 19 A. Next-generation sequencing enables sequencing 20 from mixtures of nucleic acids. 21 Q. Is there benefits in next-generation sequencing 22 to having a more pure sample?	67 1 In the next paragraph, so it's the fourth 2 paragraph: 3 "We have improved upon the adaptor 4 ligation method by combining Vectorette PCR 5 with a newly developed method termed 6 'suppression PCR.'" 7 Do you have an understanding of how 8 Siebert's suppression PCR method works? 9 A. During the PCR reactions described by Siebert, 10 certain nucleic acid fragments form hairpin structures. 11 He refers to them as panhandle structures, that reduce 12 the efficiency with which those nucleic acid fragments 13 are amplified. 14 Q. So in the second page of Siebert, and I'm 15 looking at the third paragraph from the end in the 16 right-hand column, he states: 17 "We have found that the high 18 specificity of the method described is 19 primarily due to the suppression effect of the 20 adaptor/adaptor primer combination; although in 21 some cases additionally having an amine group 22 in the lower strand of the adapter (Vectorette
66 1 A. This is entirely application-specific. There 2 are many cases where we try to make samples that have as 3 much breadth as possible, very complex mixtures of 4 nucleic acids; other cases where we might be interested 5 in particular nucleic acids. 6 Q. So in instances where you're interested in 7 particular nucleic acids, are there benefits to the 8 sample being more pure for that particular nucleic acid? 9 A. One benefit might be reduced cost. 10 Q. Are there other benefits? 11 A. Other benefits include higher coverage for the 12 purposes of mutation detection. 13 Q. And what do you mean by "higher coverage"? 14 A. Coverage is the number of reads that traverses 15 a specific nucleotide position. 16 Q. Are there any other benefits that you can think 17 of? 18 A. In certain app -- excuse me, in certain 19 applications, computational analysis of the resulting 20 data could be simpler. 21 Q. Okay. So turning back to Siebert. Siebert 22 reports -- let me make sure I can find it.	68 1 blocking) yielded better results." 2 Do you see that? 3 A. I see that. 4 Q. So Siebert found that his PCR suppression 5 method was necessary to fix some of the non-specific 6 nature of the PCR reaction he used. 7 Is that fair? 8 A. The suppression effect plays a role in the 9 specificity of the PCR reaction. 10 Q. Well, Siebert said that the suppression effect 11 was the primary driver of specificity, right? 12 A. I see that Siebert attributes the suppression 13 effect as the primary driver of the high specificity. 14 But a POSA would understand, and I'm sure Siebert would 15 understand that primer designer is very important as 16 well. 17 Siebert could have used primers that 18 facilitated a suppression effect and also gave poor 19 specificity. 20 Q. Can you explain what you mean by that last 21 statement? 22 A. What I think Siebert means here is that given

69 1 the proper design of the primers and adaptors, the 2 suppression effect is really critical to the results 3 that were achieved. You could design this experiment so 4 that it wouldn't work very well also. 5 Q. Understood. Understood. 6 MS. CIPRIANO: I'd like to look at 7 another paper, one that might be a little more 8 familiar with you. So we'll mark this as 9 Exhibit 2023. 10 MR. FLETCHER: Counsel, this is the 11 same as one of the exhibits cited in the 12 petition, I believe. 13 MS. CIPRIANO: It is? 14 MR. FLETCHER: Perhaps not. Perhaps 15 I'm mistaken, okay. Exhibit 2023? 16 MS. CIPRIANO: Well, let's 17 double-check. If it is, that was inadvertent. 18 THE WITNESS: I have removed my 19 glasses, so until it comes to me. 20 MS. CIPRIANO: Oh, is it? 21 MR. FLETCHER: I believe it's Exhibit 22 1030.	71 1 A. I see that. 2 Q. What do you mean by "digital RNA sequencing"? 3 A. There was an older technique called digital 4 PCR, that usually did not use sequencing as a readout. 5 But it was also useful for accurately quantifying 6 nucleic acids, and so we were drawing an analogy to 7 digital PCR in naming this method digital RNA 8 sequencing. 9 Q. And so can you explain what digital PCR means? 10 A. Digital PCR uses a method called limiting 11 dilution in which individual nucleic acid fragments are 12 distributed into containers, such that they can each be 13 amplified individually and separately from each other. 14 This serves to mitigate certain artifacts in 15 quantifying those individual nucleic acid fragments that 16 can occur when they're amplified together in a mixture. 17 Q. And can you explain what you mean by 18 "artifacts"? 19 A. For example, DNA polymerase might amplify some 20 molecules of DNA more efficiently than others. And in 21 certain applications, this is undesirable. 22 Q. So I guess I don't quite understand your answer
70 1 MS. CIPRIANO: 1030? 2 MR. FLETCHER: Yeah, that's fine. 3 MS. CIPRIANO: Okay, then we don't need 4 to mark it. Sorry. It's just an oversight. 5 THE WITNESS: Oh, yeah. 6 MS. CIPRIANO: So it's a paper that's 7 already been marked Exhibit 1030. Thank you 8 for that catch. 9 BY MS. CIPRIANO: 10 Q. So do you recognize Exhibit 1030? 11 A. I recognize Exhibit 1030. 12 Q. And you were a coauthor of this paper; is that 13 accurate? 14 A. I am a coauthor of this paper. 15 Q. And at a high level, what is the focus of the 16 work recorded in this paper? 17 A. The paper reports a barcoding and 18 next-generation sequencing strategy for accurate 19 quantification of RNA from a sample. 20 Q. And the title starts with "Digital RNA 21 Sequencing." 22 Do you see that?	72 1 as it refers to the term "artifacts." How is the 2 amplification of certain molecules more efficiently than 3 others in artifacts in the context that you use that 4 term? 5 A. In Figure 1A of the paper, there's a cartoon 6 illustration of what I mean. I'll use that to explain. 7 Q. Okay. 8 A. In this illustration, there's an original 9 sample that has three copies of cDNA molecule, a cDNA 1 10 and two copies of cDNA 2. 11 After amplification, there are nine amplicons 12 corresponding to cDNA 1 and 12 amplicons corresponding 13 to cDNA 2. So the relative abundance of those two cDNA 14 species is actually flipped. Now, cDNA 2 is more 15 abundant than cDNA 1, presumably because cDNA 2 was more 16 efficiently amplified; even though it was less abundant 17 in the original sample. 18 Q. So if we're looking for a definition of the 19 term artifact as it's used in this context, would you 20 agree that it means an anomaly or an error in the data 21 that doesn't reflect the original sample? 22 MR. FLETCHER: Objection.

73 1 A. PCR can distort the relative abundance of 2 nucleic acid fragments, relative to their original 3 relative abundance in the sample. 4 Q. So this difference in relative abundance is 5 that the only example that you would catalog as an 6 artifact of the process? 7 MR. FLETCHER: Objection. 8 A. DNA polymerases used in PCR can also insert 9 substitution errors into PCR products. Sometimes they 10 make mistakes and incorporate the wrong nucleotide 11 during primer extension. 12 Q. And that would also be termed an artifact? 13 A. One could refer to those PCR-induced mutations 14 as artifacts or errors. 15 Q. So you've given two examples of scenarios that 16 could be artifacts. 17 Are there any others that you can think of that 18 would be categorized as an artifact? 19 A. PCR can lead to spurious recombination of 20 nucleic acids. So two nucleic acids that are not 21 attached to each other in the original sample might 22 become attached to each other during a PCR reaction.	75 1 to try to clarify its meaning. 2 Q. Well, you used it in reference to this paper. 3 Is that the only way that you use the term 4 "artifact" in your everyday work? 5 A. It's not the only way what I use the term 6 artifact in my everyday work. It's a commonly used 7 phrase or term. 8 Q. So in the way that you use it, in your everyday 9 work, what does it mean? 10 MR. FLETCHER: Objection. 11 A. In the lab, we use a number of techniques to 12 make measurements, and sometimes the observations that 13 we make with those techniques are caused by limitations 14 of those techniques and don't reflect what we're trying 15 to actually measure. Those would be examples of 16 artifacts. 17 Q. And so to the extent it's helpful to answer 18 your question, if you look at paragraph 7 of your 19 declaration, in the last two sentences you refer to 20 artifacts? 21 A. I see that. 22 Q. And your reference is to -- I'm looking at the
74 1 Q. So is it fair to say that, if we're trying to 2 create a definition of the term artifact as you used it 3 in the term "mitigating certain artifacts," that it's 4 instances that occur in the final sample that is 5 sequenced that do not appear in the original sample? 6 MR. FLETCHER: Objection. 7 A. Can you please repeat the question? 8 Q. Sure. 9 Let me rephrase it and turn it around to you. 10 When I've asked for a definition of the term 11 artifact, you've given me certain examples. But can you 12 give me a definition of the term artifact as you used it 13 when talking about how digital PCR can mitigate certain 14 artifacts? 15 A. The reference to digital PCR in this paper is 16 particularly related to the type of artifact shown in 17 Figure 1A. 18 Q. Are you able to give me a definition of the 19 term artifact as you use it in your declaration and in 20 your work? 21 A. If you can point me to a specific place in my 22 declaration where I used the word "artifact," I'm happy	76 1 last two sentences of paragraph 7: 2 "PCR can result in artifacts that 3 reduce the accuracy of nucleic acid 4 quantification and mutational analysis. 5 To mitigate these artifacts, I have 6 frequently developed an important library 7 construction and computational methods for 8 single-cell analysis that incorporate UMIs." 9 So when you use artifacts in these two 10 sentences, are you referring to the 11 observations that are caused by limitations in 12 the techniques you are using that don't reflect 13 what you're trying to actually measure? 14 A. For example, the use of the term artifact in 15 the first sentence, where it says, "PCR can result in 16 artifacts that reduce the accuracy of nucleic acid 17 quantification," that's a direct reference to the type 18 of artifact that's illustrated in Figure 1A of the 19 Shiroguchi et al., paper. 20 So PCR can distort the relative abundance of 21 nucleic acids in a sample, and we use, as it states 22 here, library construction and computational methods

77 1 that incorporate UMIs to mitigate those artifacts. 2 Q. So after nucleic acid quantification, there is 3 end mutational analysis. 4 So the artifacts that you are referring to are 5 not limited to the distortion in the relative abundances 6 reflected in your paper, correct? 7 A. PCR can also result in artifacts that impact 8 mutational analysis and library construction, and 9 computational methods that incorporate UMIs can also 10 serve to mitigate those types of artifacts. 11 Q. So sitting here today, you can't give me a 12 definition of what you mean by artifacts? 13 MR. FLETCHER: Objection. 14 Q. You've given me examples, but can you give me a 15 definition? 16 MR. FLETCHER: Objection. 17 A. The word "artifact" is extremely context 18 dependent, and so that's why I am limiting the way in 19 which I use it to these specific examples. I think I 20 have accurately described my perspective on the word 21 "artifact." 22 Q. So if we look at your paper, in the second	79 1 A. By stochastic I mean random. 2 Q. So a little bit further down in that same 3 paragraph -- I guess it's the second sentence from the 4 end -- the paper states "other methods." 5 Do you see the sentence starting -- 6 A. I see that. 7 Q. "Other methods reduce bias in RNA seq by 8 eliminating PCR and directly sequencing single molecules 9 of RNA or sequencing single clonal populations of cDNA." 10 Do you see that? 11 A. I see that. 12 Q. So how do these methods reduce bias in the RNA 13 seq? 14 A. PCR can distort the relative abundance of 15 nucleic acid fragments in a sample. These methods forgo 16 PCR. They sequence the molecules from the sample 17 directly. 18 MS. CIPRIANO: Okay. I think I'm done 19 with this paper, and it might be a good time to 20 break for lunch. 21 MR. FLETCHER: Yes, lunch is ready. 22 Thank you.
78 1 paragraph after the abstract, that sentence reads: 2 "The interpretation of conventional RNA 3 seq is complicated by sequence-dependent bias 4 and amplification noise from reverse 5 transcription adaptor ligation library 6 amplification by PCR solid-phase clonal 7 amplification and sequencing." 8 Do you see that? 9 A. I see that. 10 Q. And do you have an understanding as to what's 11 meant by "amplification noise" here? 12 A. In this sentence we're drawing a contrast 13 between sequence-dependant bias and amplification noise 14 to distinguish two different situations, one in which 15 DNA polymerase acts with different efficiency on nucleic 16 acid fragments with different sequences and another in 17 which DNA polymerase stochastically amplifies nucleic 18 acids with the same sequence with different 19 efficiencies. The latter is referred to as 20 "amplification noise." 21 Q. Can you explain what you mean by 22 "stochastically amplifies nucleic acids"?	80 1 (Whereupon, a luncheon recess was taken 2 from 12:26 p.m. to 1:13 p.m.) 3 BY MS. CIPRIANO: 4 Q. Okay. Welcome back, Dr. Sims. Okay. You 5 still have your declarations in front of you, right? 6 A. I do. 7 Q. If you could turn to paragraph 84. 8 Are you there? 9 A. I'm there. 10 Q. And this -- you talk about the common 11 high-level process of next-generation platforms; is that 12 accurate? 13 A. Yeah. This paragraph discusses some of the 14 common procedures used in next-generation sequencing 15 with multiple platforms. 16 Q. Okay. So I'd like to walk through and talk 17 about each of these steps a little bit and get on the 18 same page with that -- what we mean. The first bullet 19 point under paragraph 84 is entitled "Library 20 Preparation." 21 What do you -- what does library preparation 22 mean to you?

81 1 A. Library preparation is a series of molecular 2 biology steps that makes nucleic acid fragments 3 compatible with, for example, next-generation 4 sequencing. 5 Q. And in your experience, are there aspects of 6 the library preparation process that can cause errors in 7 the ultimate sequencing data that is gathered end of the 8 process? 9 (Reporter clarification.) 10 Q. Did you understand my question? 11 A. Can you repeat the question? 12 Q. Yes. 13 A. Thank you. 14 Q. Yes, we can -- 15 A. Sorry. 16 Q. That's okay. 17 In your experience, are there aspects of the 18 library preparation process that can cause errors in the 19 ultimate sequencing data that is gathered at the end of 20 the next-generation sequencing process? 21 A. Some library preparation methods include PCR, 22 and as we discussed earlier today, PCR can lead to the	83 1 that can impact the output of a sequencing experiment. 2 Q. And what are the others steps that can impact 3 the output of a sequencing experiment? 4 A. Some library preparation methods involve other 5 steps such as ligation. There are various ways in which 6 a ligation reaction can go wrong. 7 Q. Are there any other examples of steps in the 8 library preparation process, then, that can introduce 9 errors? 10 A. Some library preparation processes require 11 nucleic acid fragmentation. There are many methods for 12 fragmenting nucleic acids. There are things that can go 13 wrong during those processes as well. 14 Q. Are there any others? 15 A. There are probably others, but those are the 16 ones that come to mind. 17 Q. Okay. So the next step -- the next bullet 18 point you have in paragraph 84 is "annealing to a 19 surface." 20 Can you explain what annealing to a surface 21 means in terms of the steps that go into a 22 next-generation platform?
82 1 incorporation of substitution errors, for example, in 2 two nucleic acid fragments. 3 Q. So earlier today we talked about a couple of 4 different aspects of PCR reactions that can lead to, in 5 the umbrella term of "error," in the ultimate library 6 preparation; is that accurate? What we talked about 7 earlier? 8 A. Earlier we discussed some of the things that 9 can happen in a PCR reaction that can lead to, for 10 example, distortion of the relative abundance of nucleic 11 acids, the inclusion of errors like substitution errors. 12 Q. Okay. So all of the problems of PCR have the 13 potential of impacting the ultimate data that is 14 gathered from next-generation sequencing processes, 15 right? 16 A. Artifacts from PCR can impact the output of a 17 sequencing experiment like a next-generation sequencing 18 experiment. 19 Q. Is PCR the only source of error in library 20 preparation that can impact the output of a sequencing 21 experiment? 22 A. PCR is not the only step in library preparation	84 1 A. In this context, the word "annealing" means 2 hybridization by Watson-Crick base pairing. And in this 3 section of my declaration, there are three 4 next-generation sequencing platforms referred to. All 5 three of those platforms use surfaces with 6 oligonucleotide primers attached to them. 7 So in this context, annealing to a surface 8 means that members of your nucleic acid fragment library 9 anneal, or hybridize, to the primers fixed to those 10 solid surfaces. 11 Q. And you've listed three -- you mentioned that 12 you listed three of the next-generation platforms -- the 13 454, Illumina, and Ion Torrent. 14 Were those -- why do you list those three in 15 this section of your declaration? 16 A. Those three platforms are used in some of the 17 references in my declaration -- some of the prior art 18 references, and so I thought it would be appropriate to 19 explain how they work. 20 Q. Were those the three most popular 21 next-generation platforms in the 2011/2012 timeframe? 22 A. It's fair to say that, by that time, Illumina

85 1 was significantly more widely used than the other two. 2 Q. Is the process of annealing the fragments to a 3 surface a source of error in the sequencing data that 4 that results from a next-generation sequencing process? 5 A. I wouldn't consider that step to be a major 6 source of error. 7 Q. Okay. The next step you talk about is 8 on-surface amplification. Can you explain what the 9 on-surface amplification step is referring to? 10 A. After annealing members of a nucleic acid 11 fragment library to a surface, these three platforms use 12 various methods of clonally amplifying those fragments 13 on the surface. 14 Q. What do you mean by clonally amplifying? 15 A. I'll use the 454 platform as an example, 16 because they all do it slightly differently. 17 So, for example, in the 454 platform, an 18 individual nucleic acid fragment molecule would anneal 19 to primers on the surface of a single bead. So you'll 20 typically have a situation where one bead has one 21 nucleic acid fragment bound to its surface and then a 22 PCR reaction takes place that results in the amplicons	87 1 fraction of the clonally amplified fragments that end up 2 on the surface. And so when you then sequence that 3 population of amplicons, the rare subset of them that 4 contain an error are very unlikely to distort the 5 sequencing results. This is part of the -- this is an 6 important part of the design of these platforms. 7 Q. And when you say "this" is important, the 8 clonal amplification? Is that what you're referring to? 9 A. The clonal amplification strategy is an 10 important part of the design of these platforms in part 11 because it greatly limits the impact of such errors. 12 Q. And since here, you're not dealing with a 13 mixture of nucleic acid fragments, the distortion of the 14 relative proportion of fragments is not an issue here 15 either, right? 16 A. I would not expect it to be a major problem 17 except in extreme cases. 18 Q. Okay. The next bullet point in this section of 19 your declaration is "Massively Parallel Sequencing." 20 Do you see that? 21 A. I see that. 22 Q. What do you mean by "massively parallel
86 1 also being bound to that same surface. 2 Q. To the same bead? 3 A. The same bead. 4 Q. Okay. 5 A. And so the reason I use the word "clonal" is 6 because the amplicons originate from one molecule. 7 Q. Understood. 8 And so when PCR is used in this on-surface 9 amplification step, do all of the issues that we've 10 talked about with PCR generating errors, do they apply 11 equally to the onsite amplification step? 12 A. The types of errors that we discussed can 13 occur, but because of the clonal nature of the PCR, they 14 are far less likely to impact the sequencing results. 15 Q. And why are they far less likely to impact the 16 sequencing results? 17 A. I think it might help to give an example. 18 Q. Okay. 19 A. During a PCR reaction that's clonal, it's 20 possible that a subset of the molecules on the surface 21 might have an error in them because the DNA polymerase 22 makes a mistake. But that will typically be a minor	88 1 sequencing"? 2 A. What I mean by massively parallel sequencing is 3 that these three platforms are able to sequence many DNA 4 fragments in parallel; millions or even billions of 5 them. 6 Q. So this is the step where the sequence data is 7 collected by the -- by the platform; is that accurate? 8 A. We would refer to this step as the sequencing 9 step, but it's important to note that the form of the 10 data that results from this step can be somewhat removed 11 from actual sequences. For example, on the Illumina 12 platform, the sequencing process involves imaging. 13 Those images are then converted into sequencing 14 information -- 15 Q. Okay. 16 A. -- by the computer. 17 Q. So this is -- when you refer to the "massively 18 parallel sequencing," it is, like several of the other 19 categories that you put in this, it's a sequence of 20 steps of data collection where you're converting the 21 sequencing library to data; is that fair? 22 A. The sequencing step takes that clonally

89 1 amplified nucleic acid fragment library and generates 2 sequencing data, but there are many components of that. 3 Q. All right. In your experience is the 4 sequencing step of next-gen sequencing processes a 5 source of error in the ultimate sequencing data? 6 A. All three of these platforms use DNA polymerase 7 as part of the sequencing process, and DNA polymerase 8 can make mistakes. 9 Also, all three of these platforms rely on 10 chemical steps happening in parallel on many clonal 11 copies of a given nucleic acid fragment, and 12 occasionally those steps get out of synch with each 13 other. That can cause errors. 14 There's also instrumentation associated with 15 these machines, imaging systems that have limitations, 16 so there are sources of errors. 17 Q. And so the last step in this paragraph that you 18 have bulleted is computational processing in sequence 19 determination. 20 Can you explain what you mean by this step? 21 A. So this process is platform-specific, but for 22 example, on the Illumina sequencing platform, this	91 1 of the sequencing data because of its clonal nature. 2 Q. And so in your opinion, which sources of 3 error -- sorry. Let me rephrase. 4 In your opinion, which steps would be most 5 impactful to attempt to mitigate errors in a 6 next-generation sequencing process? 7 A. This is very application-specific, but for 8 example, if one is trying to detect mutations on the 9 genome, then errors that induce artifactual mutations 10 are particularly problematic. 11 Q. So, sorry, I don't think your answer exactly 12 answers my question. 13 You're giving one example when you're looking 14 for mutations; you want to avoid artifact mutations. 15 What step would you target in the 16 next-generation sequencing process to mitigate those 17 kinds of errors? 18 A. Well, it sort of depends who you are. If 19 you're working at Illumina, you might try to improve the 20 sequencing instrumentation, and Illumina, for example, 21 has made improvements by changing the accuracy of the 22 sequencing instrumentation.
90 1 process would convert fluorescence imaging data into 2 nucleic acid sequence data using computer algorithms. 3 Q. And is the computational process and sequence 4 determination a source of error in next-generation 5 sequencing processes? 6 A. I don't want to imply that the computer is 7 going to make a mistake in executing an algorithm that 8 you give it, but the computer programs used for tasks 9 like base calling, are trying to compensate for some of 10 the errors that can occur during the sequencing process, 11 and they are imperfect. 12 Q. Now, would you agree that reducing the amount 13 of error in any one step has the ability to improve the 14 quality of the ultimate sequencing that results from a 15 next-generation sequencing process? 16 A. I think there are some steps where attempting 17 to mitigate errors would have a negligible impact on the 18 data for a lot of applications. 19 Q. And what are those steps? 20 A. As one example, trying to mitigate errors made 21 by the DNA polymerase during clonal amplification is 22 probably not going to have a huge impact on the quality	92 1 If you're working in my lab, you might 2 implement steps in library preparation that could help. 3 Q. So you'd agree that there are various ways to 4 improve on the ultimate sequencing data by impacting 5 various steps in the next-generation process -- 6 next-generation sequencing process? 7 A. The process as described in paragraph 84 of my 8 declaration have many steps, and there are multiple 9 opportunities to intervene and improve the quality of 10 sequencing data as a result. 11 Q. And each individual improvement has a potential 12 to ultimately impact the sequencing data that's the 13 result of the next-generation process, right? 14 A. As I mentioned before, I think there are some 15 steps where you are very unlikely to make substantial 16 improvements. 17 Q. But there are some steps where you would expect 18 to see substantial improvements, correct? 19 A. There are some steps where you are more likely 20 to improve the sequencing data in an 21 application-specific way. 22 Q. And the two ways that you specifically

93 1 mentioned that may have a significant impact would be a 2 library preparation step and potentially the sequencing 3 instrumentation steps. Is that accurate? 4 A. Those are the two steps that I mentioned. 5 Q. Are there other steps that you think would have 6 a significant impact if you improve the error rate? 7 A. I wouldn't discount the possibility, but those 8 are two steps with which I am very familiar. 9 Q. Okay. So in both of your declarations, you 10 have a section on -- that describes the work that is 11 done -- that was done at MGH. And this is in the 12 section of your declarations that are differently 13 numbered. 14 So in the declaration we've been looking at, 15 which is Exhibit 1079, I have that down as starting on 16 paragraph 176. 17 A. Okay. I'm there. 18 Q. And just for the record, in the other 19 declaration for the other proceedings in Exhibit 1085, 20 that starts at paragraph 112. 21 And from my read, the paragraphs are slightly 22 different but both of the sections have the same heading	95 1 that accurate? 2 A. Yeah, this patent application is referred to in 3 my declaration. I've been pronouncing it Iafrate. 4 Q. Okay. 5 A. I don't know if I'm correct or not. 6 Q. I'll try to get on the same page. That's been 7 stuck in my head for a while, so I don't know if I'll be 8 able to correct the habit. 9 So it's your understanding that the Iafrate 10 reference is a patent on the work that was done at MGH? 11 Patent application -- excuse me, that was done on the 12 work at MGH; is that accurate? 13 A. That's consistent with my understanding. 14 Q. Now, in paragraph 120 of your Exhibit 1085 15 declaration, you state your opinion that: 16 "A POSA would understand that the MGH 17 method is fundamentally different from the 18 method disclosed by NuGen in the '012 and '108 19 patents." 20 Do you see that? 21 A. I'm sorry, which paragraph? We're in 1085? 22 Q. Yeah. 120.
94 1 which is the MGH Archer Anchored Multiplex PCR Library 2 Preparation Method. 3 Are you there? 4 A. I see that. 5 Q. Okay. So here, you talk about work that was 6 done at Massachusetts General Hospital and published in 7 an article. And in your declaration that's marked 1085 8 for the '00015 and '00016 -- 9 A. Mm-hmm. 10 Q. -- proceedings -- I'll give you a second to get 11 there. 12 In paragraph 113, you say: 13 "Prior to the publications of the Zheng 14 paper, I understand that MGH authors, the BMGH 15 authors filed for patents on their work." 16 Do you see that? 17 A. I see that. 18 Q. And that's including a patent application that 19 was filed as US Publication Number 2013/0303461, and 20 that's a -- I believe you pronounced it differently than 21 I have been pronouncing it in my head, but the Iafrate 22 reference that you talk about in your declarations; is	96 1 A. 120. Sorry. 2 I see that. 3 Q. You'd also agree that the MGH method described 4 in the Iafrate -- is the way that it is in my head. 5 A. That's fine. 6 Q. I'm sorry. 7 You agree that the MGH described in the Iafrate 8 is different from the method disclosed in the '241, '357 9 and '399 patents, correct? 10 MR. FLETCHER: Objection. 11 A. There are definitely differences in what is 12 disclosed in those patent applications. 13 Q. Let's clarify that. There are definitely 14 differences between what's disclosed in Iafrate and the 15 '241, '357 and '399 patents; is that accurate? 16 A. There are definitely differences in what's 17 disclosed in the '399, '357, '241 patents and what is 18 disclosed in the Iafrate application. 19 Q. Sitting here now, and we'll go into this in 20 detail, but do you have examples in your mind of how 21 they are different? 22 A. The '399, '357 and '241 patents are focused on

Conducted on June 26, 2025

97 1 methods for de-duplicating reads in sequencing data. 2 The Iafrate application is not focused on this. 3 Q. Okay. So looking at your 1079 declaration, 4 Exhibit 1079, could we turn to paragraph 183? 5 A. I'm there. I'm there. 6 Q. And this is a section that's entitled, "A 7 Person of Ordinary Skill in the Art," I think we've 8 already been using the abbreviation, but you understand 9 that POSA is a shorthand for person of ordinary skill in 10 the art? 11 A. I understand that. 12 Q. And your declarations, you assumed a particular 13 level of expertise for this person of ordinary skill in 14 the art. 15 How did you arrive at the skill set you 16 supplied here? 17 A. I discussed this topic with counsel and drew on 18 my experience training scientists in this field. 19 Q. Do you understand that the PTAB panel disagreed 20 with portions of your definition of a person of ordinary 21 skill in the art? 22 A. I have some recollection that they commented on	99 1 to explore using the sequence of the nucleic 2 acid fragment from the sample as a unique 3 identifier or an endogenous molecular tag." 4 Do you see that? 5 A. I see that. 6 Q. There's no citation to this sentence. Do you 7 recall where -- what you were referring to when you said 8 this? 9 A. As someone working in this field in 2010, this 10 sentence reflects my perspective on how the field was 11 evolving. However, in my declaration, I do discuss 12 specific examples of these technologies. 13 Q. And what you're talking about is where it says, 14 for example, in paragraph 130 and later? Is that what 15 the examples you're referring to? 16 A. Those are some of the examples. 17 Q. Okay. You're not saying that McCloskey 18 disclosed that concept, right? 19 A. Which concept? 20 Q. The use of -- the sequence of the nucleic acid 21 fragment from the sample as a unique identifier or an 22 endogenous molecular tag?
98 1 my definition. I don't recall the details sitting here 2 right now. 3 Q. I can show you the panel's decision, if it's 4 helpful, but if you were to apply the panel's definition 5 that it set forth, if you recall it, would it change 6 your positions in your declaration? 7 A. I don't recall the panel's comments on the 8 definition of a POSA as the type of thing that would 9 impact the opinions set forth in my declaration. 10 Q. Okay. If we can skip ahead to -- no, skip 11 back -- to backtrack in your declaration a little bit to 12 the prior art sections, and specifically I want to turn 13 to paragraph 129. 14 And just to orient you, feel free to look at 15 whatever you need to to answer my questions, but this is 16 a section that's talking about the McCloskey reference. 17 A. I see that. 18 Q. Now, the last sentence of paragraph 129 -- 19 yeah, the last sentence of paragraph 129 says: 20 "Along with continuing to improve on 21 the use of molecular tags incorporated into 22 adaptors, scientists in the field also started	100 1 A. Sitting here today, I don't recall whether 2 McCloskey used, for example, features -- sequence 3 features of the nucleic acid fragment as part of the 4 unique identifier. 5 Q. Okay. If we could -- I'd like to talk about 6 another reference you talk about, referred to as 7 Schmidt, which is at paragraph 164 of your declaration. 8 A. I'm there. 9 Q. Do you recall the Schmidt reference, or would 10 you like to see it? 11 A. Probably depends on your next question. 12 Q. So you let me know. I have copies. 13 A. I'll let you know. 14 Q. Understood. 15 So if you look at paragraph 125, you have a 16 quote from Schmidt. And in that -- in, I guess, the 17 second part of the first sentence: 18 "After sequencing, members of each PCR 19 family are identified and grouped by virtue of 20 sharing an identical tag sequence." 21 A. Sorry. You said paragraph 125? 22 Q. I'm sorry. 165.

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Tecan Ex. 2036, Page 26 of 76

IDT, Inc. v. Tecan Genomics - IPR2025-00016

Conducted on June 26, 2025

101 1 A. Okay. 2 Q. I misspoke. 3 A. Okay. Yeah, I see that. 4 Q. And then you go onto explain that, after 5 grouping by tags, the sequences were compared to create 6 a consensus sequence. 7 Do you see that? There's another quote from 8 Schmidt further down in that paragraph. 9 A. I see that. 10 Q. What is a consensus sequence in your 11 understanding? 12 A. A consensus sequence is a sequence that one 13 arrives at by analyzing multiple reads and then making a 14 judgment as to what the correct sequence of the 15 originating nucleic acid fragments likely is. 16 Q. So in Schmidt, it was a two-step process to 17 arrive at the consensus sequence. First they grouped 18 the reads into -- by virtue of their identical tag 19 sequences, and then they generated the consensus 20 sequence; is that right? 21 A. I agree that there are multiple steps involved 22 in the process described by Schmidt, but I would	103 1 1D of -- this is of the '399 patent in paragraph 248. 2 And it's your opinion that Kivioja discloses 3 this limitation, which is limitation 1D -- sorry. I'm 4 going to start over anyway because I'm -- thank you. 5 So what's been defined as limitation 1D is the 6 limitation that recites: 7 8 "Identifying a duplicate sequencing 9 read comprising the same identifier site and 10 nucleic acid fragment as another sequencing 11 read in a population of sequence reads." 12 Is that right? 13 A. I see that's the text of Claim 1D. 14 Q. And that's of the '399 patent as it's cited in 15 paragraph 248 of your declaration? 16 A. Yes. That's the '399 patent, yeah. 17 Q. And for this limitation in part of 248, you 18 pointed to the quote in Kivioja that reads -- and this 19 is a couple of lines down: 20 "The mapped reads with the same gene, 21 position, and label were collected to one UMI, 22 and the number of such reads was recorded as
102 1 probably need to see the reference to fully refresh my 2 memory on the details. 3 Q. Okay. I don't think that -- I think that's 4 helpful enough. Thank you. 5 Okay. I'd like to next talk about the Kivioja 6 reference. And that's again, how it's stuck in my head, 7 but I know that -- I believe you pronounced it 8 differently. We can look at -- to the extent you want 9 to look at your declaration, we can look here starting 10 paragraph 248, I think, I have in my notes? 11 A. I'm there. 12 Q. It starts before that but understood. 13 So in your declaration, you have made arguments 14 that the asserted claims -- the challenged claims, 15 excuse me -- of the '241, '357 and '399 patents are 16 obvious in light of a combination of Kivioja and 17 Iafrate; is that right? 18 A. My opinion is that claims of the '399, '357 and 19 '241 patents are obvious given the combination of 20 Iafrate and Kivioja. 21 Q. So I'd like to focus on limitation 1D, what 22 we've -- what your declaration identifies as limitation	104 1 the copy number of that UMI." 2 Do you see that? 3 A. I see that. 4 Q. Now, the challenge claims don't use the term 5 "UMI," right? 6 A. The challenge claims do not use that term. 7 Q. The challenge claims require a comparison of an 8 identifier site and a nucleic acid fragment. 9 Is that your understanding of the terminology? 10 MR. FLETCHER: Objection. 11 A. I see that Claim 1D uses the terms "identifier 12 site" and "nucleic acid fragment." 13 Q. And am I correct that you interpret the label 14 in Kivioja to be what is referred to as an identifier 15 site of the '399 patent? 16 A. So as stated in my declaration, in paragraph 17 276, the last sentence: 18 "Kivioja discloses identifying a 19 duplicate sequencing read as a sequencing read 20 comprising the same identifier site," and then 21 in parentheses, "the label." And then it goes 22 on.

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Tecan Ex. 2036, Page 27 of 76

IDT, Inc. v. Tecan Genomics - IPR2025-00016

105 1 So that's where I'm drawing the 2 equivalence between the identifier site and the 3 label. 4 Q. And in that same sentence, you equate nucleic 5 acid fragment, which is a term used in the claim, with 6 the gene and position referred to in Kivioja, right? 7 A. The gene and position is a way in which Kivioja 8 encodes the nucleic acid fragment information. 9 Q. What do you mean by "encodes"? 10 A. Kivioja sequences nucleic acid fragments and, 11 among other things, records their gene and position. 12 And that information is part of the unique molecular 13 identifier that Kivioja uses for de-duplicating 14 sequencing reads. 15 Q. You agree that the nucleic acid sequence and 16 the gene that that sequence is a part of are different 17 types of information? 18 MR. FLETCHER: Objection. 19 A. When one sequences a nucleic acid fragment, 20 that sequence -- that observed sequence can differ from 21 the sequence on the genome from which that nucleic acid 22 fragment originated.	107 1 A. When you align a sequencing read to a genome, 2 you get multiple pieces of information including the 3 name of the gene to which it aligns, the position within 4 the gene and within the genome to which it aligns, and 5 you can also get an assessment of how that sequencing 6 read differs from the reference genome. 7 Q. So the information that Kivioja uses as part of 8 its -- what it calls its UMI are the first two pieces of 9 information on your list -- the name of the gene and the 10 fragment's position in that gene, right? 11 A. Kivioja uses the name of the gene and the 12 position to -- the position within that gene to which 13 the sequencing read aligned. 14 Q. So in order to do the -- to create the UMIs 15 that Kivioja used and talked about in its -- in that 16 paper -- sorry. Let me pause there. 17 Okay. So let's look at paragraph 248 of your 18 declaration. 19 A. I'm there. 20 Q. So the -- I'm looking at the sentence that 21 spans pages 137 and 138 that reads: 22 "Specifically, for each gene, Kivioja
106 1 Q. That's not quite my question. 2 A. Okay. 3 Q. So when we are talking about the nucleic acid 4 sequence, that's going to be the data that is the order 5 of As, Ts, Gs and Cs. 6 Is that your understanding? 7 A. I think the subtlety here is that, in a 8 sequencing experiment, one has an observed sequence for 9 a given read corresponding to a nucleic acid fragment, 10 and one may also have a reference sequence that's known 11 a priori. I'm sort of pointing out that those can be 12 different from each other. 13 Q. Okay. But that's -- so my question is simply 14 that when we're talking about a nucleic acid sequence, 15 we are talking about a series of letters, and that's the 16 data that is the sequence, correct? 17 A. A nucleic acid sequence can be described as a 18 series of letters. 19 Q. And when -- when you take the other step and 20 map it to a known genome, when you identify a sequence 21 as part of a gene, then you're identifying how ever the 22 gene is named; is that accurate?	108 1 mapped the sequencing read against the longest 2 transcript of that gene which was used as the 3 reference sequence." 4 Do you see that? 5 A. I see that. 6 Q. So Kivioja's first step is to take the sequence 7 data and compare it to a reference sequence; is that 8 accurate? 9 A. Kivioja used a reference containing many 10 transcript sequences and performed an alignment against 11 that reference for each sequencing read in the data to 12 determine where each sequencing read aligned to the 13 extent that that read aligns anywhere. 14 Q. So let's look at the actual reference of 15 Kivioja. We're going to look at Exhibit 1012. I'd like 16 to look at -- well, first of all, you recognize Exhibit 17 1012, right? 18 A. I recognize Exhibit 1012. 19 Q. And it's the Kivioja reference that you cite to 20 in your declaration? 21 A. This is the Kivioja reference that I cite in my 22 declaration.

109 1 Q. And I'd like you to turn to -- it's the page -- 2 it's part of the "Online Methods" section. It's the 3 page that's marked at the bottom as Exhibit 1012.0004? 4 A. I'm there. 5 Q. Okay. At the bottom of the first paragraph of 6 the "Digital Karyotyping" section -- it's in the 7 left-hand column of that page -- in the last sentence, 8 it says: 9 "Sequences were generated on an 10 Illumina Genome Analyzer with 76 bp single 11 reads for the mixed sample and 100 bp 12 paired-end reads for the adult male sample. 13 Reads were mapped to the genome using Bowtie." 14 Do you see that? 15 A. I see that. 16 Q. Do you know what is referenced as Bowtie here? 17 A. Bowtie is a computer program which, among other 18 things, can align or map sequencing reads to a reference 19 set of sequencing reads such as a reference genome. 20 Q. So if we look at the next page in the section 21 that's -- has the heading "mRNA SEQ Data Analysis"? 22 A. I see that.	111 1 about with the reference sequence sentence, there's an 2 explanation of some data analysis where reads were 3 discarded for certain -- under certain circumstances. 4 Do you see that? 5 A. I see that. 6 Q. This section of data analysis, that happened 7 after the reads were mapped to the genome using Bowtie; 8 is that accurate? 9 MR. FLETCHER: Objection. 10 A. Bowtie was not used for alignment in this 11 section of the paper. Instead a different piece of 12 software called the Burrows-Wheeler Aligner was used. 13 Q. I understand. 14 A. However, these steps likely occurred after 15 alignment. Some of these steps require information from 16 the aligner. 17 Q. So then in the next paragraph, in that same 18 section, in the first sentence of that third paragraph 19 reads: 20 "The mapped reads that the same gene 21 position and label were collected to one UMI 22 and the number of such reads was recorded as
110 1 Q. You see that? Okay. In the second paragraph 2 of that section, it says: 3 "For each gene, the sequence of its 4 longest transcript was used as the reference 5 sequence." 6 Do you have an understanding of what is 7 being referred to as the reference sequence 8 here? 9 A. So the sample under study in this section of 10 the paper is from Drosophila, and some genes in the 11 Drosophila genome have multiple isoforms. Kivioja 12 selected the longest isoform in terms of number of 13 nucleotides for each gene and used that as the reference 14 sequence for that gene. 15 Q. So when it talks about the longest transcript, 16 it's not talking about the longest transcript detected 17 in the Kivioja sequence, right? This is a pre-published 18 or known sequence of the Drosophila genome; is that 19 accurate? 20 A. This is in reference to a pre-published 21 reference for the Drosophila transcriptome. 22 Q. So in that same paragraph we were just talking	112 1 the copy number of that UMI." 2 Do you see that? 3 A. I see that. 4 Q. And that's the -- that's the sentence that you 5 quote in your declaration as supporting your position 6 that Kivioja discloses the limitation 1D of the 7 challenge claims; is that accurate? 8 I can point you to paragraph 248, if that's 9 helpful. 10 A. Yeah. I quote that sentence in reference to my 11 opinion that Kivioja discloses the limitation in Claim 12 1D. 13 Q. Okay. And that analysis where Kivioja collects 14 mapped reads to UMI, that's -- we have talked about the 15 third step of data analysis after sequencing at least, 16 right? 17 MR. FLETCHER: Objection. 18 A. We've discussed alignment as a first step, a 19 second multistep process where reads are discarded based 20 on certain criteria and then the third step, which is 21 described in that sentence that you read. 22 Q. So after the reads are collected to their UMIs

113 1 in Kivioja, the process there is that Kivioja counts the 2 reads, right? 3 And I can point you to paragraph 239, to the 4 extent it's helpful. 5 A. Kivioja describes a process by which UMIs are 6 established from the data and then those UMIs are used 7 for quantifying or counting the number of molecules 8 corresponding to a given nucleic acid fragment in the 9 original sample. 10 Q. You describe this in paragraph 239 of your 11 declaration as "collapsing." 12 Do you see that? 13 A. I see the sentence where I used the term 14 "collapsed." 15 Q. But is collapsing data the same as removing 16 data, in your opinion? 17 A. Some sequence information is removed in this 18 collapsing process. 19 Q. In what way is it removed? 20 A. For example, if a pair of reads each have the 21 same label or molecular tag and the same nucleic acid 22 fragment sequence, one of them might be removed in the	115 1 counting method in Kivioja. 2 MR. FLETCHER: We've been going about 3 an hour and a half, let's take a break. 4 MS. CIPRIANO: Okay, let me finish this 5 reference. I have two questions on this 6 article. 7 MR. FLETCHER: Okay. 8 MS. CIPRIANO: And you know what, we 9 can -- yeah, we can move on, so let's take a 10 break. 11 (Whereupon, a short break was taken.) 12 BY MS. CIPRIANO: 13 Q. Okay. We can dive back in. So I'm going to 14 switch gears and talk a little bit about the Iafrate, is 15 that -- 16 A. Yep, that's how we're saying it, but, yeah. 17 Q. Iafrate reference. 18 A. Okay. 19 Q. So if we can look in your declaration, we'll 20 start there, at paragraph 211. 21 A. I'm there. 22 Q. In the second half of paragraph 211, on this
114 1 collapsing process. 2 So you would -- you would have two reads, but 3 you would only count them as one. 4 Q. Right. Is only counting them as one the same 5 as removing a duplicate? 6 MR. FLETCHER: Objection. 7 A. The process I just described is often referred 8 to as de-duplication, so that could be construed as 9 removing duplicates or removing a duplicate. 10 Q. Does Kivioja refer to de-duplication? 11 A. I don't believe that Kivioja uses the term 12 "de-duplication," but it is a widely used term in 13 next-generation sequencing. 14 Q. And for the counting method that you're relying 15 on for this process in Kivioja, that's depicted in 16 Figure 1A of the reference of Exhibit 1012; is that 17 right? 18 A. Figure 1A is one illustration of the counting 19 method in Kivioja. 20 Q. Is there another illustration of the counting 21 method in Kivioja? 22 A. Figure 1B is also an illustration of the	116 1 page, you walk through the adaptor that's identified in 2 Iafrate. 3 Do you see that? 4 A. I see that. 5 Q. And so you agree that the Iafrate adaptor does 6 not disclose the use of an identifier as part of this 7 adaptor, correct? 8 A. The Iafrate adaptor does not include an 9 identifier or molecular tag as typically employed for 10 PCR de-duplication, for example. 11 Q. And what do you mean by "typically" in that 12 sentence? 13 A. I just mean that molecular tags are commonly 14 used for PCR de-duplication. 15 Q. Okay. But the Iafrate adaptor does not include 16 a molecular tag or identifier site, right? 17 A. The Iafrate adaptor does not include a 18 molecular tag or identifier site. 19 Q. Okay. Let's flip to paragraph 454 of your 20 declaration. This is the beginning of the section where 21 you talk about your arguments related to the reference 22 that we've been referring to as Bielas, correct?

117 1 A. This is the section about the Bielas reference. 2 We've been saying Bielas. 3 Q. Okay. So for -- just to make sure that we are 4 speaking the same language and that we are -- I don't 5 have to ask you the same question over and over again, 6 in this section, the section titles include the '399 7 patent, '357 patent and the '241 patents, right? 8 A. I see that. 9 Q. And you have a section that is, the section 10 starting at paragraph 456 is not patent-specific in your 11 discussion of the Bielas disclosures; is that an 12 accurate representation? 13 A. This paragraph is a general discussion of the 14 Bielas disclosure that is related to all three of the 15 challenged patents. 16 Q. Okay. And then starting at paragraph 487. 17 A. I'm there. 18 Q. At 487, you have a section that starts to talk 19 about the '399 patent specifically, right? 20 A. This paragraph is about the '399 patent, 21 specifically. There may be some aspects that are 22 related to the other two, but the paragraph is focused	119 1 which extends through page -- midway through page 275. 2 Do you see that? 3 A. I see that. 4 Q. Okay. Then the remaining sections, so section 5 3 on page 275 starts talking about the '357 patent. 6 Do you see that? 7 A. I see that. 8 Q. And then in many of these sections, it refers 9 back to the discussion of the '399 patent. 10 Does that -- do you recall that? 11 A. I recall that. 12 Q. Okay. Now, can we agree that if we -- if I ask 13 you about a paragraph specifically related to the '399 14 patent and that paragraph is also referenced in the '357 15 patent or the '241 patent, that your testimony would 16 apply to the testimony -- the information that you 17 cross-referenced between the patents? 18 A. Can you repeat that question? 19 Q. Sure. 20 So we can look at an example. So for example, 21 on page 280 -- 22 A. Okay.
118 1 on the '399 patent. 2 Q. Okay. So I'd just like to make sure we're on 3 the same page. So the section starting at the top of 4 page 244 focuses on the '399 patent, and then in the 5 next -- in the following pages, you have an analysis of 6 Claim 1 of the '399 patent, and that extends through the 7 bottom of page 255 if -- if you could confirm that 8 that's your understanding as well? 9 A. Those pages are focused on Claim 1 of the '399 10 patent. 11 Q. And specifically anticipation of Claim 1, 12 correct? 13 A. Those pages comprise section A entitled 14 "Bielas Anticipates Claim 1." 15 Q. Okay. And then you have a couple of pages 16 devoted to the obviousness. Your position is that Claim 17 1 of the '399 patent is obvious based on Bielas, and 18 that's spanning pages 256 through the top of 260? 19 A. 260 discusses how Claim 1 would have been 20 obvious based on Bielas. 21 Q. Okay. And then following that section, there's 22 a discussion of the dependent claims of the '399 patent	120 1 Q. -- there's a section for -- that's referring to 2 the element an identifying sequence reads with identical 3 identifier and target sequence as duplicates, right? 4 A. I see that. 5 Q. And here, you have a comparison of the language 6 of the '357 patent and the '399 patent, right, in the 7 chart? 8 A. I see that. 9 Q. And then you go through in paragraph 578, the 10 differences between the '357 and the '399? 11 A. I see that. 12 Q. Right? 13 And then in paragraph 579, you say: 14 "Because the identification step of the 15 '357 patent is also present in the '399 patent, 16 Bielas discloses this limitation for the 17 reasons state in section 6D.2.A.5 of my 18 declaration." 19 Do you see that? 20 A. I see that. 21 Q. So if I ask you questions about section 6D.2.A5 22 of your declaration, is it fair to also say that that

121 1 testimony would apply to this element of the '357 2 patent? 3 A. My testimony on section VI.D.2.A5 of my 4 declaration would apply to the identification step in 5 both the '357 patent and the '399 patent. 6 Q. Okay. So thanks for being patient and walking 7 through that level setting with me. 8 If we could go back to the beginning of the 9 Bielas discussion and look at paragraph 459. 10 And in -- in paragraph 459, let's just get on 11 the same page. It reads: 12 "Thus, Bielas teaches a method of using 13 random molecular tags to identify PCR 14 duplicates of original molecules and then 15 de-duplicate those PCR copies in order to 16 determine, for example, whether a particular 17 mutation is present in the original fragment (a 18 true mutation) or was created during PCR 19 amplification (an artifact mutation)." 20 Do you see that? 21 A. I see that. 22 Q. Okay. So the purpose of identifying duplicates	123 1 after the introductory clause, you state: 2 "Bielas identified duplicate sequencing reads 3 using the sequence of a cypher and the sequence of a DNA 4 sequencing fragment in both Example 1 and Example 3," 5 correct? 6 A. I see that. 7 Q. And do you rely on any other portions of Bielas 8 for this disclosure, or is it just examples 1 and 3? 9 MR. FLETCHER: Objection. 10 A. There are other relevant sections of Bielas. 11 There are sections where certain terms that are used in 12 examples 1 and 3 are defined. Examples 1 and 3 refer to 13 figures. So it's multiple components taken together 14 with those two examples that I examined to form this 15 opinion. 16 Q. Okay. So I'd like to take a look at the text 17 of Example 1 and Example 3. And this is -- we're going 18 to hand you Exhibit 1013, which was already marked as 19 the Bielas reference. 20 So, first of all, the exhibit I handed you 21 that's previously marked as Exhibit 1013, do you 22 recognize this document?
122 1 in Bielas was to determine if a mutation was an artifact 2 of PCR or a true mutation in the sample; is that 3 accurate? 4 A. That is one application of the technology 5 disclosed in Bielas. 6 Q. But that's how Bielas uses it, right? 7 A. Bielas focused on that application. 8 Q. So let's look at paragraph 508. 9 Are you there? 10 A. I'm there, yes. Sorry. 11 Q. And this -- again, this is in the section where 12 you are doing an element-by-element analysis of Claim 1 13 of the '399 patent, correct? 14 A. That's correct. 15 Q. And this is focusing on the element 1D, which 16 is identifying a duplicate sequencing read as a 17 sequencing read comprising the same identifier sites and 18 nucleic acid fragment as another sequencing read in the 19 population of sequencing reads, right? That's the 20 element we're talking about? 21 A. I agree. 22 Q. And in the second sentence of this paragraph,	124 1 A. I recognize this document. 2 Q. And this is the Bielas reference that you refer 3 to in your declaration? 4 A. This is the Bielas reference. 5 Q. So let's turn to page 24, which is the 6 beginning of the text of Example 1. 7 A. I'm there. 8 Q. Now, in your declaration -- and we can refer 9 back and forth if it's handy -- in paragraph 508, you 10 quote a section from the last paragraph of Example 1. 11 It's that first -- a portion of that first sentence of 12 the last paragraph of Example 1 which reads: 13 "The unique cypher tags are used to 14 computationally deconvolute the sequencing data 15 and map all sequence reads to single molecules 16 (i.e., distinguish PCR and sequencing errors 17 and from real mutations)." 18 Do you see that? 19 A. I see that. 20 Q. Do you understand what is meant by 21 "computationally deconvolute" in this sentence? 22 A. My understanding of the term "computationally

Conducted on June 26, 2025

125 1 deconvolute" in Bielas is that Bielas used computer 2 programs to de-duplicate sequencing reads. 3 Q. And what -- how are you making the connection 4 between deconvolute and de-duplicate? 5 A. Aside from the broader context of the 6 disclosure in Bielas, a key phrase is "map all sequence 7 reads to single molecules." 8 So you have -- you can have multiple sequence 9 reads that are then considered to be single molecules or 10 to have originated from single molecules following the 11 deconvolution procedure. 12 Q. So here, the sentence -- the "map all sequence 13 reads" is separate from computationally deconvolute, 14 right? The sentence reads: 15 "The cypher tags are used to, one" -- 16 I'm adding that -- "computationally deconvolute 17 the sequencing data" and two, "map all sequence 18 reads." 19 What leads you to believe that they are 20 one and the same? 21 MR. FLETCHER: Objection. 22 A. My interpretation of the sentence is that	127 1 Q. Let me clarify. Good point. 2 So Bielas explains that the cypher tags were 3 used to deconvolute and map sequences to single 4 molecules but doesn't refer to using any part of the 5 sequence of the target sequence in this process, right? 6 MR. FLETCHER: Objection. 7 A. My interpretation of Bielas is that both the 8 sequence of the molecular tag or cypher and the sequence 9 of the DNA fragment are used in the de-duplication 10 process. 11 Q. And what in Example 1 leads you to that 12 conclusion? 13 A. There are multiple things in Example 1 in 14 addition to the broader context of the disclosure which 15 has a lot more information than is just in this 16 paragraph, but specific to this paragraph, there are a 17 few things. 18 One, that same sentence that we're reading 19 refers to real mutations. Real mutations cannot be 20 assessed without comparing the sequence of the DNA 21 fragment to, for example, a reference. 22 Another aspect of this paragraph is the second
126 1 Bielas used a word "deconvolute," which has a broad 2 range of context-specific meanings, and then clarified 3 its meaning in this context with that second phrase, 4 "map all sequencing reads to single molecules." 5 Q. Deconvolute can mean something other than 6 de-duplication, right? 7 A. The word "deconvolute" can be used in different 8 ways in different contexts in different applications. 9 My interpretation is that, in this context, deconvolute 10 refers to the de-duplication process described in 11 Bielas. 12 Q. Bielas doesn't call it de-duplication, right? 13 A. I don't believe Bielas uses the term 14 "de-duplication." 15 Q. Now, based on this sentence in Example 1, 16 Bielas states that the cypher tags were used to 17 deconvolute and map all sequence reads to single 18 molecules. 19 Bielas doesn't mention using the -- any 20 sequence information; is that accurate? 21 MR. FLETCHER: Objection. 22 A. The cypher tags are sequence information.	128 1 sentence. In the second sentence, Bielas mentions 2 sequence alignment. So this is presumably an assessment 3 of the target sequence with respect to a reference 4 genome. 5 Q. What you're talking about in that second 6 sentence, that's done as a separate step from mapping 7 the sequence to single molecules, right? 8 MR. FLETCHER: Objection. 9 A. Sequence alignment is a separate step. 10 Q. Okay. So you also point to Example 3 in Bielas 11 that starts on paragraph 26 -- not paragraph, page 26 of 12 the reference. 13 A. I see that. 14 Q. And I believe in your declaration you 15 specifically quote from the results section of Example 16 3, and that starts on page 29. 17 A. Sorry. Yes, I'm there. 18 Q. Okay. And in that first sentence, the second 19 half, it says: 20 "All sequencing reads with identical 21 cypher pairs and their reverse complements were 22 grouped into families to create a consensus

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Tecan Ex. 2036, Page 33 of 76

IDT, Inc. v. Tecan Genomics - IPR2025-00016

129 1 sequence." 2 Do you see that? 3 A. I'm sorry. Can you tell me which line number 4 we're -- 5 Q. Yeah. It's the second half of that first 6 sentence. So it's line 27, the second half of line 27. 7 A. Okay. Yes, I see that. 8 Q. And we talked about the concept of a consensus 9 sequence earlier today, right? 10 A. I recall discussing that. 11 Q. Okay. Now, here it says -- this grouping into 12 families, that was based on the cypher pairs and their 13 reverse complements, right? 14 A. The cypher pairs and their reverse complements 15 are used to group sequencing reads into families. 16 Q. And based on this disclosure, nothing else was 17 used to create these families, correct? 18 A. My interpretation of Example 3 is similar to my 19 interpretation of Example 1, which is that the cypher 20 sequence and the sequence of the DNA fragment are used 21 to identify duplicate sequencing reads and to collapse 22 those into single molecules.	131 1 nucleotide identities in the DNA fragment. 2 (Reporter clarification.) 3 A. I'm sorry. Nucleic acid fragment I think is 4 what I said. I think. 5 Q. So the members of Cypher Family 1 do not all 6 contain the same nucleic acid sequence, correct? 7 A. The sequencing reads in Cypher Family 1 do not 8 all have the same sequence. 9 Q. They do, though, all have the same two cyphers, 10 right? 11 A. They all have the same two cypher sequences. 12 Q. So if we turn back to the paragraph at the 13 bottom of page 29 of Bielias? 14 A. I see that. 15 Q. Sorry. If we turn back to the bottom of page 16 29, I'd like to go through the steps that are outlined 17 in the results section. So in the top of that section: 18 "TP53 Exon 4 DNA from a dual cypher 19 vector library produced in E. Coli was 20 sequenced with a depth of over a million." 21 So that's the -- the samples were 22 sequenced, to put it in laymen's terms?
130 1 Q. And what in Example 3 allows you to make that 2 conclusion? 3 A. My conclusion is based, in part, on Figure 3B 4 which is referenced in Example 3 to illustrate the 5 process used by Bielias. 6 Q. So Figure 3B, it's on the first page of the 7 exhibit. It's also in a bigger form on page -- the 8 easiest is at the bottom of the page. It's 1013.0043. 9 A. I see that. 10 Q. And here you have Cypher Family 1. And that 11 has a striped -- the batches on the ends of the lines 12 are the cyphers; is that accurate? 13 A. Cypher Family 1 has vertical stripes and a dark 14 black rectangle that denote the cyphers. 15 Q. Okay. And so Cypher Family 1, those all have 16 the vertical stripes on one end and a solid black 17 rectangle on the other end, correct? 18 A. I see that. 19 Q. And they have different dots in the -- in the 20 lines connecting the cyphers, which is, I think, 21 supposed to represent the sequence, correct? 22 A. The little circles are representing certain	132 1 A. The samples were sequenced. 2 Q. Okay. Then: 3 "All sequencing reads with identical 4 cypher pairs and their reverse complements were 5 grouped into families to create a consensus 6 sequence." 7 So that's what we were talking about 8 that's represented in Figure 3B, right? 9 A. Figure 3B is describing this process. 10 Q. Okay. So then -- then it goes on to say: 11 "As illustrated in Figure 3B, errors 12 introduced during library preparation (open 13 circle) and during sequencing (gray circle and 14 triangle) were computationally eliminated from 15 the consensus sequence, and only mutations 16 present in all reads (black diamonds, Figure 17 3B) of a cypher family were counted as true 18 mutations (see bottom of Figure 3B)." 19 Do you see that? 20 A. I see that. 21 Q. So Bielias decided whether to eliminate reads 22 based on the frequency of new mutations; is that

133 1 accurate? 2 MR. FLETCHER: Objection. 3 A. There are several things going on in the 4 analysis performed by Bielas. Bielas is removing 5 certain reads that contain single-nucleotide differences 6 that occur at lower frequencies than in other reads. 7 Bielas is also comparing the sequences of different 8 strands of the same originating molecule. Bielas is 9 also, in Figure 3B, annotating a specific nucleotide as 10 a "true mutation," which necessitates comparison to a 11 reference genome. 12 That is part of why I interpret Bielas as using 13 both information in the DNA fragment and the cypher in 14 this process. 15 Q. Okay. Let's go back to my question. 16 Bielas -- when looking at the mutations in the 17 sequencing reads, Bielas eliminated unique mutations; is 18 that accurate? 19 MR. FLETCHER: Objection. 20 A. There is an example in Figure 3B of a mutation 21 that occurs in only one fragment that was removed and 22 does not appear in the de-duplicated fragment. That	135 1 Q. And when those errors are removed, they're not 2 looking for duplicates, right? They're looking for 3 errors? 4 MR. FLETCHER: Objection. 5 A. Errors can arise in the form of PCR duplicates. 6 So for example, in Figure 3B, the nucleic acid fragment 7 with the triangle mutation is a PCR duplicate of the 8 other DNA fragments that are depicted there. 9 They originate from the same original -- sorry, 10 they originate from the same fragment in the original 11 sample. 12 Q. But you would agree that the -- the nucleic 13 acid with the triangle mutation or indication in Figure 14 3B, that does not have a duplicate that is depicted in 15 Figure 3B, correct? 16 A. My understanding of Figure 3B is that all of 17 the nucleic acid fragments depicted there are PCR 18 amplicons that came from the same original fragment. 19 They are all duplicates of each other. 20 I just will add one point of clarification. I 21 think of -- and I think the field broadly thinks of PCR 22 as a duplication process and what's shown in Figure 3B
134 1 would be, for example, the white triangle. 2 Q. And so when Bielas is talking about 3 eliminating -- computationally eliminating -- from the 4 consensus sequence -- 5 (Reporter clarification.) 6 MS. CIPRIANO: Consensus sequence. 7 (Reporter clarification.) 8 MS. CIPRIANO: I don't remember what I 9 said. Let me start over then. 10 BY MS. CIPRIANO: 11 Q. So Bielas is talking about computationally 12 eliminating data from the consensus sequence. And the 13 data that he's excluding in that process are errors 14 introduced during library preparation and errors 15 introduced during sequencing. 16 Is that a fair read of the information at the 17 bottom of page 29? 18 MR. FLETCHER: Objection. 19 A. The Bielas technology is designed to remove 20 mutations that occur due to errors made by DNA 21 polymerase during PCR amplification and errors made 22 during sequencing.	136 1 is a de-duplication process. 2 Q. So if these are all duplicates in your 3 definition, how does Bielas distinguish between "real 4 mutations" and "error mutations"? 5 A. The most basic criterion for identifying a real 6 mutation is that a nucleotide position must differ from 7 some reference. 8 Secondarily, Bielas is also assessing the 9 frequency with which a given nucleotide substitution 10 occurs among a group of reads. 11 And also, Bielas is comparing strands that 12 originate from the same original fragment and therefore 13 should have the same sequence. 14 Q. So in Example 3 on page 30, looking at the 15 second paragraph for the results section, it says: 16 "Wild type TP53 exon 4 sequence was 17 compared to the actual sequence results and 18 substitutions were plotted." 19 Can you explain to me the difference 20 between the exon -- the wild exon 4 sequence 21 and the actual sequence results? 22 A. In this context, the sequence of wild type TP53

137 1 exon 4 is used as a reference sequence to which the 2 sequencing results from the experiment in Example 4 are 3 compared. 4 Q. Okay. If we can go back to your declaration 5 and specifically if we looked at paragraph 512. 6 A. Okay. 7 Q. Here, we talked about before that -- this is 8 starting on paragraph 512, you're talking about the 9 obviousness or obviousness arguments based on Bielas, 10 right? You're talking about the obviousness arguments 11 based on Bielas? 12 A. This paragraph refers to my obvious arguments 13 based on Bielas. 14 Q. Okay. And the specific limitations that you 15 talk about in your obviousness analysis are in paragraph 16 513, you talk about the sample indexing and multiplexing 17 limitations, right? 18 A. I see that. 19 Q. And then in paragraphs 514 through 519, the 20 limitations you talk about in those paragraphs are the 21 limitations related to the length of the identifier 22 site; is that accurate?	139 1 duplicates limitation in your obviousness analysis? 2 A. This section does not have a specific 3 discussion about Claim 1D, but my opinion is that all of 4 Claim 1 would have been obvious based on Bielas. 5 There's a statement here -- 6 Q. Where are you? 7 A. Sorry. 8 Q. Okay. 9 A. One second. To the extent that Example 1 -- 10 sorry. I'm looking at paragraph 512. 11 Q. Okay. 12 A. "To the extent that Example 1 and Example 3 do 13 not teach every element of Claim 1 arranged as in the 14 claim so as to anticipate Claim at a minimum, Bielas 15 renders Claim 1 obviousness for the same reasons I 16 discuss above," I won't read the section numbers but 17 they're there, so the anticipation -- I'm applying the 18 anticipation argument to an assessment of obviousness in 19 this statement. 20 Q. And just to confirm, you don't specifically 21 call out the obviousness of the identifying duplicates 22 limitation in this obviousness section that starts at
138 1 A. Those paragraphs discuss the length of the 2 identifier site. 3 Q. And you did not provide any other analysis 4 regarding whether the identifying duplicates limitation 5 of Claim 1 would have been obvious, correct? 6 A. Those are the two major arguments related to 7 obviousness described in this section. 8 Q. And there's no discussion about the obviousness 9 of the identifying duplicates limitations, correct? 10 A. There is quite a bit of discussion here about 11 the de-duplication process in Bielas as relates to the 12 length of the identifier site. 13 Q. Okay. But are you -- have you taken the 14 position in your declaration that to the extent Bielas 15 does not disclose the identifying duplicates limitation 16 of the challenged claims, that it would have been 17 obvious to a person of ordinary skill in the art? 18 A. The title of the section is, to the extent that 19 Bielas does not anticipate Claim 1, Claim 1 would have 20 been obvious based on Bielas. So that statement 21 encapsulates all of Claim 1. 22 Q. And I'm asking, did you address the identifying	140 1 512, paragraph 512, right? You just rely on your 2 previous discussion of that limitation? 3 A. In this section, I refer specifically to other 4 sections and apply them to my assessment of obviousness. 5 Those sections have very detailed discussions of the 6 limitations of, for example, Claim 1D. 7 Q. Sure, and I understand that. I'm saying, you 8 refer to other sections in your declaration, you also 9 call out specific limitations in the obviousness section 10 of your declaration and talk about why those would have 11 been obvious. 12 The identifying duplicates limitation are not 13 included in those additional limitations that you call 14 out in your obviousness analysis, correct? 15 A. There isn't a detailed discussion of Claim 1D 16 in this section, where I'm analyzing obviousness. This 17 section focuses on other limitations. 18 MS. CIPRIANO: Okay. It might be a 19 good time to take a break. 20 MR. FLETCHER: We can go off the 21 record. 22 (Time Noted: 4:05 p.m.)

Transcript of Peter Sims, Ph.D.
Conducted on June 26, 2025

36 (141 to 144)

141	143																																																																																
1 ACKNOWLEDGMENT 2 3 STATE OF NEW YORK) :ss 4 COUNTY OF QUEENS) 5 6 I, PETER SIMS, Ph.D., hereby certify that I 7 have read the transcript of my testimony taken under 8 oath in my deposition of the 26th day of June, 2025; 9 that the transcript is a true, complete and correct 10 record of my testimony, and that the answers on the 11 record as given by me are true and correct. 12 13 14 _____ 15 PETER SIMS, Ph.D. 16 17 Signed and subscribed to before me, this day 18 of , 2025. 19 20 _____ Notary Public, State of New York 21 22	1 ERRATA SHEET 2 CASE NAME: INTEGRATED DNA TECHNOLOGIES, INC. V. 3 TECAN GENOMICS, INC. 4 DATE OF DEPOSITION: June 26, 2025 5 WITNESS'S NAME: PETER SIMS, Ph.D. 6 <table border="1"><thead><tr><th>7</th><th>PAGE</th><th>LINE (S)</th><th>CHANGE</th><th>REASON</th></tr></thead><tbody><tr><td>8</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>9</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>10</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>11</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>12</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>13</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>14</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>15</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>16</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>17</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>18</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>19</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>20</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>21</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr><tr><td>22</td><td>_____</td><td>_____</td><td>_____</td><td>_____</td></tr></tbody></table>	7	PAGE	LINE (S)	CHANGE	REASON	8	_____	_____	_____	_____	9	_____	_____	_____	_____	10	_____	_____	_____	_____	11	_____	_____	_____	_____	12	_____	_____	_____	_____	13	_____	_____	_____	_____	14	_____	_____	_____	_____	15	_____	_____	_____	_____	16	_____	_____	_____	_____	17	_____	_____	_____	_____	18	_____	_____	_____	_____	19	_____	_____	_____	_____	20	_____	_____	_____	_____	21	_____	_____	_____	_____	22	_____	_____	_____	_____
7	PAGE	LINE (S)	CHANGE	REASON																																																																													
8	_____	_____	_____	_____																																																																													
9	_____	_____	_____	_____																																																																													
10	_____	_____	_____	_____																																																																													
11	_____	_____	_____	_____																																																																													
12	_____	_____	_____	_____																																																																													
13	_____	_____	_____	_____																																																																													
14	_____	_____	_____	_____																																																																													
15	_____	_____	_____	_____																																																																													
16	_____	_____	_____	_____																																																																													
17	_____	_____	_____	_____																																																																													
18	_____	_____	_____	_____																																																																													
19	_____	_____	_____	_____																																																																													
20	_____	_____	_____	_____																																																																													
21	_____	_____	_____	_____																																																																													
22	_____	_____	_____	_____																																																																													
1 CERTIFICATE 2 I, BROOKE E. PERRY, Certified Reporter and Notary Public within and for the State of New York, do hereby 3 certify: That PETER SIMS, Ph.D., the witness whose deposition 4 is hereinbefore set forth, was duly sworn by me before the commencement of such deposition and that such 5 deposition was taken before me and is a true record of the testimony given by such witness. 6 I further certify that the adverse party, TECAN GENOMICS, INC., was represented by counsel at the 7 deposition. I further certify that the deposition of PETER 8 SIMS, Ph.D., occurred at the offices of Williams & Connolly LLP 650 Fifth Avenue Suite 1500 New York, NY 9 10019 on Thursday, June 26, 2025, commencing at 9:15 a.m. to 4:05 p.m. 10 I further certify that I am not related to any of the parties to this action by blood or marriage, 11 I am not employed by or an attorney to any of the parties to this action, and that I am in no way 12 interested, financially or otherwise, in the outcome of this matter. 13 IN WITNESS WHEREOF, I have hereunto set my hand this 30th day of June, 2025. 14 15 <i>Brooke E. Perry</i> 16 _____ BROOKE E. PERRY 17 18 19 20 21 22	1 PETER SIMS, Ph.D. 2 3 SUBSCRIBED AND SWORN TO BEFORE ME 4 THIS ____ DAY OF _____, 20__. 5 _____ 6 (NOTARY PUBLIC) MY COMMISSION EXPIRES: 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22																																																																																

A			
a5	137:7, 137:8,	117:12, 122:3,	48:18, 48:19,
120:21, 121:3	137:10, 137:15,	126:20, 130:12,	49:1, 58:6,
abbreviation	137:16, 137:20,	133:1, 133:18,	62:19, 65:20,
97:8	138:8, 138:10,	137:22	66:4, 66:5,
ability	139:3, 140:10	accurately	66:7, 71:6,
7:1, 90:13	above	13:16, 34:22,	73:20, 76:21,
able	139:16	61:4, 71:5,	78:18, 78:22,
8:19, 74:18,	absolutely	77:20	82:11, 83:12
88:3, 95:8	50:20	accused	action
about	abstract	6:5, 6:9	142:19, 142:21
9:18, 12:12,	78:1	achieved	active
18:3, 20:15,	abundance	69:3	43:11
27:6, 27:13,	72:13, 73:1,	acid	activity
28:9, 28:18,	73:3, 73:4,	32:3, 32:12,	55:13, 55:15
33:17, 34:6,	76:20, 79:14,	43:19, 49:7,	acts
34:8, 35:22,	82:10	50:17, 51:2,	78:15
36:17, 38:5,	abundances	51:5, 51:12,	actual
38:10, 39:7,	77:5	52:1, 52:11,	88:11, 108:14,
39:8, 40:3,	abundant	52:14, 56:2,	136:17, 136:21
45:12, 46:10,	72:15, 72:16	57:12, 57:13,	actually
47:15, 47:22,	accomplished	62:12, 62:16,	21:13, 22:5,
49:19, 50:1,	55:10	64:3, 64:4,	24:7, 35:12,
50:9, 50:10,	according	66:8, 67:10,	35:17, 36:16,
50:21, 51:7,	26:4	67:12, 71:11,	37:3, 37:5,
51:18, 52:18,	accuracy	71:15, 73:2,	49:16, 72:14,
55:21, 56:14,	76:3, 76:16,	76:3, 76:16,	75:15, 76:13
63:10, 64:11,	91:21	77:2, 78:16,	adapter
64:17, 74:13,	accurate	79:15, 81:2,	52:12, 54:9,
80:10, 80:17,	9:22, 10:1,	82:2, 83:11,	55:1, 57:19,
82:3, 82:6,	10:19, 17:6,	84:8, 85:10,	59:3, 59:22,
85:7, 86:10,	17:7, 17:8,	85:18, 85:21,	60:19, 61:19,
94:5, 94:22,	23:18, 27:1,	87:13, 89:1,	67:22
98:16, 99:13,	34:20, 36:19,	89:11, 90:2,	adapter-specific
100:5, 100:6,	39:11, 39:22,	99:2, 99:20,	54:18, 57:11
102:5, 106:3,	40:1, 42:5,	100:3, 101:15,	adapters
106:14, 106:15,	42:7, 43:7,	103:10, 104:8,	50:11, 50:12,
107:15, 110:15,	48:2, 48:18,	104:12, 105:5,	51:8, 51:9,
110:16, 111:1,	48:21, 49:21,	105:8, 105:10,	51:10, 51:16,
112:14, 115:2,	51:21, 52:3,	105:15, 105:19,	51:20, 51:22,
115:14, 116:21,	53:3, 56:2,	105:21, 106:3,	52:2, 52:4,
117:1, 117:19,	58:4, 60:15,	106:9, 106:14,	52:8, 52:15
117:20, 119:5,	70:13, 70:18,	106:17, 113:8,	adaptor
119:13, 120:21,	80:12, 82:6,	113:21, 122:18,	67:3, 67:20,
122:20, 128:5,	88:7, 93:3,	131:3, 131:6,	78:5, 116:1,
129:8, 132:7,	95:1, 95:12,	135:6, 135:13,	116:5, 116:7,
134:2, 134:11,	96:15, 106:22,	135:17	116:8, 116:15,
	108:8, 110:19,	acids	116:17
	111:8, 112:7,	32:10, 41:17,	adaptors
			69:1, 98:22

add 135:20 adding 52:16, 125:16 addition 37:4, 127:14 additional 52:16, 65:10, 140:13 additionally 67:21 address 4:8, 138:22 adult 109:12 advancement 65:18 adverse 142:10 after 26:22, 34:4, 34:5, 34:6, 47:6, 52:18, 61:5, 62:4, 63:7, 72:11, 77:2, 78:1, 85:10, 100:18, 101:4, 111:7, 111:14, 112:15, 112:22, 123:1 again 61:2, 61:9, 102:6, 117:5, 122:11 against 1:10, 108:1, 108:10 ago 5:10, 5:12, 14:7 agree 20:22, 21:2, 33:10, 34:10, 37:21, 38:12, 72:20, 90:12, 92:3, 96:3, 96:7, 101:21, 105:15, 116:5,	119:12, 122:21, 135:12 ahead 53:13, 98:10 al 10:6, 76:19 alert 13:9 algorithm 90:7 algorithms 19:5, 45:11, 90:2 align 107:1, 109:18 aligned 107:13, 108:12 aligner 111:12, 111:16 alignment 31:2, 108:10, 111:10, 111:15, 112:18, 128:2, 128:9 aligns 107:3, 107:4, 108:13 all 9:13, 13:15, 20:13, 28:7, 33:6, 33:9, 52:4, 52:8, 58:7, 58:11, 82:12, 84:4, 85:16, 86:9, 89:3, 89:6, 89:9, 108:16, 117:14, 123:20, 124:15, 125:6, 125:12, 125:17, 126:4, 126:17, 128:20, 130:15, 131:5, 131:8, 131:9, 131:11, 132:3, 132:16, 135:16, 135:19, 136:2, 138:21, 139:3	allow 29:3 allows 36:7, 130:1 alludes 28:12 almost 20:13 along 7:20, 98:20 already 52:15, 58:12, 70:7, 97:8, 123:18 also 2:22, 4:18, 8:11, 12:22, 14:19, 19:15, 20:2, 20:4, 40:22, 41:9, 41:16, 42:15, 51:16, 56:13, 57:14, 64:5, 68:18, 69:4, 71:5, 73:8, 73:12, 77:7, 77:9, 86:1, 89:9, 89:14, 96:3, 98:22, 106:10, 107:5, 114:22, 119:14, 120:15, 120:22, 128:10, 130:7, 133:7, 133:9, 136:8, 136:11, 140:8 although 29:11, 64:19, 67:20 always 8:3, 16:16, 43:4, 46:20, 49:3 amend 15:9, 15:14 amine 67:21 amino 41:17	among 30:9, 38:8, 61:2, 105:11, 109:17, 136:10 amount 28:20, 90:12 amplicons 72:11, 72:12, 85:22, 86:6, 87:3, 135:18 amplification 31:12, 31:15, 31:18, 31:20, 32:2, 33:7, 53:19, 53:22, 54:14, 54:16, 57:9, 57:12, 57:21, 58:1, 58:3, 62:12, 62:16, 72:2, 72:11, 78:4, 78:6, 78:7, 78:11, 78:13, 78:20, 85:8, 85:9, 86:9, 86:11, 87:8, 87:9, 90:21, 121:19, 134:21 amplified 32:13, 52:12, 62:20, 64:5, 67:13, 71:13, 71:16, 72:16, 87:1, 89:1 amplifies 78:17, 78:22 amplify 48:5, 48:11, 54:22, 55:6, 56:13, 58:9, 64:3, 71:19 amplifying 85:12, 85:14 analogy 45:17, 45:21, 71:6 analysis 20:1, 29:21,
---	--	--	---

31:22, 64:6, 64:19, 66:19, 76:4, 76:8, 77:3, 77:8, 109:21, 111:2, 111:6, 112:13, 112:15, 118:5, 122:12, 133:4, 137:15, 138:3, 139:1, 140:14 analytical 28:14 analyzer 109:10 analyzing 19:5, 101:13, 140:16 anchored 52:20, 94:1 anna 2:10, 4:18 anneal 84:9, 85:18 annealing 83:18, 83:20, 84:1, 84:7, 85:2, 85:10 annotating 133:9 anomaly 72:20 another 7:7, 69:7, 78:16, 100:6, 101:7, 103:10, 114:20, 122:18, 127:22 answer 6:22, 7:1, 7:11, 7:15, 8:9, 8:20, 43:6, 60:3, 61:4, 61:10, 63:3, 71:22, 75:17, 91:11, 98:15 answers 6:15, 91:12, 141:11	anticipate 138:19, 139:14 anticipates 118:14 anticipation 35:9, 35:22, 118:11, 139:17, 139:18 any 8:4, 8:19, 9:2, 13:19, 14:12, 14:15, 16:12, 22:2, 23:6, 23:8, 31:7, 63:8, 63:22, 66:16, 73:17, 83:7, 83:14, 90:13, 123:7, 126:19, 127:4, 138:3, 142:18, 142:20 anyone 9:7, 9:9, 14:10 anything 15:7, 15:14, 16:7 anyway 103:4 anywhere 20:18, 22:10, 108:13 apart 10:22 apologies 19:16, 25:8 app 66:18 appeal 1:2, 16:3 appear 24:18, 33:21, 34:2, 74:5, 133:22 appears 12:22 application 10:4, 10:7, 14:5, 30:20,	52:6, 60:14, 62:17, 94:18, 95:2, 95:11, 96:18, 97:2, 122:4, 122:7 application-spec- ific 66:1, 91:7, 92:21 applications 17:22, 18:11, 44:20, 44:22, 52:7, 65:14, 66:19, 71:21, 90:18, 96:12, 126:8 applied 59:8, 63:1 applies 34:10 apply 86:10, 98:4, 119:16, 121:1, 121:4, 140:4 applying 139:17 appreciate 39:17 approach 61:19 approaches 28:14 appropriate 52:15, 84:18 approximately 5:9, 5:10, 9:16, 21:16 archer 94:1 ardsley 4:9 area 17:19, 17:21, 18:9 areas 18:1, 49:7 argument 139:18	arguments 102:13, 116:21, 137:9, 137:10, 137:12, 138:6 arise 135:5 arises 19:6 around 51:21, 74:9 arranged 139:13 arrive 97:15, 101:17 arrives 101:13 arrow 54:6 art 13:14, 13:18, 13:19, 13:22, 35:11, 35:12, 35:17, 35:20, 35:21, 36:1, 36:7, 36:16, 37:3, 84:17, 97:7, 97:10, 97:14, 97:21, 98:12, 138:17 article 10:6, 36:9, 58:20, 62:22, 63:2, 63:4, 63:14, 94:7, 115:6 articles 27:3, 27:5, 27:6, 27:8, 27:11, 27:14, 27:16 artifact 72:19, 73:6, 73:12, 73:18, 74:2, 74:11, 74:12, 74:16, 74:19, 74:22, 75:4, 75:6, 76:14, 76:18,
---	---	---	--

77:17, 77:21, 91:14, 121:19, 122:1 artifacts 31:21, 32:1, 71:14, 71:18, 72:1, 72:3, 73:14, 73:16, 74:3, 74:14, 75:16, 75:20, 76:2, 76:5, 76:9, 76:16, 77:1, 77:4, 77:7, 77:10, 77:12, 82:16 artifactual 91:9 aside 125:5 asked 74:10 asking 5:3, 6:15, 8:14, 138:22 aspect 36:5, 127:22 aspects 36:13, 81:5, 81:17, 82:4, 117:21 assemble 45:3, 45:6 assembled 45:13 assembly 45:9 asserted 102:14 assessed 127:20 assessing 136:8 assessment 107:5, 128:2, 139:18, 140:4 assigned 24:19, 27:3, 48:17	associate 17:16, 18:4 associated 14:14, 89:14 assume 8:10 assumed 97:12 attached 41:17, 52:4, 52:8, 52:15, 73:21, 73:22, 84:6 attempt 64:9, 91:5 attempting 45:3, 51:3, 58:9, 64:3, 90:16 attempts 44:3 attention 10:9 attorney 14:10, 142:20 attorneys 2:3, 2:13, 8:16 attributes 68:12 author 22:8, 64:13 authors 35:11, 35:16, 36:1, 36:15, 37:3, 37:8, 54:5, 54:21, 55:7, 59:14, 94:14, 94:15 available 22:13, 58:21 avenue 1:19, 2:4, 2:14, 142:15 average 44:1, 44:2 avoid 91:14 aware 14:21	B back 11:9, 40:15, 45:17, 66:21, 80:4, 98:11, 115:13, 119:9, 121:8, 124:9, 131:12, 131:15, 133:15, 137:4 background 12:20, 13:2, 13:14, 20:19, 33:15 background-relat- ed 13:3, 14:6 backtrack 98:11 barcoding 70:17 base 33:1, 55:11, 56:18, 57:1, 58:21, 84:2, 90:9 based 35:10, 35:21, 36:18, 42:2, 60:17, 60:19, 61:8, 61:18, 62:21, 112:19, 118:17, 118:20, 126:15, 129:12, 129:16, 130:3, 132:22, 137:9, 137:11, 137:13, 138:20, 139:4 bases 44:6 basic 136:5 basically 51:20 basis 20:1 batches 130:11	bead 85:19, 85:20, 86:2, 86:3 beavers 2:19, 4:13, 4:14 because 27:8, 27:11, 48:22, 50:8, 58:5, 59:9, 72:15, 85:16, 86:6, 86:13, 86:21, 87:11, 91:1, 103:4, 120:14 become 73:22 been 4:1, 5:5, 5:6, 5:8, 6:8, 6:10, 6:21, 10:8, 14:13, 14:18, 14:19, 44:3, 47:8, 50:11, 58:12, 59:7, 64:2, 70:7, 93:14, 94:21, 95:3, 95:6, 97:8, 103:5, 115:2, 116:22, 117:2, 118:19, 138:5, 138:16, 138:20, 139:4, 140:11 before 1:2, 1:21, 5:5, 5:6, 7:15, 11:9, 23:7, 23:9, 26:5, 26:10, 34:9, 53:2, 64:17, 92:14, 102:12, 137:7, 141:18, 142:6, 142:8, 144:3 began 21:18 begin 21:17
---	---	--	--

beginning 21:10, 58:19, 116:20, 121:8, 124:6 behind 48:11 being 6:14, 66:8, 86:1, 110:7, 121:6 believe 24:8, 69:12, 69:21, 94:20, 102:7, 114:11, 125:19, 126:13, 128:14 below 54:6, 54:8 bench 19:2 benefit 66:9 benefits 65:21, 66:7, 66:10, 66:11, 66:16 besides 9:7, 9:9, 10:2, 22:11 best 7:1, 12:18 better 33:8, 68:1 between 13:8, 18:21, 23:4, 34:9, 38:7, 38:16, 41:14, 55:1, 78:13, 96:14, 105:2, 119:17, 120:10, 125:4, 136:3, 136:20 bias 32:2, 32:9, 32:11, 78:3, 78:13, 79:7, 79:12 biased 55:14, 55:16	bielas 10:7, 14:5, 116:22, 117:1, 117:2, 117:11, 117:14, 118:14, 118:17, 118:20, 120:16, 121:9, 121:12, 122:1, 122:5, 122:6, 122:7, 123:2, 123:7, 123:10, 123:19, 124:2, 124:4, 125:1, 125:6, 126:1, 126:11, 126:12, 126:13, 126:16, 126:19, 127:2, 127:7, 128:1, 128:10, 130:5, 131:13, 132:21, 133:4, 133:7, 133:8, 133:12, 133:16, 133:17, 134:2, 134:11, 134:19, 136:3, 136:8, 136:11, 137:9, 137:11, 137:13, 138:11, 138:14, 138:19, 138:20, 139:4, 139:14 bigger 130:7 billions 88:4 bind 39:5, 48:10, 56:1, 57:5 binf 3:8, 23:22, 24:13 biology 18:1, 18:11, 81:2 biophysics 21:11 biosciences 5:20, 19:14,	20:10 bit 10:20, 20:15, 23:16, 25:15, 46:10, 47:21, 79:2, 80:17, 98:11, 115:14, 138:10 black 130:14, 130:16, 132:16 blocking 68:1 blocks 41:17 blood 142:19 blot 65:1 bmgh 94:14 board 1:2, 14:20, 16:3 both 10:18, 16:20, 18:15, 23:1, 33:22, 34:10, 38:14, 39:13, 39:20, 40:3, 40:4, 51:17, 51:21, 53:20, 57:18, 62:2, 63:5, 93:9, 93:22, 121:5, 123:4, 127:7, 133:13 bottom 11:10, 12:7, 16:22, 109:3, 109:5, 118:7, 130:8, 131:13, 131:15, 132:18, 134:17 bound 10:22, 85:21, 86:1 bowtie 109:13, 109:16,	109:17, 111:7, 111:10 box 54:8 bp 109:10, 109:11 breadth 36:6, 36:14, 66:3 break 7:14, 7:16, 7:21, 7:22, 32:7, 45:5, 46:4, 46:7, 79:20, 115:3, 115:10, 115:11, 140:19 breaks 7:13 broad 25:4, 30:8, 30:11, 38:3, 126:1 broader 125:5, 127:14 broadly 135:21 brooke 142:2, 142:29 build 21:13 building 2:14, 21:16, 23:5, 38:19, 41:17 bulk 23:2 bullet 80:18, 83:17, 87:18 bulleted 89:18 burrows-wheeler 111:12 bustamante 15:18, 15:19 bustamante's 15:5, 15:6,
---	---	--	---

15:13, 15:16	66:2, 66:4,	57:12, 61:20,	cipriano
C	67:21, 87:17	62:19, 64:3,	2:17, 3:3,
call	catalog	66:18, 67:10,	4:11, 4:12,
126:12, 139:21,	73:5	71:14, 71:21,	4:21, 5:2,
140:9, 140:13	catalytic	72:2, 74:3,	23:20, 24:3,
called	41:10	74:11, 74:13,	29:15, 46:3,
23:17, 23:19,	catch	111:3, 112:20,	46:8, 69:6,
25:10, 25:11,	70:8	123:11, 130:22,	69:13, 69:16,
39:3, 43:2,	categories	133:5	69:20, 70:1,
47:9, 47:11,	41:2, 88:19	certainly	70:3, 70:6,
71:3, 71:10,	categorized	38:21	70:9, 79:18,
111:12	73:18	certified	80:3, 115:4,
calling	cause	142:2	115:8, 115:12,
90:9	32:18, 33:7,	certify	134:6, 134:8,
calls	33:9, 33:11,	141:7, 142:4,	134:10, 140:18
107:8	55:7, 81:6,	142:10, 142:13,	circle
came	81:18, 89:13	142:18	132:13
47:6, 135:18	caused	chain	circles
can't	75:13, 76:11	48:1, 48:3	130:22
60:3, 63:8,	cdna	challenge	circumstances
77:11	45:9, 46:19,	104:4, 104:6,	111:3
cancer	47:1, 47:3,	104:7, 112:7	citation
18:1, 18:11	47:17, 47:19,	challenged	99:6
cannot	72:9, 72:10,	102:14, 117:15,	cite
127:19	72:12, 72:13,	138:16	108:19, 108:21
capabilities	72:14, 72:15,	change	cited
28:16	79:9	15:11, 15:14,	13:20, 13:22,
capacity	cell	16:8, 98:5,	69:11, 103:14
23:10	37:22, 38:2,	143:7	claim
careful	40:19, 41:3,	changes	58:5, 64:17,
7:6	41:7, 42:8	15:8, 15:16,	103:13, 104:11,
carefully	cells	16:10, 17:9	105:5, 112:11,
8:2, 45:22,	18:17, 18:18,	changing	118:6, 118:9,
60:4, 63:3	18:19, 18:20,	91:21	118:11, 118:14,
cartoon	19:2, 31:10,	characterization	118:16, 118:19,
72:5	41:13, 41:21,	65:1, 65:7	122:12, 138:5,
case	42:1	chart	138:19, 138:21,
1:4, 4:13,	cellular	120:7	139:3, 139:4,
5:16, 5:22, 6:1,	38:19	chemical	139:13, 139:14,
6:2, 6:3, 6:9,	center	89:10	139:15, 140:6,
6:11, 13:17,	17:18, 19:17,	china	140:15
42:20, 49:16,	19:21, 20:6,	22:13	claims
52:6, 52:16,	20:14	choi	102:14, 102:18,
56:10, 65:17,	certain	2:20	104:4, 104:6,
143:2	31:20, 32:3,	chose	104:7, 112:7,
cases	32:10, 36:10,	27:11	118:22, 138:16
49:14, 62:18,	36:13, 44:20,	chunk	clarification
	52:14, 55:8,	33:17	37:11, 81:9,

131:2, 134:5, 134:7, 135:20 clarified 126:2 clarify 8:5, 49:22, 57:17, 75:1, 96:13, 127:1 class 30:8, 30:11 classes 23:13, 23:15, 23:17 clause 123:1 clear 8:4, 39:19 clearer 44:10 clonal 78:6, 79:9, 86:5, 86:13, 86:19, 87:8, 87:9, 89:10, 90:21, 91:1 clonally 85:12, 85:14, 87:1, 88:22 cloned 59:1 cloning 65:2 coauthor 70:12, 70:14 code 40:6 coded 40:5 codes 38:14 coding 38:12, 38:15, 38:16, 38:18, 39:4, 39:10, 39:12, 39:14, 39:16, 39:20, 42:8, 42:19 coli 131:19	collapse 129:21 collapsed 113:14 collapsing 113:11, 113:15, 113:18, 114:1 colleagues 4:17 collected 88:7, 103:21, 111:21, 112:22 collection 88:20 collects 112:13 columbia 17:16, 17:18, 18:4, 19:21, 20:2, 20:14 column 67:16, 109:7 com 2:8, 2:18 combination 30:22, 57:10, 61:16, 67:20, 102:16, 102:19 combining 61:13, 67:4 come 47:7, 83:16 comes 61:5, 69:19 comfortable 27:13 commencement 142:7 commencing 142:16 comment 60:3, 64:2 commented 97:22 comments 98:7 commercially 22:12	commission 144:6 common 39:16, 40:18, 80:10, 80:14 commonly 75:6, 116:13 communication 9:3 communications 14:21 company 47:9, 47:11 compare 108:7 compared 101:5, 136:17, 137:3 comparing 127:20, 133:7, 136:11 comparison 16:19, 33:20, 104:7, 120:5, 133:10 compatible 28:15, 81:3 compensate 90:9 compilation 45:16 complementary 33:1, 54:7, 56:7, 56:11, 57:10 complements 128:21, 129:13, 129:14, 132:4 complete 141:10 completely 7:9, 14:7, 21:2 complex 66:3 complicate 64:5, 64:22, 65:6 complicated 59:9, 59:14,	60:1, 78:3 complimentary 49:14, 51:5 component 42:13 components 42:9, 42:11, 89:2, 123:13 comprising 103:9, 104:20, 122:17 compromise 118:13 computational 16:1, 18:16, 18:22, 19:4, 19:22, 28:10, 28:12, 28:16, 28:22, 29:20, 66:19, 76:7, 76:22, 77:9, 89:18, 90:3 computationally 124:14, 124:21, 124:22, 125:13, 125:16, 132:14, 134:3, 134:11 computer 19:5, 45:11, 88:16, 90:2, 90:6, 90:8, 109:17, 125:1 concept 33:10, 33:12, 33:13, 56:20, 57:9, 99:18, 99:19, 129:8 concepts 12:20, 12:21, 13:2, 27:14, 35:1, 35:4 conceptually 51:18 conclusion 127:12, 130:2, 130:3 conduit 38:6
---	--	---	--

confidence 61:11 confidently 59:17, 60:3, 63:3 confirm 10:18, 34:1, 118:7, 139:20 confused 50:20 confuses 42:21 confusion 8:5 connecting 130:20 connection 10:11, 14:13, 15:4, 125:3 connolly 1:19, 2:2, 4:16, 142:15 consensus 101:6, 101:10, 101:12, 101:17, 101:19, 128:22, 129:8, 132:5, 132:15, 134:4, 134:6, 134:12 consider 17:19, 85:5 considered 45:22, 125:9 consistent 95:13 construct 31:12, 31:16 constructing 21:22 construction 29:20, 44:16, 76:7, 76:22, 77:8 construed 114:8 consult 14:10 contain 38:19, 38:20,	40:11, 57:18, 87:4, 131:6, 133:5 containers 71:12 containing 108:9 contains 38:12, 38:14, 41:10, 42:8 content 24:9 context 31:14, 50:14, 72:3, 72:19, 77:17, 84:1, 84:7, 125:5, 126:3, 126:9, 127:14, 136:22 context-specific 126:2 contexts 126:8 continuing 98:20 continuous 39:10, 39:16 contrast 78:12 convenience 7:17 convention 25:19 conventional 78:2 convert 46:18, 47:17, 90:1 converted 47:3, 88:13 converting 47:19, 88:20 copied 56:8, 56:13, 57:6, 57:7, 57:14 copies 10:19, 10:22,	72:9, 72:10, 89:11, 100:12, 121:15 copy 55:19, 56:1, 56:16, 104:1, 112:1 copying 32:5, 32:17, 33:11 core 19:21 corner 11:10, 12:7, 45:18, 45:21 correct 10:12, 11:7, 11:18, 11:19, 12:5, 17:13, 19:18, 21:5, 23:14, 27:15, 33:3, 40:6, 40:7, 40:16, 42:6, 51:3, 53:4, 54:1, 54:12, 56:9, 57:6, 57:21, 77:6, 92:18, 95:5, 95:8, 96:9, 101:14, 104:13, 106:16, 116:7, 116:22, 118:12, 122:13, 122:14, 123:5, 129:17, 130:17, 130:21, 131:6, 135:15, 138:5, 138:9, 140:14, 141:10, 141:12 corrected 31:21 corrections 16:12 correctly 26:18 correspondence 14:19 corresponding 33:1, 72:12,	106:9, 113:8 cost 66:9 costs 29:11 could 7:15, 11:14, 16:18, 21:8, 23:20, 33:22, 35:5, 36:11, 37:12, 38:4, 38:10, 50:15, 56:10, 56:13, 57:14, 64:5, 66:20, 68:17, 69:3, 73:13, 73:16, 80:7, 92:2, 97:4, 100:5, 114:8, 118:7, 121:8 counsel 4:12, 6:21, 6:22, 9:3, 9:6, 9:7, 9:9, 9:12, 10:21, 13:13, 34:19, 34:21, 69:10, 97:17, 142:11 count 114:3 counted 132:17 counting 113:7, 114:4, 114:14, 114:18, 114:20, 115:1 counts 113:1 county 141:5 couple 44:5, 82:3, 103:19, 118:15 course 6:20, 23:19, 24:13, 24:14, 24:16, 24:17, 24:19, 24:21,
---	---	--	---

25:1, 25:3, 25:4, 26:4, 26:10, 26:11, 27:4, 61:20 court 6:17, 7:4, 24:4 cover 25:2 coverage 29:6, 66:11, 66:13, 66:14 create 74:2, 101:5, 107:14, 128:22, 129:17, 132:5 created 121:18 creates 33:3 criteria 112:20 criterion 136:5 critical 69:2 cross-referenced 119:17 crucial 41:11 cs 106:5 current 17:15, 18:2, 18:3, 19:7, 23:13 currently 17:13, 17:14, 19:13 cv 17:4, 17:5, 22:6, 22:16 cypher 123:3, 124:13, 125:15, 126:16, 126:22, 127:2, 127:8, 128:21, 129:12, 129:14, 129:19, 130:10,	130:13, 130:15, 131:5, 131:7, 131:11, 131:18, 132:4, 132:17, 133:13 cyphers 130:12, 130:14, 130:20, 131:9 D danaher 2:23, 4:19 dark 130:13 data 19:5, 28:20, 63:22, 64:14, 66:20, 72:20, 81:7, 81:19, 82:13, 85:3, 88:6, 88:10, 88:20, 88:21, 89:2, 89:5, 90:1, 90:2, 90:18, 91:1, 92:4, 92:10, 92:12, 92:20, 97:1, 106:4, 106:16, 108:7, 108:11, 109:21, 111:2, 111:6, 112:15, 113:6, 113:15, 113:16, 124:14, 125:17, 134:12, 134:13 date 17:8, 17:10, 24:2, 143:4 day 141:9, 141:19, 142:25, 144:4 days 38:4 dc 2:5 de-duplicate 121:15, 125:2, 125:4	de-duplicated 133:22 de-duplicating 97:1, 105:13 de-duplication 114:8, 114:10, 114:12, 116:10, 116:14, 126:6, 126:10, 126:12, 126:14, 127:9, 136:1, 138:11 dealing 87:12 decided 132:21 decision 16:4, 16:5, 16:10, 98:3 decisions 16:7 declaration 9:5, 9:6, 10:2, 10:5, 10:14, 11:5, 11:15, 12:2, 12:12, 13:20, 13:22, 14:4, 14:17, 15:5, 15:6, 15:9, 15:12, 15:13, 15:15, 15:16, 15:17, 20:17, 29:17, 33:15, 33:18, 34:7, 34:13, 40:20, 43:14, 46:13, 47:15, 53:6, 58:16, 58:18, 74:19, 74:22, 75:19, 84:3, 84:15, 84:17, 87:19, 92:8, 93:14, 93:19, 94:7, 95:3, 95:15, 97:3, 98:6, 98:9, 98:11, 99:11, 100:7, 102:9, 102:13,	102:22, 103:15, 104:16, 107:18, 108:20, 108:22, 112:5, 113:11, 115:19, 116:20, 120:18, 120:22, 121:4, 124:3, 124:8, 128:14, 137:4, 138:14, 140:8, 140:10 declarations 10:10, 10:13, 10:18, 12:13, 12:16, 13:4, 13:12, 13:15, 14:9, 16:9, 16:11, 16:13, 16:20, 33:22, 34:10, 48:5, 48:16, 80:5, 93:9, 93:12, 94:22, 97:12 deconvolute 124:14, 124:21, 125:1, 125:4, 125:13, 125:16, 126:1, 126:5, 126:7, 126:9, 126:17, 127:3 deconvolution 125:11 decreasing 29:12 deep 3:8, 23:17, 23:19, 23:22, 24:13, 24:19 deeply 29:8, 29:9 define 30:21, 47:4 defined 103:5, 123:12 definitely 96:11, 96:13, 96:16 definition 72:18, 74:2,
---	---	---	---

74:10, 74:12, 74:18, 77:12, 77:15, 97:20, 98:1, 98:4, 98:8, 136:3 degenerate 61:5 denote 130:14 dependent 77:18, 118:22 depends 47:4, 91:18, 100:11 depicted 114:15, 135:8, 135:14, 135:17 depleting 61:20 deposed 5:5, 5:6, 5:8 deposition 1:17, 5:12, 5:21, 6:1, 6:12, 6:20, 8:14, 8:15, 8:22, 9:1, 9:4, 9:8, 9:10, 9:14, 9:22, 12:11, 141:9, 142:5, 142:7, 142:8, 142:12, 142:13, 143:4 depositions 6:13 depth 131:20 derived 64:20 describe 53:14, 113:10 described 10:14, 53:18, 53:19, 53:22, 64:12, 67:9, 67:18, 77:20, 92:7, 96:3, 96:7, 101:22, 106:17, 112:21,	114:7, 126:10, 138:7 describes 48:13, 53:10, 61:13, 93:10, 113:5 describing 132:9 description 3:7, 24:17, 61:9 design 55:18, 55:21, 56:14, 69:1, 69:3, 87:6, 87:10 designed 28:14, 48:10, 57:8, 134:19 designer 68:15 desired 48:15, 49:11, 49:13 detail 64:15, 96:20 detailed 140:5, 140:15 details 14:7, 64:16, 98:1, 102:2 detect 28:22, 91:8 detected 110:16 detecting 29:3, 29:7, 45:17 detection 66:12 determination 89:19, 90:4 determine 108:12, 121:16, 122:1 develop 18:15 developed 27:10, 29:19,	47:10, 47:12, 61:14, 67:5, 76:6 developing 19:4, 21:22 development 17:22, 18:11, 18:14, 23:11, 53:2 devices 21:22 devoted 118:16 diamonds 132:16 differ 105:20, 136:6 difference 18:21, 34:5, 38:16, 73:4, 136:19 differences 13:7, 96:11, 96:14, 96:16, 120:10, 133:5 different 12:19, 37:22, 38:1, 40:16, 62:10, 78:14, 78:15, 78:16, 78:18, 82:4, 93:22, 95:17, 96:8, 96:21, 105:16, 106:12, 111:11, 126:7, 126:8, 130:19, 133:7 differently 85:16, 93:12, 94:20, 102:8 differs 107:6 difficult 25:7 digital 70:20, 71:2, 71:3, 71:7, 71:9, 71:10,	74:13, 74:15, 109:6 dilution 71:11 direct 46:22, 47:8, 47:10, 47:12, 76:17 directed 49:20, 50:2, 51:1 directionality 48:17 directly 79:8, 79:17 director 17:17, 19:17 disagreed 97:19 discarded 111:3, 112:19 disclose 116:6, 138:15 disclosed 95:18, 96:8, 96:12, 96:14, 96:17, 96:18, 99:18, 122:5 discloses 103:2, 104:18, 112:6, 112:11, 120:16 disclosure 36:19, 117:14, 123:8, 125:6, 127:14, 129:16 disclosures 117:11 discount 93:7 discuss 8:15, 99:11, 138:1, 139:16 discussed 81:22, 82:8, 86:12, 97:17, 112:18 discusses 60:10, 80:13,
--	---	---	--

118:19 discussing 51:14, 129:10 discussion 117:11, 117:13, 118:22, 119:9, 121:9, 138:8, 138:10, 139:3, 140:2, 140:15 discussions 140:5 distinction 39:17 distinguish 78:14, 124:16, 136:3 distort 73:1, 76:20, 79:14, 87:4 distortion 77:5, 82:10, 87:13 distributed 71:12 dive 115:13 dna 1:4, 4:17, 19:2, 22:9, 23:6, 23:8, 23:9, 27:22, 28:1, 30:22, 32:4, 32:5, 32:16, 32:17, 32:20, 33:6, 33:10, 33:11, 37:14, 37:21, 38:1, 38:3, 38:5, 38:12, 38:14, 39:7, 40:3, 43:1, 54:8, 55:13, 55:16, 55:19, 56:1, 56:4, 56:15, 56:20, 58:6, 59:1, 59:9, 60:16, 71:19, 71:20,	73:8, 78:15, 78:17, 86:21, 88:3, 89:6, 89:7, 90:21, 123:3, 127:9, 127:20, 129:20, 131:1, 131:18, 133:13, 134:20, 135:8, 143:2 document 12:4, 24:5, 24:7, 24:11, 25:7, 26:13, 123:22, 124:1 documents 9:21, 10:3, 14:12, 14:16, 16:10 doing 23:16, 45:14, 54:14, 122:12 domain 41:10 done 23:3, 23:6, 23:8, 33:20, 64:13, 64:15, 79:18, 93:11, 94:6, 95:10, 95:11, 128:6 dots 130:19 double-check 69:17 double-stranded 49:1 doubt 20:18, 57:13 down 7:5, 25:11, 25:15, 32:7, 45:5, 79:2, 93:15, 101:8, 103:19 downstream 48:15, 49:3, 49:6, 49:10, 55:14, 55:17,	55:20, 56:5, 56:16, 64:6 dr 4:22, 15:5, 15:6, 15:13, 15:16, 15:18, 15:19, 80:4 drawing 36:8, 71:6, 78:12, 105:1 drew 97:17 driver 68:11, 68:13 drosophila 110:10, 110:11, 110:18, 110:21 dual 131:18 due 67:19, 134:20 duly 4:2, 142:6 duplicate 103:8, 104:19, 114:5, 114:9, 122:16, 123:2, 129:21, 135:7, 135:14 duplicates 30:9, 114:9, 120:3, 121:14, 121:22, 135:2, 135:5, 135:19, 136:2, 138:4, 138:9, 138:15, 139:1, 139:21, 140:12 duplication 135:22 during 6:20, 8:14, 21:4, 21:6, 23:3, 32:4, 61:20, 67:9, 73:11, 73:22, 83:13, 86:19, 90:10, 90:21,	121:18, 132:12, 132:13, 134:14, 134:15, 134:21, 134:22 E each 26:22, 39:21, 51:17, 55:3, 65:11, 71:12, 71:13, 73:21, 73:22, 80:17, 89:12, 92:11, 100:18, 106:12, 107:22, 108:11, 108:12, 110:3, 110:13, 113:20, 135:19 earlier 5:11, 5:21, 81:22, 82:3, 82:7, 82:8, 129:9 ease 34:12 easier 16:6, 28:21, 50:8 easiest 130:8 easy 56:12 economic 29:9 edits 16:12 educational 20:16 effect 67:19, 68:8, 68:10, 68:13, 68:18, 69:2 effects 40:13 efficiencies 78:19 efficiency 43:13, 67:12,
---	--	--	---

78:15 efficiently 32:13, 56:13, 71:20, 72:2, 72:16 eighth 2:14 either 12:13, 49:8, 52:1, 59:9, 87:15 element 19:14, 20:10, 120:2, 121:1, 122:15, 122:20, 139:13 element-by-element 122:12 eliminate 132:21 eliminated 132:14, 133:17 eliminating 79:8, 134:3, 134:12 else 20:18, 129:16 employed 17:13, 17:14, 29:20, 37:9, 116:9, 142:20 enables 65:19 encapsulates 138:21 encode 28:7, 42:9, 42:12, 42:16 encodes 28:6, 39:8, 105:8, 105:9 encountered 16:15 end 21:12, 23:2, 42:15, 45:19, 48:19, 48:21,	52:1, 55:1, 55:2, 65:10, 67:15, 77:3, 79:4, 81:7, 81:19, 87:1, 130:16, 130:17 endogenous 99:3, 99:22 ends 42:14, 51:17, 51:21, 58:7, 130:11 enhance 62:18 enough 102:4 ensure 61:3 ensured 13:16 entail 18:5, 19:20, 21:19 entailed 21:20 entails 18:6 entire 29:9, 46:2 entirely 66:1 entitled 22:8, 34:16, 46:12, 80:19, 97:6, 118:13 equally 86:11 equate 105:4 equivalence 105:2 errata 143:1 error 33:3, 72:20, 82:5, 82:19, 85:3, 85:6, 86:21, 87:4,	89:5, 90:4, 90:13, 91:3, 93:6, 136:4 errors 33:4, 33:5, 33:7, 33:9, 33:11, 73:9, 73:14, 81:6, 81:18, 82:1, 82:11, 83:9, 86:10, 86:12, 87:11, 89:13, 89:16, 90:10, 90:17, 90:20, 91:5, 91:9, 91:17, 124:16, 132:11, 134:13, 134:14, 134:20, 134:21, 135:1, 135:3, 135:5 esq 2:7, 2:9, 2:10, 2:17, 2:19, 2:20 established 113:6 et 10:6, 76:19 eunbi 2:20 even 32:13, 36:12, 62:4, 63:7, 72:16, 88:4 ever 5:5, 106:21 every 52:6, 139:13 everyday 75:4, 75:6, 75:8 everything 7:5 evolving 99:11 exactly 49:4, 63:11, 91:11 examination 3:2, 4:20	examined 4:3, 60:16, 123:14 example 28:17, 28:19, 29:1, 30:9, 32:16, 32:22, 33:5, 35:19, 36:9, 38:6, 43:21, 62:11, 62:15, 65:15, 71:19, 73:5, 76:14, 81:3, 82:1, 82:10, 85:15, 85:17, 86:17, 88:11, 89:22, 90:20, 91:8, 91:13, 91:20, 99:14, 100:2, 113:20, 116:10, 119:20, 121:16, 123:4, 123:17, 124:6, 124:10, 124:12, 126:15, 127:11, 127:13, 127:21, 128:10, 128:15, 129:18, 129:19, 130:1, 130:4, 133:20, 134:1, 135:6, 136:14, 137:2, 139:9, 139:12, 140:6 examples 30:12, 39:2, 73:15, 74:11, 75:15, 77:14, 77:19, 83:7, 96:20, 99:12, 99:15, 99:16, 123:8, 123:12, 123:14 except 87:17 excluding 134:13 excuse 6:7, 20:21,
---	--	--	--

46:12, 47:21, 66:18, 95:11, 102:15 executing 90:7 exhibit 3:7, 10:5, 10:6, 10:8, 11:2, 11:5, 11:9, 11:16, 11:20, 12:2, 12:6, 12:21, 12:22, 14:3, 14:4, 16:19, 16:21, 20:17, 23:21, 24:1, 24:5, 24:6, 34:4, 34:13, 58:12, 58:14, 58:15, 69:9, 69:15, 69:21, 70:7, 70:10, 70:11, 93:15, 93:19, 95:14, 97:4, 108:15, 108:16, 108:18, 109:3, 114:16, 123:18, 123:20, 123:21, 130:7 exhibits 3:6, 69:11 exists 47:10 exome 28:3, 28:4, 28:5, 28:19, 29:5, 29:6, 29:8 exon 131:18, 136:16, 136:20, 137:1 exons 28:6, 39:13, 39:20, 40:3 expect 87:16, 92:17 expecting 6:22 experience 36:6, 36:8,	81:5, 81:17, 89:3, 97:18 experiment 69:3, 82:17, 82:18, 82:21, 83:1, 83:3, 106:8, 137:2 experimental 18:15, 18:22, 19:1, 26:14, 27:18, 27:20, 28:9, 28:10, 28:12, 28:13 experiments 19:22, 30:15, 30:19, 31:6, 31:8, 31:9 expert 5:13, 5:14 expertise 17:20, 17:21, 97:13 expires 144:6 explain 18:21, 21:8, 48:5, 48:9, 48:16, 55:15, 68:20, 71:9, 71:17, 72:6, 78:21, 83:20, 84:19, 85:8, 89:20, 101:4, 136:19 explained 20:21, 21:3 explains 127:2 explanation 111:2 explicitly 36:12 explore 99:1 exponential 57:8, 57:11, 57:20, 57:22, 58:3	exponentially 58:9 expression 40:12, 40:13 extends 32:20, 118:6, 119:1 extension 56:4, 57:3, 58:8, 73:11 extensive 19:9, 65:2 extent 12:20, 12:22, 13:7, 57:14, 75:17, 102:8, 108:13, 113:4, 138:14, 138:18, 139:9, 139:12 external 20:2 extreme 87:17 extremely 77:17 F face 12:4 facilitate 52:2, 56:4, 57:3, 57:8, 58:8 facilitated 68:18 facilitates 57:11 facility 19:22, 20:3, 20:5, 20:8, 20:9 factors 39:3 fair 7:8, 8:7, 8:8, 8:11, 8:12, 12:15, 49:9, 64:7, 68:7, 74:1, 84:22, 88:21, 120:22,	134:16 fall 10:22 familiar 69:8, 93:8 familiarity 27:12 families 128:22, 129:12, 129:15, 129:17, 132:5 family 100:19, 130:10, 130:13, 130:15, 131:5, 131:7, 132:17 far 13:1, 16:15, 86:14, 86:15 fast 29:12 feature 41:9 features 100:2, 100:3 fee-for-service 20:1 feel 20:18, 98:14 few 10:8, 17:11, 127:17 fewer 29:5 field 16:1, 25:4, 27:10, 97:18, 98:22, 99:9, 99:10, 135:21 fifth 142:15 figure 72:5, 74:17, 76:18, 114:16, 114:18, 114:22, 130:3, 130:6, 132:8, 132:9, 132:11, 132:16,
---	---	--	--

132:18, 133:9, 133:20, 135:6, 135:13, 135:15, 135:16, 135:22 figures 123:13 filed 94:15, 94:19 fill 36:3 final 44:18, 74:4 financially 142:22 find 66:22 finding 45:18 fine 34:11, 70:2, 96:5 finish 7:10, 7:11, 115:4 finished 21:15 firm 5:19 first 4:2, 22:8, 26:3, 26:8, 33:17, 61:2, 63:13, 64:8, 76:15, 80:18, 100:17, 101:17, 107:8, 108:6, 108:16, 109:5, 111:18, 112:18, 123:20, 124:11, 128:18, 129:5, 130:6 fix 68:5 fixed 84:9 flank 49:10, 49:12 fletcher 2:7, 4:15, 6:6,	10:21, 36:4, 36:20, 37:7, 44:15, 46:5, 52:5, 54:15, 60:7, 69:10, 69:14, 69:21, 70:2, 72:22, 73:7, 74:6, 75:10, 77:13, 77:16, 79:21, 96:10, 104:10, 105:18, 111:9, 112:17, 114:6, 115:2, 115:7, 123:9, 125:21, 126:21, 127:6, 128:8, 133:2, 133:19, 134:18, 135:4, 140:20 flip 116:19 flipped 72:14 fluorescence 90:1 fluorescently 21:21 fluorogenic 22:8 focus 70:15, 102:21 focused 21:9, 21:10, 96:22, 97:2, 117:22, 118:9, 122:7 focuses 18:10, 27:21, 28:11, 118:4, 140:17 focusing 122:15 following 25:18, 118:5, 118:21, 125:10 follows 4:3, 61:9 forgo 79:15	form 36:4, 43:3, 67:10, 88:9, 123:14, 130:7, 135:5 formed 45:22, 60:8 forth 33:15, 34:22, 98:5, 98:9, 124:9, 142:6 forward 62:12, 62:15 found 40:18, 64:20, 67:17, 68:4 fourth 67:1 fraction 28:21, 87:1 fragment 45:10, 51:6, 51:17, 55:3, 84:8, 85:11, 85:18, 85:21, 89:1, 89:11, 99:2, 99:21, 100:3, 103:10, 104:8, 104:12, 105:5, 105:8, 105:19, 105:22, 106:9, 113:8, 113:22, 121:17, 122:18, 123:4, 127:9, 127:21, 129:20, 131:1, 131:3, 133:13, 133:21, 133:22, 135:6, 135:10, 135:18, 136:12 fragment's 107:10 fragmentation 83:11 fragmenting 83:12 fragments 32:3, 32:12,	45:11, 45:13, 51:12, 51:19, 52:1, 52:4, 52:8, 52:11, 52:15, 57:12, 57:13, 57:17, 57:20, 57:22, 58:2, 62:13, 62:16, 64:3, 64:4, 67:10, 67:12, 71:11, 71:15, 73:2, 78:16, 79:15, 81:2, 82:2, 85:2, 85:12, 87:1, 87:13, 87:14, 88:4, 101:15, 105:10, 135:8, 135:17 free 20:18, 98:14 frequencies 133:6 frequency 33:9, 132:22, 136:9 frequently 29:19, 30:14, 30:21, 31:5, 76:6 front 10:18, 11:21, 12:1, 48:10, 80:5 full 44:13, 51:19, 61:22 fully 8:20, 58:17, 102:1 function 38:3, 39:6, 41:3, 41:6 functions 37:22, 38:1, 38:21, 39:1 fundamentally 95:17
--	--	--	--

further 25:11, 25:15, 64:22, 65:6, 79:2, 101:8, 142:10, 142:13, 142:18	generate 45:9 generated 28:20, 62:3, 63:6, 63:18, 101:19, 109:9 generates 89:1 generating 86:10 generation 20:5, 20:6, 47:5 genes 110:10 genetic 19:2, 42:8, 42:19, 48:6, 55:1, 55:2, 55:12 genome 17:18, 18:18, 19:17, 19:21, 20:6, 20:14, 28:2, 28:5, 28:21, 29:3, 29:10, 31:2, 38:7, 39:6, 42:1, 50:3, 50:4, 52:20, 53:11, 53:20, 54:17, 91:9, 105:21, 106:20, 107:1, 107:4, 107:6, 109:10, 109:13, 109:19, 110:11, 110:18, 111:7, 128:4, 133:11 genomes 18:16 genomic 18:10, 18:13, 19:7, 54:8, 58:6, 59:1, 59:9, 60:16 genomics 1:13, 16:1,	16:2, 17:21, 17:22, 25:4, 26:14, 26:19, 27:19, 142:11, 143:3 getting 36:22 give 26:11, 28:17, 30:11, 39:2, 74:12, 74:18, 77:11, 77:14, 86:17, 90:8, 94:10 given 26:9, 63:5, 68:22, 73:15, 74:11, 77:14, 89:11, 102:19, 106:9, 113:8, 136:9, 141:12, 142:9 giving 64:14, 91:13 glasses 69:19 gleaned 36:11, 36:13, 37:10 go 6:13, 27:6, 46:5, 83:6, 83:12, 83:21, 96:19, 101:4, 120:9, 121:8, 131:16, 133:15, 137:4, 140:20 goal 44:8, 52:3 goals 25:11, 44:8 goes 59:6, 104:21, 132:10 going 5:3, 8:9, 20:16, 33:16, 34:12, 38:9,	45:17, 90:7, 90:22, 103:4, 106:4, 108:15, 115:2, 115:13, 123:17, 133:3 good 4:22, 5:1, 28:19, 46:3, 79:19, 127:1, 140:19 goodwin 2:12 grad 22:22 graduate-level 25:3 gray 132:13 great 13:6 greatly 87:11 greenfield 5:19 ground 6:14 group 67:21, 129:15, 136:10 grouped 100:19, 101:17, 128:22, 132:5 grouping 101:5, 129:11 gs 106:5 guess 9:18, 26:5, 51:8, 61:8, 71:22, 79:3, 100:16 guessing 20:4
G			H
gain 29:6 gaps 36:3 gathered 81:7, 81:19, 82:14 gave 10:21, 18:2, 27:4, 32:16, 62:15, 68:18 gears 115:14 gene 39:9, 40:11, 40:13, 103:20, 105:6, 105:7, 105:11, 105:16, 106:21, 106:22, 107:3, 107:4, 107:9, 107:10, 107:11, 107:12, 107:22, 108:2, 110:3, 110:13, 110:14, 111:20 gene-specific 53:15, 54:1, 54:3, 54:6, 54:13, 54:17, 55:12, 55:20, 56:3, 56:8, 56:12, 56:16, 57:5, 57:10, 57:19 general 25:1, 43:1, 46:15, 50:9, 94:6, 117:13 generally 59:8			habit 95:8 hairpin 67:10

half 115:3, 115:22, 128:19, 129:5, 129:6 hand 123:18, 142:24 handed 24:4, 123:20 hands 62:2, 63:5, 64:14 handy 124:9 happen 82:9 happened 111:6 happening 89:10 happens 32:11, 32:18, 44:19, 56:20 happy 7:21, 74:22 head 94:21, 95:7, 96:4, 102:6 heading 93:22, 109:21 held 1:18 helicos 47:9 help 86:17, 92:2 helpful 31:15, 31:17, 75:17, 98:4, 102:4, 112:9, 113:4 here 9:19, 14:1, 16:13, 33:16, 41:2, 46:16, 55:6, 55:22, 60:6, 61:19, 63:10, 64:1, 68:22, 76:22,	77:11, 78:11, 87:12, 87:14, 94:5, 96:19, 97:16, 98:1, 100:1, 102:9, 106:7, 109:16, 110:8, 120:5, 125:12, 129:11, 130:10, 137:7, 138:10, 139:5 hereby 141:7, 142:3 herein 4:1 hereinbefore 142:6 hereunto 142:24 hi 4:11 high 9:3, 13:11, 67:17, 68:13, 70:15 high-level 80:11 high-throughput 25:20, 26:5, 26:7 higher 39:12, 39:19, 43:8, 66:11, 66:13 historical 27:9 hoagland-hanson 2:9, 4:18 holder 6:5, 6:8, 6:10 homopolymer 43:15, 43:18, 43:19 hospital 94:6 hour 115:3 hours 9:16, 9:18	however 59:7, 99:11, 111:14 huge 90:22 human 18:17, 18:19, 18:20 hundred 44:5 hybridization 65:2, 84:2 hybridize 58:7, 84:9 I iafrate 10:4, 94:21, 95:3, 95:9, 96:4, 96:7, 96:14, 96:18, 97:2, 102:17, 102:20, 115:14, 115:17, 116:2, 116:5, 116:8, 116:15, 116:17 identical 12:14, 34:3, 100:20, 101:18, 120:2, 128:20, 132:3 identification 24:2, 120:14, 121:4 identified 13:21, 14:2, 14:5, 100:19, 116:1, 123:2 identifier 30:7, 30:21, 99:3, 99:21, 100:4, 103:9, 104:8, 104:11, 104:14, 104:20, 105:2, 105:13, 116:6, 116:9, 116:16, 116:18, 120:3, 122:17,	137:21, 138:2, 138:12 identifies 102:22 identify 13:19, 106:20, 121:13, 129:21 identifying 14:3, 30:9, 103:8, 104:18, 106:21, 120:2, 121:22, 122:16, 136:5, 138:4, 138:9, 138:15, 138:22, 139:21, 140:12 identities 131:1 illumina 19:14, 20:10, 47:16, 84:13, 84:22, 88:11, 89:22, 91:19, 91:20, 109:10 illustrate 130:4 illustrated 76:18, 132:11 illustration 72:6, 72:8, 114:18, 114:20, 114:22 images 88:13 imaging 88:12, 89:15, 90:1 immunology 18:1, 18:12 impact 63:9, 77:7, 82:16, 82:20, 83:1, 83:2, 86:14, 86:15, 87:11, 90:17, 90:22, 92:12, 93:1, 93:6, 98:9 impactful 91:5
--	--	---	---

impacting 82:13, 92:4 imperfect 90:11 implement 92:2 implementations 62:10 imply 90:6 importance 27:9 important 35:4, 40:11, 40:13, 41:8, 44:21, 45:1, 45:2, 45:15, 68:15, 76:6, 87:6, 87:7, 87:10, 88:9 importantly 41:9 improve 90:13, 91:19, 92:4, 92:9, 92:20, 93:6, 98:20 improved 67:3 improvement 92:11 improvements 91:21, 92:16, 92:18 inadvertent 69:17 inc 1:4, 1:13, 142:11, 143:2, 143:3 include 39:13, 39:20, 40:4, 42:22, 43:4, 44:13, 50:15, 51:1, 66:11, 81:21, 116:8, 116:15, 116:17, 117:6	included 49:15, 52:19, 54:2, 140:13 includes 40:3, 40:21, 43:3 including 13:21, 17:21, 28:2, 94:18, 107:2 inclusion 44:17, 82:11 incorporate 29:22, 30:15, 30:16, 31:6, 32:22, 73:10, 76:8, 77:1, 77:9 incorporated 30:12, 30:18, 51:12, 98:21 incorporates 32:21 incorporation 32:5, 82:1 indeed 9:20 independently 13:19 index 3:1 indexing 137:16 indication 135:13 individual 31:10, 71:11, 71:15, 85:18, 92:11 individually 71:13 induce 91:9 inefficient 59:10, 59:15, 60:1 inferences 36:18, 45:12 information 31:1, 37:1,	37:2, 37:4, 37:9, 38:5, 38:7, 38:20, 42:3, 64:1, 64:11, 88:14, 105:8, 105:12, 105:17, 107:2, 107:7, 107:9, 111:15, 113:17, 119:16, 126:20, 126:22, 127:15, 133:13, 134:16 infringer 6:5, 6:9 initially 60:16 innumerate 58:7 input 58:6 insert 73:8 instance 63:10 instances 30:12, 66:6, 74:4 instead 111:11 institution 16:4, 16:7 instructed 6:22 instructions 38:19 instrumentation 89:14, 91:20, 91:22, 93:3 instruments 20:9, 20:11, 47:20 integrated 1:4, 4:16, 143:2 interact 41:15 interest 58:10	interested 66:4, 66:6, 142:22 interpret 35:20, 36:7, 54:12, 59:17, 104:13, 133:12 interpretation 60:12, 78:2, 125:22, 126:9, 127:7, 129:18, 129:19 interpreting 26:3 interrogating 18:16 interspersed 39:21 intervene 92:9 introduce 83:8 introduced 51:20, 54:5, 132:12, 134:14, 134:15 introduction 25:3, 25:19, 26:5, 26:7 introductory 123:1 introns 39:13, 39:14, 39:21, 40:4, 42:22, 43:3, 43:4 inventors 35:12, 35:17, 36:1, 36:16, 37:3 inverse 59:2, 59:21 investigated 60:14 investigators 20:2, 20:3 involve 51:16, 83:4
---	---	---	---

involved 21:21, 101:21 involves 61:5, 88:12 ion 47:16, 84:13 ipr 1:4, 1:6, 1:8, 1:10, 1:12, 1:14 iprs 11:6, 11:21 isoform 110:12 isoforms 110:11 issue 10:11, 35:1, 87:14 issues 86:9	108:9, 108:15, 108:19, 108:21, 110:11, 110:17, 112:6, 112:11, 112:13, 113:1, 113:5, 114:10, 114:11, 114:15, 114:19, 114:21, 115:1 kivioja's 108:6 know 7:21, 8:1, 13:8, 15:18, 15:19, 15:20, 20:20, 33:19, 37:9, 45:19, 45:21, 61:7, 95:5, 95:7, 100:12, 100:13, 102:7, 109:16, 115:8 knowledge 33:9, 44:4, 47:19 known 33:12, 33:13, 48:10, 48:14, 49:20, 50:3, 50:5, 50:16, 50:22, 51:2, 51:5, 51:11, 53:20, 54:7, 55:2, 55:12, 58:22, 60:11, 106:10, 106:20, 110:18	104:21, 105:3, 111:21, 113:21 labeled 21:21 laboratory 35:13, 35:18, 36:17 laid 15:11, 15:17, 16:11 language 32:8, 117:4, 120:5 last 11:8, 30:1, 30:2, 68:20, 75:19, 76:1, 89:17, 98:18, 98:19, 104:17, 109:7, 124:10, 124:12 later 99:14 latter 78:19 law 1:18, 5:19 laymen's 131:22 lcipriano@goodwi- nlaw 2:18 lead 31:20, 73:19, 81:22, 82:4, 82:9 leads 32:5, 125:19, 127:11 least 26:4, 112:15 lecture 26:4, 26:6, 26:8, 26:9, 26:11, 26:12, 26:13, 26:17, 27:1, 27:19, 27:20, 27:21,	28:11, 28:18 lectures 27:4, 27:7 left-hand 109:7 legal 34:16, 35:1, 35:3 length 44:1, 44:3, 44:4, 137:21, 138:1, 138:12 less 56:8, 57:5, 57:7, 72:16, 86:14, 86:15 let's 6:13, 10:17, 11:15, 16:18, 39:8, 45:5, 50:7, 51:8, 58:11, 69:16, 96:13, 107:17, 108:14, 115:3, 115:9, 116:19, 121:10, 122:8, 124:5, 133:15 letters 106:15, 106:18 level 9:3, 13:11, 25:1, 70:15, 97:13, 121:7 leveraging 57:2 levy 2:23, 4:19 libraries 45:10 library 29:20, 31:12, 31:16, 32:4, 32:10, 44:14, 44:16, 44:18, 51:12, 76:6, 76:22, 77:8, 78:5, 80:19, 80:21, 81:1,
J			
judgment 101:14 june 1:20, 9:14, 141:9, 142:16, 142:25, 143:4			
K			
karyotyping 109:6 kevin 2:9, 4:18 key 36:5, 53:4, 125:6 kinds 28:1, 91:17 kivioja 10:6, 102:5, 102:16, 102:20, 103:2, 103:18, 104:14, 104:18, 105:6, 105:7, 105:10, 105:13, 107:7, 107:11, 107:15, 107:22,			
	L		
	lab 19:12, 19:13, 20:12, 20:13, 21:14, 22:11, 75:11, 92:1 lab's 18:10 label 103:21, 104:13,		

81:6, 81:18, 81:21, 82:5, 82:19, 82:22, 83:4, 83:8, 83:10, 84:8, 85:11, 88:21, 89:1, 92:2, 93:2, 94:1, 131:19, 132:12, 134:14 ligated 50:11, 54:9 ligating 51:16 ligation 50:12, 51:22, 52:13, 59:3, 59:22, 60:19, 61:19, 67:4, 78:5, 83:5, 83:6 light 36:14, 102:16 likely 14:5, 55:19, 56:8, 56:15, 57:5, 57:7, 86:14, 86:15, 92:19, 101:15, 111:14 limitation 102:21, 102:22, 103:3, 103:5, 103:6, 103:17, 112:6, 112:11, 120:16, 138:4, 138:15, 139:1, 139:22, 140:2, 140:12 limitations 75:13, 76:11, 89:15, 137:14, 137:17, 137:20, 137:21, 138:9, 140:6, 140:9, 140:13, 140:17 limited 64:1, 77:5 limiting 29:2, 71:10,	77:18 limits 28:20, 87:11 line 129:3, 129:6, 143:7 lines 7:20, 103:19, 130:11, 130:20 link 41:14 linnaea 2:17, 3:3, 4:11, 5:2 list 22:17, 26:22, 40:21, 41:2, 84:14, 107:9 listed 59:17, 59:20, 84:11, 84:12 listen 8:2 litigation 14:13 little 10:20, 20:15, 23:16, 25:7, 25:11, 25:15, 41:4, 44:10, 46:10, 47:21, 48:22, 64:11, 69:7, 79:2, 80:17, 98:11, 115:14, 130:22 llp 2:2, 2:12, 4:16, 142:15 loci 53:20 locus 54:16 logistics 10:20 long 44:6, 44:17, 60:15 longer 29:13, 47:10,	54:9 longest 108:1, 110:4, 110:12, 110:15, 110:16 look 11:2, 11:14, 11:20, 16:20, 20:18, 20:19, 23:20, 24:10, 24:17, 25:5, 25:9, 35:6, 37:12, 58:11, 64:16, 69:6, 75:18, 77:22, 98:14, 100:15, 102:8, 102:9, 107:17, 108:14, 108:15, 108:16, 109:20, 115:19, 119:20, 121:9, 122:8, 123:16 looked 10:3, 10:4, 10:5, 10:7, 137:5 looking 10:19, 22:16, 27:18, 34:13, 44:7, 44:12, 45:19, 46:11, 48:4, 53:13, 60:4, 61:22, 67:15, 72:18, 75:22, 91:13, 93:14, 97:3, 107:20, 133:16, 135:2, 136:14, 139:10 lost 11:1 lot 6:12, 9:19, 20:4, 20:6, 31:12, 31:15, 31:17, 64:12, 64:15, 90:18, 127:15	lower 39:15, 67:22, 133:6 lunch 79:20, 79:21 luncheon 80:1 M machines 47:18, 89:15 made 17:9, 55:18, 56:15, 90:20, 91:21, 102:13, 134:20, 134:21 main 18:6 maine 2:4 major 85:5, 87:16, 138:6 make 6:21, 15:14, 16:8, 16:13, 17:10, 19:9, 32:4, 32:7, 32:17, 34:6, 36:18, 38:5, 44:10, 45:12, 50:8, 58:5, 66:2, 66:22, 73:10, 75:12, 75:13, 89:8, 90:7, 92:15, 117:3, 118:2, 130:1 makes 15:8, 15:11, 28:21, 50:4, 81:2, 86:22 making 27:12, 28:8, 28:14, 64:17, 101:13, 125:3 male 109:12
--	---	--	--

mammalian 41:7, 41:13, 41:21, 42:1, 42:7 mammals 39:12, 43:9 manner 41:16 manufactured 19:13, 20:10 many 5:7, 9:16, 13:13, 28:6, 33:16, 40:10, 40:16, 40:17, 40:22, 43:6, 44:3, 52:10, 53:4, 57:13, 62:10, 65:14, 66:2, 83:11, 88:3, 89:2, 89:10, 92:8, 108:9, 119:8 map 106:20, 109:18, 124:15, 125:6, 125:12, 125:17, 126:4, 126:17, 127:3 mapped 103:20, 108:1, 109:13, 111:7, 111:20, 112:14 mapping 128:6 mark 23:21, 69:8, 70:4 marked 11:2, 11:10, 12:7, 16:22, 24:1, 24:5, 58:13, 70:7, 94:7, 109:3, 123:18, 123:21 marriage 142:19 massachusetts 94:6	massively 87:19, 87:22, 88:2, 88:17 material 9:19, 19:2, 24:19, 42:8, 42:18, 42:19, 48:6 materials 10:13, 19:3 math 22:14 matter 5:13, 5:15, 5:16, 5:18, 5:22, 142:23 matters 16:4, 16:5 mature 43:3 mccloskey 98:16, 99:17, 100:2 mean 18:14, 28:4, 30:6, 32:1, 32:11, 35:16, 43:18, 49:3, 51:9, 55:6, 55:15, 66:13, 68:20, 71:2, 71:17, 72:6, 75:9, 77:12, 78:21, 79:1, 80:18, 80:22, 85:14, 87:22, 88:2, 89:20, 105:9, 116:11, 116:13, 126:5 meaning 75:1, 126:3 meanings 126:2 means 7:6, 19:1, 19:4, 61:17, 68:22, 71:9, 72:20, 83:21,	84:1, 84:8 meant 60:22, 61:7, 78:11, 124:20 measure 44:3, 75:15, 76:13 measurements 19:3, 19:6, 28:15, 36:10, 36:12, 75:12 mechanism 57:2 meetings 9:12, 9:13 members 84:8, 85:10, 100:18, 131:5 memory 102:2 mention 126:19 mentioned 84:11, 92:14, 93:1, 93:4 mentions 128:1 mentoring 18:7 messenger 40:22, 41:15, 41:19, 41:20, 41:22, 42:4 met 9:6, 13:13, 15:20 method 53:10, 53:14, 53:22, 54:2, 56:21, 57:2, 60:17, 61:12, 61:14, 67:4, 67:5, 67:8, 67:18, 68:5, 71:7, 71:10, 94:2, 95:17, 95:18, 96:3, 96:8, 114:14,	114:19, 114:21, 115:1, 121:12 methods 27:21, 28:1, 28:2, 28:13, 28:22, 29:21, 30:8, 44:16, 44:18, 46:22, 47:2, 51:13, 53:19, 58:21, 59:2, 59:7, 59:20, 60:6, 60:9, 60:11, 76:7, 76:22, 77:9, 79:4, 79:7, 79:12, 79:15, 81:21, 83:4, 83:11, 85:12, 97:1, 109:2 mgh 93:11, 94:1, 94:14, 95:10, 95:12, 95:16, 96:3, 96:7 michael 2:23 microfluidic 21:22 microreactors 22:9 micrornas 41:1 microscopy 22:1 midway 119:1 might 32:13, 32:15, 46:3, 49:10, 50:8, 52:13, 61:4, 66:4, 66:9, 69:7, 71:19, 73:21, 79:19, 86:17, 86:21, 91:19, 92:1, 113:22, 140:18
--	--	--	---

mike 4:19 million 131:20 millions 88:4 mind 28:14, 47:7, 83:16, 96:20 minimum 139:14 minor 86:22 missing 17:11 misspoke 101:2 mistake 32:17, 86:22, 90:7 mistaken 69:15 mistakes 32:5, 73:10, 89:8 mitigate 71:14, 74:13, 76:5, 77:1, 77:10, 90:17, 90:20, 91:5, 91:16 mitigating 74:3 mix 50:7 mixed 65:9, 109:11 mixture 71:16, 87:13 mixtures 65:20, 66:3 mm-hmm 25:14, 94:9 mocking 52:20 molecular 30:7, 30:21, 30:22, 81:1,	98:21, 99:3, 99:22, 105:12, 113:21, 116:9, 116:13, 116:16, 116:18, 121:13, 127:8 molecule 43:2, 72:9, 85:18, 86:6, 133:8 molecules 71:20, 72:2, 79:8, 79:16, 86:20, 113:7, 121:14, 124:15, 125:7, 125:9, 125:10, 126:4, 126:18, 127:4, 128:7, 129:22 month 9:14 more 26:12, 27:12, 29:7, 32:13, 39:16, 39:18, 41:4, 43:20, 46:15, 55:19, 56:15, 62:11, 62:15, 63:2, 65:22, 66:8, 69:7, 71:20, 72:2, 72:14, 72:15, 85:1, 92:19, 127:15 morning 4:22, 5:1 most 27:16, 30:2, 30:14, 31:5, 43:7, 43:8, 84:20, 91:4, 136:5 mostly 18:1, 18:11, 18:17, 18:18, 18:19 motor 21:11	move 115:9 mrna 28:6, 41:14, 41:15, 42:4, 42:7, 42:9, 42:14, 42:18, 42:22, 43:3, 43:12, 43:13, 43:15, 44:7, 44:12, 45:10, 45:13, 45:19, 109:21 mrnas 42:15, 43:7, 43:8, 45:3, 45:6 much 16:6, 29:13, 45:20, 66:3 multiple 62:4, 63:7, 63:18, 64:21, 65:6, 65:9, 80:15, 92:8, 101:13, 101:21, 107:2, 110:11, 123:13, 125:8, 127:13 multiplex 94:1 multiplexing 137:16 multistep 112:19 must 136:6 mutation 66:12, 121:17, 121:18, 121:19, 122:1, 122:2, 133:10, 133:20, 135:7, 135:13, 136:6 mutational 76:4, 77:3, 77:8 mutations 29:1, 29:4,	29:7, 32:6, 40:12, 73:13, 91:8, 91:9, 91:14, 124:17, 127:19, 132:15, 132:18, 132:22, 133:16, 133:17, 134:20, 136:4 myself 35:21, 50:20, 64:16 N name 4:4, 5:2, 24:11, 24:12, 24:13, 24:14, 24:16, 27:1, 107:3, 107:9, 107:11, 143:2, 143:5 named 106:22 naming 71:7 nanopore 47:12 nature 68:6, 86:13, 91:1 navigate 25:7 necessary 46:16, 47:20, 68:5 necessitates 133:10 need 7:20, 17:9, 20:18, 20:19, 45:20, 46:1, 47:17, 59:16, 61:3, 63:2, 65:12, 65:16, 70:3, 98:15, 102:1 negligible 90:17
--	--	--	---

nested 62:4, 62:8, 62:11, 62:14, 62:17, 62:18, 62:22, 63:7, 63:9, 63:17, 64:7 new 1:20, 1:21, 2:14, 2:15, 4:2, 4:10, 60:17, 132:22, 141:3, 141:23, 142:3, 142:15 newly 61:13, 67:5 next 20:5, 20:6, 25:18, 37:17, 54:19, 60:10, 64:18, 67:1, 83:17, 85:7, 87:18, 100:11, 102:5, 109:20, 111:17, 118:5 next-gen 89:4 next-generation 19:8, 19:9, 20:22, 21:13, 27:15, 27:17, 45:8, 47:2, 47:4, 47:14, 53:2, 65:18, 65:19, 65:21, 70:18, 80:11, 80:14, 81:3, 81:20, 82:14, 82:17, 83:22, 84:4, 84:12, 84:21, 85:4, 90:4, 90:15, 91:6, 91:16, 92:5, 92:6, 92:13, 114:13 ngs 20:21, 20:22, 21:3, 21:6,	21:16, 22:2, 23:5 nine 72:11 noise 78:4, 78:11, 78:13, 78:20 non-coding 38:13, 38:15, 38:17, 38:20, 39:5, 40:9, 40:10, 40:12, 41:1 non-exhaustive 40:21 non-specific 68:5 none 16:15 nongene 53:15, 54:14 nos 1:4 notary 1:21, 4:2, 141:23, 142:2, 144:6 note 88:9 noted 140:22 notes 102:10 nothing 15:10, 15:16, 16:10, 129:16 notice 1:18 noticed 7:4 nucleic 32:3, 32:10, 32:12, 43:19, 48:18, 48:19, 48:22, 49:7, 50:17, 51:2, 51:5, 51:12, 52:1, 52:11,	52:14, 56:2, 57:12, 57:13, 58:6, 62:12, 62:16, 62:19, 64:3, 64:4, 65:20, 66:4, 66:5, 66:7, 66:8, 67:10, 67:12, 71:6, 71:11, 71:15, 73:2, 73:20, 76:3, 76:16, 76:21, 77:2, 78:15, 78:17, 78:22, 79:15, 81:2, 82:2, 82:10, 83:11, 83:12, 84:8, 85:10, 85:18, 85:21, 87:13, 89:1, 89:11, 90:2, 99:1, 99:20, 100:3, 101:15, 103:10, 104:8, 104:12, 105:4, 105:8, 105:10, 105:15, 105:19, 105:21, 106:3, 106:9, 106:14, 106:17, 113:8, 113:21, 122:18, 131:3, 131:6, 135:6, 135:12, 135:17 nucleotide 32:22, 43:20, 50:17, 66:15, 73:10, 131:1, 133:9, 136:6, 136:9 nucleotides 21:21, 32:21, 110:13 nugen 95:18 number 22:5, 22:16, 66:14, 75:11,	94:19, 103:22, 104:1, 110:12, 111:22, 112:1, 113:7, 129:3 numbered 93:13 numbers 139:16 ny 1:20, 2:15, 142:15 o oath 6:16, 141:9 objection 6:6, 36:4, 36:20, 37:7, 44:15, 52:5, 54:15, 60:7, 72:22, 73:7, 74:6, 75:10, 77:13, 77:16, 96:10, 104:10, 105:18, 111:9, 112:17, 114:6, 123:9, 125:21, 126:21, 127:6, 128:8, 133:2, 133:19, 134:18, 135:4 objections 6:21 objective 62:17, 62:22 observations 75:12, 76:11 observed 105:20, 106:8 obvious 102:16, 102:19, 118:17, 118:20, 137:12, 138:5, 138:17, 138:20, 139:4, 140:11 obviousness 118:16, 137:9, 137:10, 137:15,
--	--	--	---

138:7, 138:8, 139:1, 139:15, 139:18, 139:21, 139:22, 140:4, 140:9, 140:14, 140:16 occasion 23:10 occasionally 32:21, 89:12 occur 9:12, 42:14, 71:16, 74:4, 86:13, 90:10, 133:6, 134:20 occurred 9:14, 111:14, 142:14 occurs 43:20, 133:21, 136:10 office 1:1 offices 1:19, 142:14 often 33:4, 39:5, 39:14, 40:11, 42:4, 45:9, 64:14, 114:7 oh 69:20, 70:5 old 24:12 older 71:3 oligonucleotide 84:6 oligonucleotides 51:11 on-surface 85:8, 85:9, 86:8 once 43:20 one 5:10, 7:7, 10:19, 12:12,	16:20, 18:6, 23:16, 28:20, 32:21, 33:1, 39:9, 39:10, 40:3, 42:13, 44:8, 46:1, 47:5, 49:22, 54:1, 54:13, 55:1, 62:11, 62:12, 62:15, 65:15, 66:9, 69:7, 69:11, 73:13, 78:14, 85:20, 86:6, 90:13, 90:20, 91:8, 91:13, 101:12, 103:21, 105:19, 106:8, 106:10, 111:21, 113:22, 114:3, 114:4, 114:18, 122:4, 125:15, 125:20, 127:18, 130:16, 133:21, 135:20, 139:9 ones 52:16, 83:16 online 109:2 only 10:19, 42:8, 58:2, 73:5, 75:3, 75:5, 82:19, 82:22, 114:3, 114:4, 132:15, 133:21 onsite 86:11 open 132:12 opinion 45:22, 59:19, 60:5, 60:8, 91:2, 91:4, 95:15, 102:18, 103:2, 112:11, 113:16, 123:15, 139:3	opinions 13:5, 13:16, 15:9, 15:11, 15:17, 16:8, 16:11, 98:9 opportunities 92:9 order 39:6, 44:5, 63:3, 106:4, 107:14, 121:15 ordinary 97:7, 97:9, 97:13, 97:20, 138:17 organic 21:20 organism 45:3 organisms 39:12, 39:15, 39:20, 43:9 orient 98:14 original 32:14, 45:13, 72:8, 72:17, 72:21, 73:2, 73:21, 74:5, 113:9, 121:14, 121:17, 135:9, 135:10, 135:18, 136:12 originate 86:6, 135:9, 135:10, 136:12 originated 105:22, 125:10 originating 101:15, 133:8 other 11:15, 12:12, 14:6, 14:10, 18:7, 20:1, 22:15, 31:7, 31:9, 32:16, 38:8, 39:21, 42:17, 44:11,	55:2, 59:16, 65:11, 66:4, 66:10, 66:11, 66:16, 71:13, 73:21, 73:22, 79:4, 79:7, 83:4, 83:7, 85:1, 88:18, 89:13, 93:5, 93:18, 93:19, 105:11, 106:12, 106:19, 109:17, 117:22, 123:7, 123:10, 126:5, 130:17, 133:6, 135:8, 135:19, 138:3, 140:3, 140:8, 140:17 others 10:8, 32:13, 33:8, 55:9, 71:20, 72:3, 73:17, 83:2, 83:14, 83:15 otherwise 142:22 out 10:17, 12:18, 15:11, 15:17, 16:11, 17:7, 25:8, 89:12, 106:11, 139:21, 140:9, 140:14 outcome 142:22 outlined 131:16 output 82:16, 82:20, 83:1, 83:3 outside 31:3 over 7:7, 8:15, 31:4, 58:8, 103:4, 117:5, 131:20, 134:9 overrepresentati- on 55:8
---	--	--	--

oversight 70:4 own 30:14 owner 1:15, 1:18, 2:13, 14:19 owner's 14:22, 15:2, 15:7, 15:10 owners 4:12 oxford 47:11	pairing 55:11, 56:18, 57:1, 84:2 pairs 128:21, 129:12, 129:14, 132:4 panel 97:19 panel's 16:4, 98:3, 98:4, 98:7 panhandle 67:11 paper 22:4, 22:15, 36:2, 37:5, 53:7, 53:17, 58:12, 58:17, 58:18, 64:12, 69:7, 70:6, 70:12, 70:14, 70:16, 70:17, 72:5, 74:15, 75:2, 76:19, 77:6, 77:22, 79:4, 79:19, 94:14, 107:16, 110:10, 111:11 papers 22:15, 22:17, 60:4 paragraphs 33:16, 33:21, 34:6, 93:21, 137:19, 137:20, 138:1 parallel 87:19, 87:22, 88:2, 88:4, 88:18, 89:10 parentheses 104:21 parenthesis 26:1 part 14:9, 28:5, 39:7, 49:16, 87:5, 87:6,	87:10, 89:7, 100:3, 100:17, 103:17, 105:12, 105:16, 106:21, 107:7, 109:2, 116:6, 127:4, 130:3, 133:12 partial 56:11 particular 10:9, 27:9, 27:22, 48:6, 49:8, 58:10, 63:4, 66:5, 66:7, 66:8, 97:12, 121:16 particularly 12:20, 14:3, 16:1, 31:14, 74:16, 91:10 parties 142:19, 142:21 parts 43:14 party 142:10 patent 1:1, 1:2, 1:7, 1:9, 1:11, 1:13, 1:15, 1:18, 2:13, 4:12, 6:2, 6:3, 6:4, 6:8, 6:10, 10:4, 10:7, 14:5, 14:19, 14:22, 15:2, 15:7, 15:10, 16:3, 94:18, 95:2, 95:10, 95:11, 96:12, 103:1, 103:14, 103:16, 104:15, 117:7, 117:19, 117:20, 118:1, 118:4, 118:6, 118:10, 118:17, 118:22, 119:5, 119:9, 119:14, 119:15,	120:6, 120:15, 121:2, 121:5, 122:13 patent-specific 117:10 patents 10:15, 11:17, 14:14, 94:15, 95:19, 96:9, 96:15, 96:17, 96:22, 102:15, 102:19, 117:7, 117:15, 119:17 patient 121:6 pause 11:15, 51:8, 107:16 pcr-induced 73:13 pdms 22:9 perform 39:6 performed 62:5, 63:8, 108:10, 133:4 performing 18:8, 19:3 performs 19:22 perhaps 69:14 period 23:3 permitted 8:15 perry 142:2, 142:29 person 15:20, 97:7, 97:9, 97:13, 97:20, 138:17 personal 27:12 perspective 77:20, 99:10 peter 1:17, 3:3, 4:6,
P			
page 3:2, 3:7, 6:14, 11:8, 11:10, 12:6, 16:21, 24:10, 25:6, 25:18, 33:19, 33:22, 34:8, 34:14, 37:12, 49:5, 53:13, 60:12, 67:14, 80:18, 95:6, 109:1, 109:3, 109:7, 109:20, 116:1, 118:3, 118:4, 118:7, 119:1, 119:5, 119:21, 121:11, 124:5, 128:11, 128:16, 130:6, 130:7, 130:8, 131:13, 131:15, 134:17, 136:14, 143:7 pages 107:21, 118:5, 118:9, 118:13, 118:15, 118:18 paid 10:9 pair 113:20 paired-end 109:12			

141:7, 141:16, 142:5, 142:13, 143:5, 144:1 petition 69:12 petitioner 1:7, 2:3, 4:16 ph 1:17, 3:3, 21:4, 21:6, 21:8, 21:10, 21:12, 21:15, 23:2, 141:7, 141:16, 142:5, 142:14, 143:5, 144:1 phrase 51:17, 61:5, 75:7, 125:6, 126:3 picture 24:11, 24:12 pictures 25:6 piece 35:20, 40:3, 45:18, 45:21, 111:11 pieces 107:2, 107:8 pine 4:9 place 58:8, 74:21, 85:22 platform 21:14, 21:16, 22:2, 23:6, 83:22, 85:15, 85:17, 88:7, 88:12, 89:22 platform-specific 89:21 platforms 19:11, 20:8, 80:11, 80:15, 84:4, 84:5, 84:12, 84:16,	84:21, 85:11, 87:6, 87:10, 88:3, 89:6, 89:9 plays 41:11, 43:12, 68:8 please 4:4, 4:7, 7:11, 7:21, 8:5, 13:8, 21:8, 36:21, 50:19, 74:7 plotted 136:18 point 12:18, 74:21, 80:19, 83:18, 87:18, 112:8, 113:3, 127:1, 128:10, 135:20 pointed 103:18 pointing 106:11 poly(a 42:15, 42:17, 43:7, 43:8, 43:10, 43:12, 43:15, 44:1, 44:2, 44:4, 44:11, 44:13, 44:17, 44:20, 45:1, 45:2, 45:15, 45:18, 45:20, 46:2 polymer 43:22 polymerase 32:4, 32:17, 32:20, 48:1, 48:3, 55:13, 55:16, 55:19, 56:1, 56:4, 56:12, 56:15, 71:19, 78:15, 78:17, 86:21, 89:6, 89:7, 90:21, 134:21 polymerases 33:6, 33:11,	73:8 poor 68:18 popular 84:20 population 87:3, 103:11, 122:19 populations 79:9 portion 48:11, 124:11 portions 48:17, 97:20, 123:7 posa 35:9, 36:6, 36:10, 36:18, 68:14, 95:16, 97:9, 98:8 posa's 36:14 position 17:15, 19:20, 31:2, 66:15, 103:21, 105:6, 105:7, 105:11, 107:3, 107:10, 107:12, 111:21, 112:5, 118:16, 136:6, 138:14 positions 16:9, 98:6 possibility 93:7 possible 65:14, 66:3, 86:20 possibly 5:3 post-doc 22:21 post-doctoral 23:3 potential 82:13, 92:11 potentially 93:2	pre-mrna 43:2 pre-published 110:17, 110:20 preliminary 14:22, 15:2, 15:8 preparation 9:8, 9:10, 9:11, 9:13, 9:22, 80:20, 80:21, 81:1, 81:6, 81:18, 81:21, 82:6, 82:20, 82:22, 83:4, 83:8, 83:10, 92:2, 93:2, 94:2, 132:12, 134:14 prepare 8:22, 9:4, 13:11 prepared 9:1, 10:10, 10:13 preparing 9:17, 14:9, 58:16, 58:18 presence 64:21 present 2:22, 4:19, 28:6, 42:1, 120:15, 121:17, 132:16 presumably 72:15, 128:2 previous 6:13, 59:21, 140:2 previously 123:21 primarily 67:19 primary 68:11, 68:13 primed 59:3, 59:21,
---	--	---	---

60:17, 60:18, 61:1, 62:3, 63:6 primer 32:20, 53:15, 54:1, 54:6, 54:8, 54:13, 54:14, 54:17, 54:18, 55:12, 55:14, 55:17, 55:20, 56:3, 56:4, 56:5, 56:8, 56:12, 56:17, 57:3, 57:5, 57:10, 57:11, 57:19, 58:8, 62:12, 62:16, 67:20, 68:15, 73:11 primers 48:10, 48:13, 49:14, 49:20, 50:2, 50:5, 50:15, 50:22, 51:1, 51:4, 54:3, 54:22, 55:22, 61:6, 68:17, 69:1, 84:6, 84:9, 85:19 principal 41:22 printed 25:8 prior 13:14, 13:18, 13:19, 13:22, 21:17, 35:11, 35:12, 35:17, 35:20, 35:21, 36:1, 36:7, 36:16, 37:3, 39:15, 84:17, 94:13, 98:12 priori 106:11 privileged 9:2 probably 7:4, 9:18,	23:1, 38:10, 42:21, 46:15, 59:16, 61:8, 83:15, 90:22, 100:11, 102:1 problem 87:16 problematic 52:17, 91:10 problems 32:19, 82:12 procedure 125:11 procedures 80:14 proceedings 10:11, 12:3, 12:4, 13:8, 14:20, 15:5, 35:2, 35:4, 58:13, 93:19, 94:10 process 49:19, 50:1, 73:6, 80:11, 81:6, 81:8, 81:18, 81:20, 83:8, 85:2, 85:4, 88:12, 89:7, 89:21, 90:1, 90:3, 90:10, 90:15, 91:6, 91:16, 92:5, 92:6, 92:7, 92:13, 101:16, 101:22, 112:19, 113:1, 113:5, 113:18, 114:1, 114:7, 114:15, 126:10, 127:5, 127:10, 130:5, 132:9, 133:14, 134:13, 135:22, 136:1, 138:11 processes 65:11, 82:14, 83:10, 83:13,	89:4, 90:5 processing 89:18 procter 2:12 produced 131:19 products 62:4, 63:7, 63:18, 63:19, 63:21, 64:9, 64:20, 64:22, 65:6, 65:9, 65:15, 65:16, 73:9 professor 17:16, 18:4 program 109:17 programs 19:5, 90:8, 125:2 projects 23:2, 23:7, 23:9 pronounced 94:20, 102:7 pronouncing 26:18, 94:21, 95:3 proper 69:1 proportion 32:2, 32:9, 32:14, 87:14 protein 28:7, 38:6, 38:8, 39:9, 39:14, 39:15, 41:11, 41:15, 41:18, 41:19, 42:2, 42:10, 42:12, 42:16, 43:13 proteins 21:12, 38:19, 39:3, 40:5, 40:6 provide 138:3	provided 34:19, 34:21 ptab 16:5, 16:10, 97:19 public 1:21, 4:2, 141:23, 142:3, 144:6 publication 94:19 publications 17:12, 22:5, 94:13 publish 22:2 published 22:14, 22:17, 94:6 pulling 37:4 pure 65:16, 65:22, 66:8 purification 65:11, 65:13 purify 65:11 purpose 43:10, 44:19, 55:22, 56:3, 62:14, 121:22 purposes 66:12 pursuant 1:18 put 29:15, 50:7, 50:14, 88:19, 131:22 puzzle 45:14, 45:17 Q quality 90:14, 90:22, 92:9 quantification 70:19, 76:4,
---	--	--	---

76:17, 77:2 quantifying 71:5, 71:15, 113:7 queens 141:5 question 6:7, 7:12, 7:15, 8:9, 15:13, 35:9, 36:21, 41:4, 44:10, 50:19, 60:4, 61:4, 63:3, 74:7, 75:18, 81:10, 81:11, 91:12, 100:11, 106:1, 106:13, 117:5, 119:18, 133:15 questions 5:3, 6:15, 7:1, 8:3, 8:14, 8:20, 39:18, 46:15, 98:15, 115:5, 120:21 quick 46:4 quite 71:22, 106:1, 138:10 quote 100:16, 101:7, 103:18, 112:5, 112:10, 124:10, 128:15	reaction 32:12, 48:1, 48:3, 50:16, 52:3, 55:13, 55:16, 56:9, 56:14, 57:6, 57:15, 57:21, 58:3, 61:21, 63:17, 64:10, 64:12, 65:10, 68:6, 68:9, 73:22, 82:9, 83:6, 85:22, 86:19 reactions 51:14, 55:18, 55:22, 64:16, 67:9, 82:4 read 14:22, 15:2, 15:5, 15:6, 15:10, 16:3, 16:5, 35:20, 58:18, 59:16, 60:2, 61:3, 63:4, 63:15, 93:21, 103:9, 103:11, 104:19, 106:9, 107:1, 107:6, 107:13, 108:1, 108:11, 108:12, 108:13, 112:21, 122:16, 122:17, 122:18, 134:16, 139:16, 141:8 readily 31:21 reading 24:18, 26:22, 27:4, 61:18, 127:18 readout 71:4 reads 29:6, 30:10, 54:20, 66:14, 78:1, 97:1,	101:13, 101:18, 103:11, 103:18, 103:20, 103:22, 105:14, 107:21, 109:11, 109:12, 109:13, 109:18, 109:19, 111:2, 111:7, 111:19, 111:20, 111:22, 112:14, 112:19, 112:22, 113:2, 113:20, 114:2, 120:2, 121:11, 122:19, 123:2, 124:12, 124:15, 125:2, 125:7, 125:9, 125:13, 125:14, 125:18, 126:4, 126:17, 128:20, 129:15, 129:21, 131:7, 132:3, 132:16, 132:21, 133:5, 133:6, 133:17, 136:10 ready 79:21 real 24:8, 124:17, 127:19, 136:3, 136:5 really 29:12, 31:11, 69:2 reason 8:19, 8:21, 52:17, 86:5, 143:7 reasonable 36:17 reasons 40:8, 40:10, 120:17, 139:15 recall 10:2, 14:1, 14:3, 14:7, 14:15, 43:16, 43:17, 53:8,	53:9, 98:1, 98:5, 98:7, 99:7, 100:1, 100:9, 119:10, 119:11, 129:10 recent 17:11 recess 80:1 recites 103:6 recognize 24:6, 24:7, 24:8, 58:14, 58:15, 70:10, 70:11, 108:16, 108:18, 123:22, 124:1 recollection 97:22 recombination 73:19 record 4:5, 4:8, 11:17, 46:6, 93:18, 140:21, 141:11, 141:12, 142:8 recorded 70:16, 103:22, 111:22 records 105:11 rectangle 130:14, 130:17 reduce 64:9, 67:11, 76:3, 76:16, 79:7, 79:12 reduced 66:9 reducing 90:12 refer 12:21, 20:16, 30:5, 33:4, 34:8, 38:10, 40:14, 43:14,
R			
random 79:1, 121:13 randomly 59:3, 59:21, 60:18 range 126:2 rare 87:3 rate 93:6			

47:22, 49:6, 50:5, 53:7, 53:10, 63:22, 73:13, 75:19, 88:8, 88:17, 114:10, 123:12, 124:2, 124:8, 127:4, 140:3, 140:8 reference 28:8, 34:12, 35:11, 36:13, 37:6, 37:8, 38:9, 45:4, 45:6, 50:4, 61:10, 64:7, 74:15, 75:2, 75:22, 76:17, 94:22, 95:10, 98:16, 100:6, 100:9, 102:1, 102:6, 106:10, 107:6, 108:3, 108:7, 108:9, 108:11, 108:14, 108:19, 108:21, 109:18, 109:19, 110:4, 110:7, 110:13, 110:20, 110:21, 111:1, 112:10, 114:16, 115:5, 115:17, 116:21, 117:1, 123:19, 124:2, 124:4, 127:21, 128:3, 128:12, 133:11, 136:7, 137:1 referenced 12:3, 109:16, 119:14, 130:4 references 9:6, 13:14, 13:18, 13:21, 13:22, 14:2, 14:6, 53:4, 59:17, 60:2, 61:2, 84:17,	84:18 referred 42:4, 51:4, 61:18, 78:19, 84:4, 95:2, 100:6, 104:14, 105:6, 110:7, 114:7 referring 30:8, 30:17, 37:2, 49:7, 59:14, 63:17, 76:10, 77:4, 85:9, 87:8, 99:7, 99:15, 116:22, 120:1 refers 50:12, 51:22, 64:13, 67:11, 72:1, 119:8, 126:10, 127:19, 137:12 reflect 35:3, 72:21, 75:14, 76:12 reflected 77:6 reflects 99:10 refresh 102:1 regard 35:8 regarding 138:4 region 43:15, 49:8, 49:11, 49:13, 49:15, 49:17, 58:22, 59:1 regions 38:13, 38:15, 38:17, 38:18, 38:20, 39:4, 39:5, 39:10, 39:16, 40:9, 40:10, 40:12, 42:8, 42:14,	48:6, 49:10 regulate 38:6, 39:4 regulating 38:22, 40:11 regulatory 26:19, 38:21, 39:1 related 5:17, 6:1, 9:13, 10:14, 23:9, 27:16, 74:16, 116:21, 117:14, 117:22, 119:13, 137:21, 138:6, 142:18 relates 11:16, 138:11 relative 32:2, 32:9, 32:14, 55:8, 72:13, 73:1, 73:2, 73:3, 73:4, 76:20, 77:5, 79:14, 82:10, 87:14 relevant 123:10 rely 89:9, 123:7, 140:1 relying 114:14 remaining 119:4 remember 134:8 remind 63:11 remove 134:19 removed 39:14, 69:18, 88:10, 113:17, 113:19, 113:22, 133:21, 135:1 removing 113:15, 114:5,	114:9, 133:4 renders 139:15 repeat 36:21, 50:19, 74:7, 81:11, 119:18 rephrase 6:7, 41:4, 44:9, 74:9, 91:3 report 36:2 reported 22:4, 47:8 reporter 4:4, 4:7, 7:5, 24:4, 81:9, 131:2, 134:5, 134:7, 142:2 reports 66:22, 70:17 represent 13:16, 42:18, 130:21 representation 117:12 represented 132:8, 142:11 representing 5:20, 6:4, 130:22 reputable 15:22 reputation 15:19, 15:21 require 47:1, 47:2, 65:10, 83:10, 104:7, 111:15 required 31:12, 31:15, 31:18, 46:20 requirements 25:16 requires 29:5 research 10:6, 18:8,
---	---	---	--

18:9, 18:10, 20:12, 22:4, 23:16, 30:14, 36:9, 43:11 researched 13:13, 13:18 respect 128:3 response 15:8, 15:10 responses 15:1, 15:3 rest 42:18 result 40:12, 44:16, 76:2, 76:15, 77:7, 92:10, 92:13 resulting 40:4, 45:11, 66:19 results 68:1, 69:2, 85:4, 85:22, 86:14, 86:16, 87:5, 88:10, 90:14, 128:15, 131:17, 136:15, 136:17, 136:21, 137:2 retained 5:18, 6:8, 6:10 revealing 9:2 reverse 46:18, 78:4, 128:21, 129:13, 129:14, 132:4 review 58:17, 63:2 reviewed 9:5, 9:21, 14:12 reviewing 14:15 ribosomal 40:21, 41:3,	41:6, 41:8 ribosome 41:9, 41:10, 41:18, 42:2 right 16:17, 22:14, 27:2, 38:13, 43:1, 48:12, 50:3, 50:11, 50:18, 53:11, 53:12, 56:22, 58:11, 68:11, 80:5, 82:15, 87:15, 89:3, 92:13, 98:2, 99:18, 101:20, 102:17, 103:12, 104:5, 105:6, 107:10, 108:17, 110:17, 112:16, 113:2, 114:4, 114:17, 116:16, 117:7, 117:19, 120:3, 120:6, 120:12, 122:6, 122:19, 125:14, 126:6, 126:12, 127:5, 128:7, 129:9, 129:13, 131:10, 132:8, 135:2, 137:10, 137:17, 140:1 right-hand 12:7, 67:16 rna 19:3, 37:19, 37:21, 38:1, 38:6, 40:14, 40:16, 40:17, 40:18, 40:21, 40:22, 41:3, 41:6, 41:8, 41:12, 41:15, 41:18, 41:19, 41:20, 41:22, 42:4, 46:10, 46:12, 46:17, 46:18, 46:20,	46:22, 47:3, 47:8, 47:10, 47:12, 47:17, 47:19, 47:20, 70:19, 70:20, 71:2, 71:7, 78:2, 79:7, 79:9, 79:12 rnas 41:1, 41:14 role 18:3, 19:19, 23:13, 41:11, 41:12, 41:20, 41:22, 68:8 roles 18:3, 43:12 row 43:21 rules 6:14 S s 2:1, 143:7 said 5:2, 9:21, 13:18, 19:15, 31:5, 43:6, 68:10, 99:7, 100:21, 131:4, 134:9 same 6:1, 6:14, 6:16, 7:20, 12:21, 13:1, 13:4, 13:5, 15:13, 16:20, 20:11, 22:15, 25:19, 32:8, 33:19, 33:21, 34:8, 34:14, 43:20, 49:5, 60:12, 69:11, 78:18, 79:2, 80:18, 86:1, 86:2, 86:3, 93:22, 95:6,	103:9, 103:20, 104:20, 105:4, 110:22, 111:17, 111:20, 113:15, 113:21, 114:4, 117:4, 117:5, 118:3, 121:11, 122:17, 125:20, 127:18, 131:6, 131:8, 131:9, 131:11, 133:8, 135:9, 135:10, 135:18, 136:12, 136:13, 139:15 sample 31:11, 32:14, 45:13, 51:19, 52:9, 52:11, 52:12, 55:9, 56:6, 57:4, 57:18, 58:7, 64:6, 65:22, 66:8, 70:19, 72:9, 72:17, 72:21, 73:3, 73:21, 74:4, 74:5, 76:21, 79:15, 79:16, 99:2, 99:21, 109:11, 109:12, 110:9, 113:9, 122:2, 135:11, 137:16 samples 66:2, 131:21, 132:1 sanger 47:6 say 7:5, 16:6, 18:13, 26:5, 28:11, 29:11, 30:11, 30:16, 30:17, 32:9, 36:15, 37:8, 38:22, 39:19, 48:20, 51:15, 57:7, 59:6,
---	--	--	---

64:7, 74:1, 84:22, 87:7, 94:12, 120:13, 120:22, 132:10 saying 54:13, 99:17, 115:16, 117:2, 140:7 says 35:7, 58:20, 60:13, 62:1, 64:18, 76:15, 98:19, 99:13, 109:8, 110:2, 128:19, 129:11, 136:15 scale 5:20 scenarios 50:15, 51:1, 73:15 schmidt 100:7, 100:9, 100:16, 101:8, 101:16, 101:22 scientific 17:17, 19:16 scientist 15:22, 40:8 scientists 46:17, 97:18, 98:22 searle 2:10, 4:18 second 24:10, 25:6, 35:6, 67:14, 77:22, 79:3, 94:10, 100:17, 110:1, 112:19, 115:22, 122:22, 126:3, 127:22, 128:1, 128:5, 128:18, 129:5, 129:6, 136:15, 139:9 secondarily 136:8	section 25:5, 25:9, 25:11, 29:3, 34:15, 34:22, 37:13, 37:17, 37:18, 39:11, 46:11, 52:18, 52:19, 56:2, 84:3, 84:15, 87:18, 93:10, 93:12, 97:6, 98:16, 109:2, 109:6, 109:20, 110:2, 110:9, 111:6, 111:11, 111:18, 116:20, 117:1, 117:6, 117:9, 117:18, 118:3, 118:13, 118:21, 119:4, 120:1, 120:17, 120:21, 121:3, 122:11, 124:10, 128:15, 131:17, 136:15, 138:7, 138:18, 139:2, 139:16, 139:22, 140:3, 140:9, 140:16, 140:17 sections 12:13, 12:16, 40:5, 56:1, 93:22, 98:12, 119:4, 119:8, 123:10, 123:11, 140:4, 140:5, 140:8 seems 60:11 select 27:3 selected 27:5, 27:8, 110:12 selecting 27:6 selectively 54:22, 55:6	sense 38:4 sensitively 28:22, 29:3, 29:7 sentence 30:1, 30:2, 30:5, 35:6, 54:4, 54:19, 54:20, 59:15, 59:21, 63:11, 63:13, 64:8, 64:18, 76:15, 78:1, 78:12, 79:3, 79:5, 98:18, 98:19, 99:6, 99:10, 100:17, 104:17, 105:4, 107:20, 109:7, 111:1, 111:18, 112:4, 112:10, 112:21, 113:13, 116:12, 122:22, 124:11, 124:21, 125:12, 125:14, 125:22, 126:15, 127:18, 128:1, 128:6, 128:18, 129:6 sentences 75:19, 76:1, 76:10 separate 20:12, 125:13, 128:6, 128:9 separately 71:13 seq 78:3, 79:7, 79:13, 109:21 sequence-dependa- nt 78:13 sequence-depende- nt 78:3 sequence-specific 41:16	sequenced 40:2, 52:12, 74:5, 131:20, 131:22, 132:1 sequencers 19:13, 47:15 sequences 39:5, 39:13, 39:20, 40:11, 42:1, 48:10, 48:14, 49:15, 49:16, 49:20, 50:2, 50:6, 50:16, 50:22, 51:2, 51:5, 52:13, 53:21, 55:8, 55:19, 56:6, 56:11, 56:16, 57:4, 58:10, 61:20, 78:16, 88:11, 101:5, 101:19, 105:10, 105:19, 108:10, 109:9, 127:3, 131:11, 133:7 sequencings 20:7 series 81:1, 106:15, 106:18 serve 37:21, 38:1, 38:22, 41:14, 77:10 serves 38:6, 71:14 serving 5:13, 5:14 set 33:15, 34:22, 52:1, 97:15, 98:5, 98:9, 109:19, 142:6, 142:24 setting 121:7 several 58:21, 88:18,
--	---	--	--

133:3 sharing 100:20 sheet 143:1 shiroguchi 76:19 short 46:7, 115:11 shorthand 97:9 should 136:13 show 98:3 showing 64:14 shown 74:16, 135:22 side 29:16, 49:8 siebert 53:7, 53:19, 54:1, 54:17, 55:10, 55:18, 56:6, 56:15, 57:6, 57:9, 58:9, 58:12, 60:10, 61:12, 61:18, 62:1, 62:21, 63:1, 63:10, 63:17, 64:2, 64:18, 66:21, 67:9, 67:14, 68:4, 68:10, 68:12, 68:14, 68:17, 68:22 siebert's 53:14, 54:2, 56:21, 57:2, 57:4, 57:17, 58:3, 58:5, 67:8 signature 11:12, 11:13, 12:9, 12:10 signature-plkal 142:27	signed 141:18 significant 93:1, 93:6 significantly 85:1 similar 12:14, 12:17, 12:19, 32:15, 34:2, 129:18 simpler 66:20 simplest 42:22 simply 106:13 sims 1:17, 3:3, 4:6, 4:22, 22:8, 26:1, 80:4, 141:7, 141:16, 142:5, 142:14, 143:5, 144:1 since 14:17, 87:12 single 39:8, 53:14, 79:8, 79:9, 85:19, 109:10, 124:15, 125:7, 125:9, 125:10, 126:4, 126:17, 127:3, 128:7, 129:22 single-cell 5:17, 29:21, 30:15, 30:18, 31:6, 76:8 single-molecule 21:11 single-nucleotide 133:5 sit 60:6 site 103:9, 104:8, 104:12, 104:15, 104:20, 105:2,	116:16, 116:18, 137:22, 138:2, 138:12 sites 122:17 sitting 14:1, 16:13, 77:11, 96:19, 98:1, 100:1 situation 49:12, 85:20 situations 52:10, 52:14, 78:14 six-word 61:8 skill 97:7, 97:9, 97:13, 97:15, 97:21, 138:17 skip 98:10 sleep 38:11 slightly 17:7, 85:16, 93:21 small 28:21, 29:2, 31:11 smaller 45:12 software 111:12 solid 84:10, 130:16 solid-phase 78:6 some 5:3, 6:13, 9:21, 13:21, 14:5, 20:2, 24:8, 27:8, 27:11, 27:14, 28:13, 30:12, 32:12, 33:8, 33:9, 33:14, 39:2, 42:15,	44:16, 44:18, 48:22, 49:14, 52:17, 57:14, 62:18, 63:18, 63:20, 64:4, 64:19, 67:21, 68:5, 71:19, 80:13, 81:21, 82:8, 83:4, 83:10, 84:16, 84:17, 90:9, 90:16, 92:14, 92:17, 92:19, 97:22, 99:16, 110:10, 111:2, 111:15, 113:17, 117:21, 136:7 someone 36:6, 99:9 something 28:17, 29:2, 36:2, 64:13, 126:5 sometimes 44:19, 73:9, 75:12 somewhat 88:10 somewhere 20:19 sorry 31:3, 38:14, 70:4, 81:15, 91:3, 91:11, 95:21, 96:1, 96:6, 100:21, 100:22, 103:3, 107:16, 122:10, 128:17, 129:3, 131:3, 131:15, 135:9, 139:7, 139:10 sort 45:14, 45:18, 91:18, 106:11 source 82:19, 85:3, 85:6, 89:5, 90:4
---	--	--	---

sources 89:16, 91:2 southern 65:1 spanning 118:18 spans 107:21 speak 7:7, 9:7, 9:9, 38:4 speaking 32:8, 117:4 species 72:14 specific 30:20, 34:7, 37:9, 39:18, 41:5, 44:11, 48:14, 50:5, 50:22, 53:15, 54:14, 54:16, 56:21, 57:1, 62:18, 66:15, 74:21, 77:19, 99:12, 127:16, 133:9, 137:14, 139:2, 140:9 specifically 10:3, 22:16, 47:16, 64:2, 92:22, 98:12, 107:22, 117:19, 117:21, 118:11, 119:13, 128:15, 137:5, 139:20, 140:3 specificity 62:19, 67:18, 68:9, 68:11, 68:13, 68:19 spend 9:16 spurious 73:19 spuriously 44:19 ss 141:4	stability 43:12 staff 20:3 standards 34:16 standpoint 29:9 stands 20:22, 30:7, 48:1, 48:3 start 31:4, 103:4, 115:20, 134:9 started 21:13, 23:1, 23:5, 98:22 starting 33:18, 34:15, 79:5, 93:15, 102:9, 117:10, 117:16, 118:3, 137:8 starts 25:6, 37:13, 37:18, 70:20, 93:20, 102:12, 117:18, 119:5, 128:11, 128:16, 139:22 state 1:21, 4:2, 4:4, 4:7, 29:18, 46:16, 54:20, 95:15, 120:17, 123:1, 141:3, 141:23, 142:3 stated 36:12, 38:18, 104:16 statement 36:5, 59:18, 63:5, 68:21, 138:20, 139:5, 139:19 statements 13:3 states 1:1, 67:16, 76:21, 79:4, 126:16 step 40:15, 82:22, 83:17, 85:5, 85:7, 85:9, 86:9, 86:11, 88:6, 88:8, 88:9, 88:10, 88:22, 89:4, 89:17, 89:20, 90:13, 91:15, 93:2, 106:19, 108:6, 112:15, 112:18, 112:20, 120:14, 121:4, 128:6, 128:9 steps 80:17, 81:2, 83:2, 83:5, 83:7, 83:21, 88:20, 89:10, 89:12, 90:16, 90:19, 91:4, 92:2, 92:5, 92:8, 92:15, 92:17, 92:19, 93:3, 93:4, 93:5, 93:8, 101:21, 111:14, 111:15, 131:16 stick 51:20 still 13:1, 65:17, 80:5 stochastic 79:1 stochastically 78:17, 78:22 stores 38:5 strand 33:2, 56:19, 67:22 strands 133:8, 136:11 strategy 70:18, 87:9	stray 16:16 street 4:9 stretches 44:17 strictly 56:10 striped 130:11 stripes 130:13, 130:16 strong 64:17 structural 41:8 structure 56:21 structures 67:10, 67:11 stuck 95:7, 102:6 student 22:22 students 18:7 studies 45:2, 45:6, 45:8 study 44:11, 61:10, 61:12, 110:9 studying 21:11 subject 5:16, 5:22, 43:11, 46:1 submitted 11:6, 12:3, 14:13 submitting 14:17 subscribed 141:18, 144:3 subset 86:20, 87:3 substance 8:16, 33:17,
--	---	--

58:19 substantial 92:15, 92:18 substitution 33:5, 73:9, 82:1, 82:11, 136:9 substitutions 136:18 subtlety 106:7 successful 15:22, 64:21 sufficient 29:6, 64:15 suite 1:19, 142:15 supervise 20:3 supplied 97:16 supporting 112:5 supposed 35:20, 130:21 suppression 61:14, 61:16, 67:6, 67:8, 67:19, 68:4, 68:8, 68:10, 68:12, 68:18, 69:2 sure 6:12, 8:3, 28:15, 32:7, 34:7, 36:22, 46:5, 66:22, 68:14, 74:8, 117:3, 118:2, 119:19, 140:7 surface 83:19, 83:20, 84:7, 85:3, 85:11, 85:13, 85:19, 85:21, 86:1, 86:20, 87:2 surfaces 84:5, 84:10	surmise 61:4 surround 49:7 sw 2:4 switch 115:14 sworn 4:2, 142:6, 144:3 syllabus 3:9, 24:1, 24:18, 24:21 synch 89:12 synthesis 21:20, 38:7, 39:15, 41:11, 41:19, 43:13, 47:1 synthesize 42:2 synthetic 51:10 system 22:1, 22:10, 22:12 systems 89:15	44:1, 44:4, 44:13, 44:20, 45:1, 45:2, 45:15, 45:18, 45:20, 46:2 tails 44:2, 44:5, 44:11, 44:17 take 6:16, 7:13, 7:14, 7:16, 7:21, 106:19, 108:6, 115:3, 115:9, 123:16, 140:19 taken 1:17, 36:10, 46:7, 80:1, 115:11, 123:13, 138:13, 141:8, 142:8 takes 85:22, 88:22 taking 7:5 talk 20:15, 28:18, 34:6, 38:10, 46:10, 47:15, 47:21, 50:9, 50:21, 51:7, 52:18, 80:10, 80:16, 85:7, 94:5, 94:22, 100:5, 100:6, 102:5, 115:14, 116:21, 117:18, 137:15, 137:16, 137:20, 140:10 talked 82:3, 82:6, 86:10, 107:15, 112:14, 129:8, 137:7 talking 12:12, 28:9, 33:17, 34:7, 35:22, 36:17,	40:2, 46:9, 49:19, 50:1, 55:21, 63:10, 74:13, 98:16, 99:13, 106:3, 106:14, 106:15, 110:16, 110:22, 119:5, 122:20, 128:5, 132:7, 134:2, 134:11, 137:8, 137:10 talks 50:10, 110:15 target 31:1, 48:15, 49:8, 49:11, 49:13, 49:15, 49:17, 53:16, 62:19, 91:15, 120:3, 127:5, 128:3 targeted 64:5 tasks 90:8 teach 23:13, 23:15, 23:19, 24:15, 24:16, 24:20, 24:22, 26:11, 36:13, 139:13 teaches 121:12 teaching 18:6, 27:13 teachings 35:10 team 14:10 tecan 1:13, 142:10, 143:3 technique 37:9, 37:10, 71:3 techniques 26:14, 27:19, 27:20, 28:9,
T			
	tag 30:22, 99:3, 99:22, 100:20, 101:18, 113:21, 116:9, 116:16, 116:18, 127:8 tags 98:21, 101:5, 116:13, 121:13, 124:13, 125:15, 126:16, 126:22, 127:2 tail 42:15, 42:17, 43:7, 43:8, 43:10, 43:12,		

28:10, 28:12, 28:13, 75:11, 75:13, 75:14, 76:12 technologies 1:4, 4:17, 21:4, 21:6, 25:20, 26:6, 26:8, 26:17, 47:6, 53:1, 99:12, 143:2 technology 17:22, 18:10, 18:13, 23:10, 47:11, 47:13, 122:4, 134:19 tell 129:3 template 33:2, 56:18 term 43:18, 72:1, 72:4, 72:19, 74:2, 74:3, 74:10, 74:12, 74:19, 75:3, 75:5, 75:7, 76:14, 82:5, 104:4, 104:6, 105:5, 113:13, 114:11, 114:12, 124:22, 126:13 termed 61:14, 67:5, 73:12 terminology 104:9 terms 42:22, 83:21, 104:11, 110:12, 123:11, 131:22 testified 4:3 testifying 6:17 testimony 8:16, 13:1, 13:4, 119:15,	119:16, 121:1, 121:3, 141:8, 141:11, 142:9 text 25:5, 103:13, 123:16, 124:6 tfletcher@wc 2:8 th 141:9, 142:25 thank 13:6, 43:5, 70:7, 79:22, 81:13, 102:4, 103:4 thanks 37:11, 121:6 therefore 136:12 thing 49:22, 98:8 things 18:6, 38:8, 82:8, 83:12, 105:11, 109:18, 127:13, 127:17, 133:3 think 18:3, 23:1, 23:8, 27:9, 34:5, 36:5, 39:7, 39:8, 43:6, 50:8, 50:20, 51:18, 66:16, 68:22, 73:17, 77:19, 79:18, 86:17, 90:16, 91:11, 92:14, 93:5, 97:7, 102:3, 102:10, 106:7, 130:20, 131:3, 131:4, 135:21 thinks 47:5, 135:21 third 61:22, 63:13, 64:8, 67:15,	111:18, 112:15, 112:20 thomas 2:7 thought 84:18 thoughtful 60:8 three 10:9, 59:2, 59:20, 72:9, 84:3, 84:5, 84:11, 84:12, 84:14, 84:16, 84:20, 85:11, 88:3, 89:6, 89:9, 117:14 three-nucleotide 43:21 through 6:13, 33:21, 33:22, 55:11, 80:16, 116:1, 118:6, 118:18, 119:1, 120:9, 121:7, 131:16, 137:19 throughout 12:11, 26:13 thursday 142:16 time 7:13, 32:21, 46:4, 79:19, 84:22, 140:19, 140:22 timeframe 22:15, 84:21 times 2:14, 5:7, 13:13, 64:12 timothy 2:19, 4:13, 4:14 title 26:8, 70:20, 138:18 titled 37:14	titles 18:2, 26:13, 117:6 today 5:3, 6:15, 7:5, 8:20, 14:1, 16:14, 60:6, 77:11, 81:22, 82:3, 100:1, 129:9 today's 8:22, 9:1 together 65:9, 71:16, 123:13 tom 4:15 tomorrow 5:4 tools 18:15, 18:22, 19:1, 19:4 top 118:3, 118:18, 131:17 topic 97:17 topics 25:10 torrent 47:16, 84:13 touch 27:14, 27:20 toward 48:20 towards 21:12, 23:2, 55:14, 55:17 tp 131:18, 136:16, 136:22 tractable 29:8 trademark 1:1 training 18:7, 20:16, 21:4, 21:7,
---	--	--	---

21:12, 97:18 transcript 108:2, 108:10, 110:4, 110:15, 110:16, 141:8, 141:10 transcriptase 46:18 transcription 39:3, 39:4, 78:5 transcriptome 45:4, 45:7, 45:9, 110:21 transcriptomes 18:17 transcriptomics 26:18 transcripts 28:7 transfer 40:22, 41:12, 41:14, 41:18 traverses 66:14 trial 1:2, 16:3 triangle 132:14, 134:1, 135:7, 135:13 tricky 48:22 tried 33:20 true 29:12, 121:18, 122:2, 132:17, 133:10, 141:10, 141:12, 142:8 truthfully 8:20 try 7:10, 7:11, 8:5, 13:9, 34:6, 39:17, 66:2, 75:1, 91:19, 95:6 trying 37:1, 50:18,	51:6, 74:1, 75:14, 76:13, 90:9, 90:20, 91:8 ts 106:5 ttt 43:21 turn 11:8, 16:18, 33:14, 35:5, 37:12, 46:9, 74:9, 80:7, 97:4, 98:12, 109:1, 124:5, 131:12, 131:15 turning 66:21 twice 5:8 two 5:10, 5:12, 6:13, 10:10, 10:13, 12:16, 13:3, 13:8, 18:2, 18:6, 22:14, 26:12, 47:7, 48:5, 49:20, 50:2, 54:22, 72:10, 72:13, 73:15, 73:20, 75:19, 76:1, 76:9, 78:14, 82:2, 85:1, 92:22, 93:4, 93:8, 107:8, 114:2, 115:5, 117:22, 123:14, 125:17, 131:9, 131:11, 138:6 two-step 101:16 type 31:7, 74:16, 76:17, 98:8, 136:16, 136:22 types 27:19, 31:20,	40:16, 40:17, 40:18, 41:1, 59:2, 77:10, 86:12, 105:17 typically 12:11, 19:11, 44:5, 44:13, 48:17, 51:10, 85:20, 86:22, 116:9, 116:11 typing 13:15 typo 16:17 U ultimate 81:7, 81:19, 82:5, 82:13, 89:5, 90:14, 92:4 ultimately 22:10, 92:12 umbrella 82:5 umi 30:5, 30:7, 30:16, 30:17, 30:18, 103:21, 104:1, 104:5, 107:8, 111:21, 112:1, 112:14 umis 29:22, 30:13, 30:15, 31:3, 31:6, 31:7, 31:9, 31:14, 31:17, 31:21, 31:22, 76:8, 77:1, 77:9, 107:14, 112:22, 113:5, 113:6 uncloned 59:1, 59:8, 60:15 under 6:16, 80:19, 110:9, 111:3,	141:8 undergo 57:20, 57:22, 58:2 underlined 25:10, 25:12, 26:12 underneath 25:5 understand 6:18, 6:19, 7:2, 7:3, 7:9, 7:18, 7:19, 8:13, 8:17, 8:18, 9:19, 14:18, 35:8, 35:10, 36:11, 37:1, 68:14, 68:15, 71:22, 81:10, 94:14, 95:16, 97:8, 97:11, 97:19, 111:13, 124:20, 140:7 understanding 35:1, 35:3, 35:19, 36:3, 36:14, 53:17, 59:13, 60:22, 61:15, 62:8, 62:21, 63:9, 63:16, 63:20, 65:5, 65:8, 67:7, 78:10, 95:9, 95:13, 101:11, 104:9, 106:6, 110:6, 118:8, 124:22, 135:16 understood 8:10, 10:16, 14:8, 16:16, 23:12, 29:14, 57:16, 69:5, 86:7, 100:14, 102:12 undesirable 52:13, 63:19,
---	--	--	---

63:21, 64:9, 71:21 undoubtedly 44:2 unique 30:7, 30:21, 99:2, 99:21, 100:4, 105:12, 124:13, 133:17 united 1:1 university 17:17 unknown 53:16, 53:20, 54:22, 58:22 unless 6:21 unlikely 87:4, 92:15 unpredictably 60:17, 61:1, 62:2, 63:6 until 69:19 untranslated 42:13 upstream 48:14, 48:20, 49:3, 49:6, 49:10 use 19:7, 19:9, 19:11, 20:11, 31:7, 45:8, 45:11, 46:17, 48:10, 48:13, 51:7, 53:2, 54:2, 54:17, 60:16, 61:19, 62:11, 71:4, 72:3, 72:6, 74:19, 75:3, 75:5, 75:8, 75:11, 76:9, 76:14, 76:21, 77:19, 84:5, 85:11, 85:15,	86:5, 89:6, 98:21, 99:20, 104:4, 104:6, 116:6 useful 71:5 uses 19:13, 20:9, 41:18, 53:14, 71:10, 104:11, 105:13, 107:7, 107:11, 114:11, 122:6, 126:13 using 30:21, 37:10, 49:19, 50:2, 50:10, 52:2, 55:7, 76:12, 90:2, 97:8, 99:1, 109:13, 111:7, 121:12, 123:3, 126:19, 127:4, 133:12 usually 42:20, 43:3, 71:4 utrs 42:13, 42:17 V variations 60:11 variety 51:13 various 83:5, 85:12, 92:3, 92:5 vector 131:19 vectorette 60:18, 61:7, 61:9, 61:13, 61:16, 62:3, 63:6, 67:4, 67:22 version 22:12 vertical 130:13, 130:16	vi 121:3 view 15:21 virtue 100:19, 101:18 vocabulary 42:21 W wait 7:10, 7:11 walk 80:16, 116:1 walking 53:11, 58:22, 59:8, 60:15, 121:6 walks 64:21 want 15:8, 15:11, 15:14, 36:22, 40:8, 48:11, 52:8, 57:7, 60:2, 61:10, 64:16, 90:6, 91:14, 98:12, 102:8 wanted 65:15 washington 2:5 watson-crick 55:11, 56:18, 57:1, 84:2 way 10:17, 25:7, 27:10, 75:3, 75:5, 75:8, 77:18, 92:21, 96:4, 105:7, 113:19, 142:21 ways 48:5, 83:5, 92:3, 92:22, 126:8 we'll 7:13, 10:19,	12:11, 23:21, 69:8, 96:19, 115:19 we're 6:14, 19:4, 32:8, 33:16, 33:19, 34:8, 34:14, 40:2, 49:5, 60:12, 72:18, 74:1, 75:14, 78:12, 95:21, 106:14, 108:15, 115:16, 118:2, 122:20, 123:17, 127:18, 129:4 we've 24:5, 86:9, 93:14, 97:7, 102:22, 112:18, 115:2, 116:22, 117:2 welcome 80:4 wet 19:2 whatever 98:15 whenever 7:22 whereof 142:24 whereupon 23:22, 46:7, 80:1, 115:11 whether 59:19, 59:22, 100:1, 121:16, 132:21, 138:4 white 54:6, 54:8, 134:1 whole 28:2 widely 85:1, 114:12 wild 136:16, 136:20,
--	--	---	---

136:22 williams 1:19, 2:2, 4:15, 142:14 within 50:2, 107:3, 107:4, 107:12, 142:3 without 9:2, 60:4, 65:1, 127:20 witness 3:2, 4:1, 4:6, 4:9, 5:14, 69:18, 70:5, 142:5, 142:9, 142:24 witness's 143:5 wolf 5:19 word 74:22, 77:17, 77:20, 84:1, 86:5, 126:1, 126:7 work 19:7, 21:9, 21:10, 21:18, 21:19, 21:20, 22:2, 22:21, 23:3, 69:4, 70:16, 74:20, 75:4, 75:6, 75:9, 84:19, 93:10, 94:5, 94:15, 95:10, 95:12 worked 20:21, 21:3, 21:6, 22:3, 22:11 working 19:1, 23:1, 91:19, 92:1, 99:9 works 39:2, 67:8	wouldn't 49:12, 58:5, 69:4, 85:5, 93:7 written 35:21 wrong 32:22, 73:10, 83:6, 83:13 Y yeah 4:14, 5:10, 60:8, 63:13, 70:2, 70:5, 80:13, 95:2, 95:22, 98:19, 101:3, 103:16, 112:10, 115:9, 115:16, 129:5 year 5:11, 5:21, 9:15 years 5:10, 5:12 yep 115:16 yielded 68:1 york 1:20, 1:21, 2:14, 2:15, 4:3, 4:10, 141:3, 141:23, 142:3, 142:15 Z zheng 94:13 . .2 120:17, 120:21, 121:3 .5 120:17 0 00015 1:12, 11:21,	15:4, 94:8 00016 1:14, 94:8 0016 11:21, 15:4 012 95:18 01502 1:6, 11:6 01504 1:8 01506 1:10 0206 12:7 0303461 94:19 0327 11:10 05 26:6, 140:22, 142:17 1 1 80:2 10,036,012 1:13 10,876,108 1:15 100 109:11 10018 2:15 10019 1:20, 142:16 1007 58:13 1011 10:5 1012 10:7, 108:15, 108:17, 108:18, 114:16 1012.0004 109:3 1013 10:8, 14:4,	123:18, 123:21 1013.0043 130:8 1030 69:22, 70:1, 70:7, 70:10, 70:11 10502 4:10 1079 11:3, 11:5, 11:16, 12:21, 14:4, 16:21, 20:17, 34:5, 34:13, 93:15, 97:3, 97:4 1079.0339 22:6 108 95:18 1085 11:20, 12:2, 12:6, 12:22, 34:5, 93:19, 94:7, 95:14, 95:21 109 26:6 11,098,357 1:9, 11:17 11,725,241 1:11, 11:18 112 93:20 113 94:12 12 72:12, 80:2 120 95:14, 95:22, 96:1 125 100:15, 100:21 129 98:13, 98:18, 98:19 13 80:2
--	---	--	---

130 99:14 137 107:21 138 107:21 15 1:20, 142:17 1500 1:19, 142:15 1504 11:6 1506 11:6 164 100:7 165 100:22 176 93:16 183 97:4 19 33:18, 33:21, 34:9, 34:15 1990 53:5 1995 65:16 1a 72:5, 74:17, 76:18, 114:16, 114:18 1b 114:22 1d 102:21, 103:1, 103:3, 103:5, 103:13, 104:11, 112:6, 112:12, 122:15, 139:3, 140:6, 140:15 2 20 144:4 20024 2:5	2007 21:18, 23:6 2009 21:15, 21:17, 23:4 2010 99:9 2011 23:4, 33:12, 33:13, 65:17, 84:21 2012 22:18, 84:21 2013 94:19 2022 3:8, 23:21, 24:1, 24:5 2023 69:9, 69:15 2024 1:6, 1:8, 1:10, 11:6 2025 1:12, 1:14, 1:20, 11:21, 17:12, 141:9, 141:20, 142:16, 142:25, 143:4 211 115:20, 115:22 22 35:5, 35:6 23 3:8 239 113:3, 113:10 24 124:5 241 10:15, 96:8, 96:15, 96:17, 96:22, 102:15, 102:19, 117:7, 119:15 244 118:4 248 102:10, 103:1,	103:15, 103:17, 107:17, 112:8 255 118:7 256 118:18 26 1:20, 80:2, 128:11, 141:9, 142:16, 143:4 260 118:18, 118:19 27 129:6 275 119:1, 119:5 276 104:17 280 119:21 29 128:16, 131:13, 131:16, 134:17 3 3 42:14, 42:15, 45:19, 48:19, 58:7 30 46:12, 136:14, 142:25 31 37:13 3290329 16:22 33 38:10, 38:18 357 10:15, 96:8, 96:15, 96:17, 96:22, 102:15, 102:18, 117:7, 119:5, 119:14, 120:6, 120:10, 120:15, 121:1, 121:5 39 37:18	399 10:15, 96:9, 96:15, 96:17, 96:22, 102:15, 102:18, 103:1, 103:14, 103:16, 104:15, 117:6, 117:19, 117:20, 118:1, 118:4, 118:6, 118:9, 118:17, 118:22, 119:9, 119:13, 120:6, 120:10, 120:15, 121:5, 122:13 3b 130:3, 130:6, 132:8, 132:9, 132:11, 132:17, 132:18, 133:9, 133:20, 135:6, 135:14, 135:15, 135:16, 135:22 4 4 140:22, 142:17 40 9:18, 40:20 4017 3:8, 23:22, 24:13 454 47:16, 84:13, 85:15, 85:17, 116:19 456 117:10 459 121:9, 121:10 487 117:16, 117:18 5 5 42:14, 48:19, 48:21, 54:9 508 122:8, 124:9
---	---	---	--

512 137:5, 137:8, 139:10, 140:1 513 137:16 514 137:19 519 137:19 53 131:18, 136:16, 136:22 54 4:9 578 120:9 579 120:13 5th 1:19 6 60 46:13 620 2:14 650 1:19, 142:15 680 2:4 6d 120:17, 120:21 7 76:1 71 48:4, 48:9, 48:13, 49:6, 49:18, 50:1, 50:4, 50:14, 50:15, 50:21, 51:4 72 48:4, 50:7, 50:10, 50:12, 50:14, 51:7, 51:9, 51:15,	51:22 76 53:6, 109:10 78 53:13, 54:4, 54:19 8 84 80:7, 80:19, 83:18, 92:7 88 22:17 89 22:17 9 9 1:20, 142:17 9,546,399 1:7, 11:17 90 22:5, 22:16 96 33:21, 34:4, 34:9	
--	--	--